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Abstract 
Metastatic melanoma is the most aggressive form of skin cancer, associated 
with a poor prognosis, and the incidence worldwide is increasing. Recently, 
selective mutant BRAF inhibitors and checkpoint blockade immunotherapy 
have advanced clinical treatment of metastatic melanoma.  However, efficacy 
of these therapies individually is limited. Combining treatments may allow 
BRAF inhibition to augment immunotherapy by increasing tumour antigen 
availability and improving immune system targeting of tumours. The success 
of this approach depends upon fully elucidating immunological interactions 
of BRAF inhibitors, and optimizing combination strategies. 
To study the immunological effects of BRAF inhibitors and their combination 
with immunotherapy, novel murine BrafV600E Pten-/- Cdkn2a cell lines were 
characterized. These were found to be moderately sensitive to BRAF 
inhibition compared with the widely used human BRAFV600E cell lines A375 
and SK-mel-5. In vitro targeted BRAF inhibition was shown to induce cell 
death through apoptosis, and partially reverse melanoma-mediated 
immunosuppression by human melanoma cell lines.  
Utilising subcutaneously injected syngeneic, murine BRAFV600E cell lines, the 
BRAF inhibitor PLX4720 was shown to decrease tumour growth in vivo. Host 
immune involvement in BRAF inhibitor efficacy was determined by 
comparing PLX4720 treatment in NOD/Scid and C57BL/6 mice. PLX4720 
control of tumour growth was significantly less effective in 
immunocompromised mice, resulting in reduced survival advantage. These 
findings demonstrate that the anti-tumour effects of mutant BRAF inhibitors 
are partially immune dependent, although the nature of this immune 
involvement remains to be defined. It was further shown that BRAFV600E 
inhibition directly affected immune responses. In vitro, both human and 
murine T cell activation were boosted by low concentrations of mutant BRAF 
inhibitors. This was confirmed in vivo, with antigen-specific T cell 
proliferation significantly increased by PLX4720 treatment. 
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The final chapters of this thesis explored the combination of active 
immunotherapy with targeted BRAF inhibition. A vaccine was devised that 
consisted of irradiated, autologous tumour cells loaded with the adjuvant α-
galactosylceramide. This vaccine was shown to be effective in both 
prophylactic and therapeutic settings in a BRAFV600E melanoma model. 
Mechanistically, vaccine increased effector T cell responses and decreased 
frequencies of Tregs. Vaccine efficacy was CD4+ T cell-dependent, and did not 
require CD8+ T cells. Combination of vaccine with targeted BRAF inhibition 
was investigated in different settings. A combination therapy strategy was 
developed that achieved additive, but not synergistic benefit. Additionally, 
targeting specific aspects of the tumour microenvironment that may confer 
tumour resistance to BRAF inhibitor-mediated cell death was investigated. 
Both depletion of Tregs and inhibition of TNFα were explored, but did not 
result in a significant improvement in therapy.  
In summary, the studies undertaken in this thesis demonstrate that BRAF 
inhibitors can augment vaccine-induced T cell responses. Moreover, this 
research revealed the anti-tumour efficacy of BRAFV600E inhibition is partially 
immune dependent and can be improved by combination with active 
immunotherapy. These discoveries generated a combination therapy strategy 
with improved efficacy over single agent treatment. Further studies are 
needed to realise the full potential of this combination therapy approach, and 
achieve a synergistic benefit.  
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 Metastatic melanoma: the clinical problem 1.1
Melanoma is caused by the malignant transformation of pigment producing 
melanocytes within the epidermis and is the deadliest form of skin cancer 
(Schadendorf et al., 2015a). Global incidence of melanoma is 15-25 cases per 
100,000 individuals, making it the fifth most common cancer in males and 
sixth most common in females (Schadendorf and Hauschild, 2014; Siegel et 
al., 2012). However, incidence varies significantly between populations and 
the highest rates worldwide are in Australia and New Zealand where 60 cases 
are recorded per 100,000 people annually (Nikolaou and Stratigos, 2014). 
Over the past thirty years worldwide incidence of melanoma has risen 
dramatically, and this concerning trend is continuing (Giblin and Thomas, 
2007; Siegel et al., 2014).  
The stage of melanoma at clinical presentation has significant impact on 
prognosis and the course of treatment (Trotter et al., 2013). The broad 
classification of melanoma is determined by the tumour, node and metastasis 
system (TNM) (Balch et al., 2009). Stage I and II melanomas are localized 
tumours, which are further classified into sub-stages based on tumour 
thickness, ulceration and mitotic rate. The prevailing gold standard treatment 
for localized disease is surgical resection, and the 10-year survival for this 
group of patients ranges from 93% for stage IA, to 39% for stage IIC (Balch et 
al., 2009; Schadendorf et al., 2015a). Following disease progression, patients 
with metastases to local lymph nodes are classed as having stage III ‘regional 
metastatic melanoma’. Sub-classification of stage III patients is based on local 
tumour size, the number of metastatic lymph nodes and the burden within 
nodes and has 10-year survival of 25-70% (Balch et al., 2009). Finally, 
metastatic melanoma with distant and visceral organ metastases is classified 
as stage IV melanoma. In 2010 this aggressive disease had an average survival 
of 8-9 months with a 3-year survival rate of only 10-15%, making it almost 
invariably incurable (Balch et al., 2009; Eggermont, 2010).  
In the decades leading up to 2010, improvements in radiation therapy 
delivery, cytotoxic chemotherapies and targeted therapies yielded significant 
advances in other forms of cancer. However, the application of these 
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therapies to metastatic melanoma achieved little benefit due to its near 
universal resistance to standard therapies (Mehnert and Kluger, 2012). 
Chemotherapy provided minimal improvement in patient survival outcomes, 
and adjuvant chemotherapy was found to be ineffective (Jilaveanu et al., 
2009). Cytokine therapy could achieve some anti-tumour responses, however 
only a small proportion of patients were responsive and within this cohort 
there was a trade-off between the modest benefit and the severe toxicities of 
treatment (Flaherty and McArthur, 2010). Thus, the only treatments that were 
US Food and Drug Association (FDA) approved in 2010 for metastatic 
melanoma were the cytokine therapy high-dose interleukin 2 (IL-2) and the 
alkylating chemotherapy Dacarbazine (Flaherty et al., 2010). In Europe in 
2010 only Dacarbazine was approved (Eggermont, 2010). These treatments 
achieved response rates of just 10-20%, with a small proportion of complete 
responses and no benefit in overall survival (Atkins et al., 1999; Comis, 1976). 
As a result, metastatic melanoma presented a dire situation that had 
progressed little over the previous 50 years and was in desperate need of new 
therapies.  
 Melanoma development and the mitogen 1.2
activated protein kinase (MAPK) pathway 
The development of melanoma occurs as a result of a complex process, 
involving both changes in genetic and environmental factors. This process is 
in part driven by an accumulation of genetic mutations that allow 
unregulated proliferation and survival of cells. Mutations are commonly 
somatic events, acquired over a lifetime, but in some cases mutations can be 
of germline origin, which generally promote cancer susceptibility but alone 
do not result in malignant transformation (Croce, 2008). A familial 
background of germline mutations is present in around 8% of melanoma 
patients, with the remaining melanomas being of sporadic origin 
(Schadendorf et al., 2015a). Mutations occurring in critical genes that regulate 
cell proliferation, differentiation and death are termed “driver mutations” 
(Stratton, 2011). These usually result in constitutive activation of the gene 
product, or activation under conditions in which the wild-type gene product 
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is inactive. The remaining mutations are recessively acting and occur in 
“tumour suppressor” genes, which encode proteins that switch off cell cycle 
progression. Mutations in tumour suppressor genes often result in 
inactivation or reduced activity of the gene product, allowing unregulated 
cell cycle progression (Stratton et al., 2009). 
Of all cancers, melanoma is one of the richest in genetic mutations per 
megabase of DNA. There are diverse genetic profiles across patients and 
tumours, although certain gene families are commonly mutated (Curtin et al., 
2005; Ilieva et al., 2014). Approximately 90% of all melanomas have 
alterations in the genes of the retinoblastoma pathway, which controls the 
progression of the cell cycle from G0 or G1 to the DNA replication phase 
(Schadendorf et al., 2015a). These events are primarily inactivating mutations 
occurring in the tumour suppressor encoding Cdkn2a or Cdk4 genes. 
Phosphatase and tensin homolog (PTEN) is another tumour suppressor 
commonly mutated in melanoma, which results in phosphoinositide 3-kinase 
(PI3K) pathway activation and promotes cell survival. Loss of PTEN function, 
through mutation or epigenetic silencing, occurs in 40-50% of melanomas 
(Mehnert and Kluger, 2012). In addition to mutations in tumour suppressors 
there are several activating mutations that commonly occur in melanoma. The 
most notable of which are mutations in the MAPK pathway. 
The MAPK pathway is a membrane-to-nucleus signal transduction cascade 
that mediates cellular responses to growth signals (mitogens). In response to 
mitogen binding to extracellular receptors, MAPK signalling regulates 
transcription factor activity to control a variety of essential cellular functions, 
including cell proliferation, differentiation, survival and apoptosis 
(Peyssonnaux and Eychene, 2001). 
Extracellular binding of a mitogen to a receptor tyrosine kinase (RTK) initiates 
MAPK signalling through activation of the membrane-bound guanosine-5'-
triphosphatase (GTPase), RAS. There are a diverse range of RTKs which can 
interact with RAS, including receptors for epidermal growth factor (EGF), 
vascular endothelial growth factor (VEGF), platelet-derived growth factor, c-
KIT and fms-related tyrosine kinase-3 (FLT-3) (Fecher et al., 2008). Binding of 
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these receptors activates RAS to recruit one of the three rapidly accelerated 
fibrosarcoma (RAF) kinases, ARAF, BRAF or CRAF (RAF-1), to the 
membrane. The RAF kinases then undergo RAS-dependent phosphorylation, 
and conformational changes (Beeram et al., 2005). Activated RAF kinases then 
trigger MAP/ERK kinase activation, which, subsequently phosphorylates and 
activates extracellular signal-related kinase (ERK) (Kolch, 2000). Once 
activated, the primary function of ERK is to translocate to the nucleus and 
regulate transcription factor activity (Peyssonnaux and Eychene, 2001), as 
shown in Figure 1.1. ERK has two isoforms, ERK-1 and ERK-2, which are 
generally co-expressed, and are thought to be functionally equivalent with a 
few exceptions (Kolch, 2000). ERK functions through targeting of a large 
number of downstream substrates, including approximately 50 transcription 
factor targets, as well as kinase, cytoskeletal, signalling and apoptotic protein 
targets (Yoon and Seger, 2006). The large number of substrates targeted by 
ERK explains the vast number of integrated cellular functions regulated by 
the MAPK pathway. However, it also raises the question of how MAPK 
pathway activation results in targeting of the appropriate substrate for a 
specific response. Several mechanisms seem to control this, including 
substrate availability as determined by subcellular localization, and docking 
domains which guide phosphorylation (Kolch, 2000). The complexity of the 
MAPK pathway and its pleotropic effects are also thought to be due to the 
diversity within the kinases (RAF/MEK/ERK), with several genes encoding 
each kinase (Peyssonnaux and Eychene, 2001). 
1.2.1 RAF protein kinases 
The greatest diversity in the MAPK pathway is due to the presence of three 
isoforms of RAF kinase, encoded by distinct genes A-raf, B-raf and C-raf 
(Daum et al., 1994).  Studies using knockout mice have shown the three RAF 
isoforms have both common and unique functions, as well distinct expression 
profiles (Chong et al., 2003; Mercer et al., 2002; Mikula et al., 2001; Wojnowski 
et al., 1997). CRAF is ubiquitously expressed in most tissues, whilst ARAF 
and BRAF have more limited expression. ARAF is primarily expressed in 
urogenital tissues and BRAF in neural, testicular, splenic and haematopoietic 
tissues (Beeram et al., 2005; Jaiswal et al., 1996). However, the most striking 
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difference between the three isoforms is not location, but function. Although 
the three proteins share MEK as their only downstream target, they differ 
significantly in their abilities to activate MEK. ARAF, the least well-
characterized isoform, appears to be a poor MEK activator and can only 
phosphorylate MEK1 (Pritchard et al., 1995). CRAF and BRAF are able to 
activate both MEK1 and MEK2, but BRAF has been identified as the most 
effective MEK activator, despite the much higher abundance of CRAF 
(Jaiswal et al., 1996; Mikula et al., 2001). Even in cells where BRAF expression 
is barely detectable by western blotting it remains the primary MEK activator, 
with a 50-fold higher affinity for MEK than CRAF (Papin et al., 1998; 
Pritchard et al., 1995). The RAF isoforms also differ in their regulatory 
mechanisms. BRAF has the highest basal kinase activity, whilst ARAF and 
CRAF require additional phosphorylation events to become active (Beeram et 
al., 2005).  
1.2.2 Mutant BRAF  
Constitutively active mutant RAF proteins have been identified in a number 
of cancers, including malignant melanoma, colorectal cancer, thyroid cancer 
and haematopoietic cancers. Initial investigations aimed at identifying RAF 
mutations were focussed on CRAF, however, in 2002 high-throughput 
sequencing revealed BRAF mutations as the most common aberration, 
present in 8% of all cancers (Davies et al., 2002). Activating BRAF mutations 
are present in approximately 40-70% of metastatic melanomas, and at lower 
frequencies in other forms of cancer (Davies et al., 2002; Lee et al., 2011; Long 
et al., 2011). 70-90 % of BRAF mutations occur at a single codon, with a valine 
to glutamic acid substitution (V600E). Valine to lysine substitution (V600K) 
accounts for 10-20 % of genotypes with other mutations occurring at a lower 
frequency(Long et al., 2011). These mutations disrupt the interaction between 
the glycine-rich loop and the activation segment, mimicking phosphorylation, 
which normally occurs at residues adjacent to V600. This allows the kinase to 
fold into the active conformation, and as such these mutations result in 
constitutively active BRAF proteins.  
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This RAS-independent BRAF activation results in the constitutive activation 
of MEK and downstream ERK, causing cell proliferation, clonal expansion 
and survival. Whilst, mutant BRAF contributes to the development of 
malignant melanoma, BRAFV600E mutations are also commonly found in 
benign nevi indicating this mutation alone is not sufficient for melanoma 
transformation in vivo (Pollock et al., 2003). This was confirmed in a mouse 
model where induction of conditional melanocyte-specific BRAFV600E 
expression resulted in benign melanocytic hyperplasia, but not melanoma. 
When expression of BRAFV600E was combined with silencing of the PTEN 
tumour suppressor, as is observed in 40-50% of human melanoma tumours 
(Hodis et al., 2012), transformation to malignant melanoma occurred 
(Dankort et al., 2009).  Despite the requirement for cooperating oncogenic 
mutations to achieve transformation, BRAF mutations are an important 
therapeutic target. BRAF mutations are the earliest and most common 
mutation found in malignant melanoma, and melanomas possessing mutant 
BRAF are dependent on MAPK pathway activation not only for melanoma 
initiation but to provide essential tumour maintenance (Hoeflich et al., 2006; 
Sharma et al., 2005). This pathway addiction renders mutant BRAF an ideal 
therapeutic target. 
1.2.3 Mouse models of BRAF mutant melanoma 
Murine models are important pre-clinical tools for understanding disease 
characteristics and for studying therapeutic responses and interactions. Two 
main mouse models of BRAFV600E melanoma have been developed. The first is 
a transgenic mouse model that has melanocytic expression of BRAFV600E and 
was developed by Goel and colleagues (Goel et al., 2009). To develop this 
model the BRAFV600E gene was cloned from the human melanoma cell line 
A375, and inserted into the vector downstream of the murine tyrosinase locus 
control region (promoter enhanced). This construct was injected into single 
cell embryos, and founder lines were generated. Transgene expression was 
identified in the skin (including melanocytes), brain and weakly in the lung. 
Mice expressing the transgene develop widespread benign melanocytic 
hyperplasia, similar to human melanocytic nevi. In some animals, 
melanocytic hyperplasia progresses to melanoma, with incidence dependent 
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on the levels of BRAF expression. Where melanoma development was 
observed disruption of the Cdkn2a locus and concurrent loss of CDKN2A was 
detected. These mice were backcrossed for more than 20 generations with 
C57BL/6 mice (Goel et al., 2009), resulting in stable BRAFV600E transgenic 
mice. Subsequently, the SM1 cell line was derived by Koya and colleagues 
from a spontaneous melanoma harvested from the BRafV600E transgenic mice. 
The tumour was excised, minced and first implanted in the highly immune-
deficient NOD/Scid gamma (NSG) mice, which lack T, B and NK cells and 
cytokine signalling, and thus also have many defects in the innate immune 
system (Schultz et al., 1995). The cell line was then passaged through NSG 
mice, and implanted in C57BL/6 mice to develop progressively growing 
tumours. After establishing a stable cell line, and confirming BRAFV600E 
expression, an OVA expressing SM1 line was also developed through 
lentiviral transduction. The SM1 cell line is a BRAFV600E driven murine 
melanoma cell line, which is syngeneic to immunocompetent mice (Koya et 
al., 2012). 
The second mouse model of BRAFV600E melanoma is a conditionally expressed, 
melanocyte-specific model developed by Dankort and colleagues. Initially, 
they developed a mouse model designated BRafCA. These mice harbour a 
germline conditional BRafV600E allele expressed at physiological levels 
following Cre-mediated recombination (Dankort et al., 2007). This 
conditionally-active BRaf allele was generated by modifying exons 14-16 of 
BRaf. Exon 16 was replaced with an HSV-thymidine kinase cassette, whilst a 
LoxP-flanked cassette containing the human BRAF exons 15-18 and mouse 
BRaf polyadenylation sequences and a PGK-neo cassette was inserted into 
intron 14. Finally, a modified exon 15 encoding BRafV600E and a silent Xba1 
restriction site polymorphism was inserted. BRafCA mice were generated 
using homologous recombination in embryonic stem cells. As a result, when 
these mice were infected with an adenovirus containing Cre recombinase, 
BRAFV600E expression was induced in one allele of BRaf (Dankort et al., 2007). 
The BRafCA mice were combined with a Tyr::CreER transgene, which encodes 
the 4-hydroxytamoxifen (4-HT)-inducible Cre recombinase estrogen receptor 
fusion transgene, under the control of the melanocyte-specific tyrosinase 
promoter (Bosenberg et al., 2006). In the absence of 4-HT application the 
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Tyr::CreER ; BRAFCA mice develop no distinguishable phenotype over ~18 
months. However, topical application of 4-HT to fur-bearing or smooth skin, 
or systemic administration of 4-HT leads to the appearance of highly 
pigmented lesions within 21-28 days. These highly pigmented lesions fail to 
progress to malignant melanoma over 15-20 months. Therefore, to create a 
model of inducible, malignant melanoma Tyr::CreER; BRAFCA mice 
homozygous for the Ptenlox5/lox5 conditional allele were generated. The Ptenlox5 
allele permits Cre recombinase-mediated deletion of exon 5 of Pten, resulting 
in a loss of PTEN in the presence of Cre recombinase. The Tyr::CreER; BRAFCA; 
Ptenlox5/lox5 mice when treated with topical 4-HT display dramatic expansion of 
highly pigmented lesions, which progress rapidly to advanced malignancy 
and require animal euthanasia within 25-50 days following 4-HT 
administration. The melanomas developed by these mice consist of BrafV600E; 
Pten-/- cells which are highly invasive and metastatic (Dankort et al., 2007). 
Cell lines were derived by resecting tumours from the Tyr::CreER; BRAFCA; 
Ptenlox5/lox5 mice and manually processing these into single cell suspensions. 
However, it was found that these cell lines could not be immortalized in vitro 
(Assoc Prof Marcus Bosenberg, personal communication, 2011). Tyr::CreER; 
BRAFCA; Ptenlox5/lox5 mice were then crossed to Cdkn2a-/- mice. Tumours were 
induced, again resected and manually processed into single cell suspensions. 
These BrafV600E; Pten-/-; Cdkn2a-/- cell lines were spontaneously immortalized 
creating malignant melanoma cell lines, syngeneic to C57BL/6 mice, which 
possess a genetic profile similar to human melanoma (Assoc Prof Marcus 
Bosenberg, personal communication, 2011).  
 BRAF Inhibitors 1.3
Early attempts to target RAF kinases were primarily aimed at CRAF, which 
was presumed to be the key player in oncogenic MAPK signalling prior to the 
discovery of the BRAF oncogene. The first RAF inhibitor to be progressed to 
the clinic was Sorafenib (BAY 43-9006), which was initially identified by high-
throughput screening as having potent inhibitory activity against CRAF. 
Further characterization showed that Sorafenib also inhibited both wild-type 
and mutant BRAF and a range of RTKs involved in tumour angiogenesis 
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(Wilhelm et al., 2004). Despite, or perhaps due to, its broad-spectrum 
inhibitory profile Sorafenib achieved underwhelming responses for metastatic 
melanoma patients clinically. Single-agent Sorafenib was shown to be 
ineffective in the treatment of metastatic melanoma (Eisen et al., 2006). 
Progression-free survival was improved when Sorafenib was combined with 
Temozolomide or Dacarbazine, but no substantial clinical benefit was 
achieved, as overall survival remained the same (Amaravadi et al., 2009; 
McDermott et al., 2008). The clinical failure of Sorafenib is thought to be due 
to inadequate inhibition of the MAPK pathway even when delivered at 
maximum tolerated dose (MTD) (Sullivan and Flaherty, 2013). 
Following the disappointing clinical performance of Sorafenib, the focus of 
RAF inhibitor research moved to targeting the mutant BRAF protein.  
BRAFV600E/K encoded kinases possess a deep ATP-binding pocket which 
provides an ideal site for inhibitor binding. However, identification of 
selective inhibitors had been impeded by the difficulty in crystallizing the 
RAF kinase structure. In 2004 the crystal structure of both wild-type and 
mutant BRAF was finally described (Wan et al., 2004), paving the way for the 
development of highly selective and potent inhibitors of mutant BRAF. A 
scaffold- and structure-based technique using the crystal structure of 
BRAFV600E was implemented to discover a potent and selective inhibitor of this 
kinase. A library of 20,000 “scaffold-like” compounds was initially screened 
for biochemical activity. From this 238 candidates were analysed by co-
crystallography to determine three-dimensional binding interactions with 
protein targets. This structural information allowed rational design of the 
next generation of compounds, and within a year the potent and selective 
sister compounds PLX4720 and Vemurafenib (PLX4032, Zelboraf) were 
developed. These two compounds demonstrated similar inhibition of the 
mutant BRAF protein in biochemical assays. PLX4720 inhibited BRAFV600E 
with an IC50 of 13 nM and Vemurafenib with an IC50 of 31 nM, 10-fold and 3-
fold lower respectively, than the concentration at which they inhibit wild-
type BRAF (Bollag et al., 2010; Tsai et al., 2008). Despite demonstrating 
modest selectivity in enzymatic assays, the selectivity for BRAFV600E over wild-
type BRAF in cellular assays was extraordinary. PLX4720 had greater than 
100-fold cellular selectivity for BRAFV600E in multiple cell lines, with similar 
 12 
results obtained for Vemurafenib (Lee et al., 2010, Tsai, 2008 #40; Tsai et al., 
2008; Yang et al., 2010). Vemurafenib was selected for further clinical 
development over PLX4720, due to a more favourable pharmacokinetic 
profile, with greater bioavailability in beagle dogs and cynomolgus monkeys 
(Bollag et al., 2010). However, PLX4720 is the preferred compound for use in 
pre-clinical mouse models, due to better pharmacokinetics in rodents (Bollag 
et al., 2012). 
 
 
 
Figure 1.1: MAPK Pathway with mutant BRAF and BRAF inhibition. A. The 
MAPK pathway under normal physiological conditions following mitogen 
binding to RTK. B. RAS-independent activation of the MAPK pathway as a 
result of an activating V600E or V600K mutation in BRAF. C. Targeted 
inhibitor of mutant BRAF inhibiting constitutive MAPK pathway activation. 
Adapted from (Gibney et al., 2013; Xing, 2013) 
1.3.1 The clinical development of Vemurafenib 
The first phase I clinical trial of Vemurafenib was a multicentre trial 
conducted by K.T. Flaherty and colleagues in 2009 (Flaherty et al., 2010). The 
initial dose-escalation phase of the study included 21 patients with metastatic 
melanoma, 16 of whom carried the BRAFV600E mutation.  These patients were 
enrolled in cohorts and received escalating doses from 200 mg to 1600 mg 
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twice daily. The initial crystalline formulation was found to have poor 
bioavailability and no anti-tumour activity. Trial enrolment was halted while 
reformulation was undertaken, and a microprecipitated bulk powder was 
developed with significantly increased bioavailability. The reformulated 
Vemurafenib was used for the remainder of the trial at doses of 160, 240, 360, 
720 and 1120 mg, twice daily. Dose limiting side effects were observed at the 
720 mg regime, and in a significant proportion of patients receiving 1120 mg 
twice daily. A dose of 960 mg twice daily was evaluated, and recommended 
for phase II trials. Following this recommendation, a phase I extension cohort 
enrolled 32 patients with BRAFV600E mutations which were treated at the 
recommend Phase II dose. Of the patients with BRAFV600E melanoma partial 
responses were demonstrated in 62% of patients in the dose-escalation phase 
and 75% of patients in the extension phase. Three complete responses were 
obtained, one in the dose-escalation cohort and two in the extension cohort. 
Overall, Vemurafenib caused partial or complete regression in 81% of patients 
with BRAFV600E mutations. The primary side effect was development of 
keratocanthomas or cutaneous squamous-cell carcinomas, which were 
evident in 31% of patients. Keratocanthomas were effectively managed with 
simple resection, however they were an indication of differential effects of 
Vemurafenib on BRAF wild-type cells.  Nonetheless, the phase I clinical trial 
demonstrated a reliable, early response to Vemurafenib in patients with the 
BRAFV600E mutation. However, the duration of tumour regression was limited, 
with responses ranging from 2 to 18 months and requiring continuous 
treatment (Flaherty et al., 2010). 
Following on from the successful phase I trial, 132 patients were enrolled in a 
multicentre phase II study (Sosman et al., 2012). All patients had previously 
treated metastatic melanoma, with a BRAF V600 mutation as detected by a 
polymerase chain reaction (PCR) based assay. At the efficacy data cut-off date 
the median follow-up was 12.9 months. An independent review committee 
(IRC) determined that a complete response was achieved in 6% of patients, 
and a partial response in 47% of patients, resulting in an overall response rate 
of 53%. The IRC response rates were similar to the investigator assessed 
overall response rate of 57%, with partial responses in 52% of patients and 
complete responses in 5% of patients. The majority of patients experienced at 
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least one adverse event, of which the most common were joint inflammation 
(arthralgia), rash, photosensitivity reactions, fatigue and hair loss (alopecia). 
Dose reduction was required in 59% of patients and dose interruption in 64%. 
Despite the common occurrence of toxic side effects, the majority of these 
were not severe and were able to be clinically managed to allow 
administration of the full dose to continue. Similar to the stage I trial, 
keratocanthomas developed in 26% of patients. Overall, the phase II clinical 
trial yielded positive results, with a final overall response rate of 56% and a 
median survival of 16 months, impressive achievements in a group of patients 
with less than favourable baseline characteristics (Sosman et al., 2012). 
Building on the results of the phase I and II trials, 675 patients with 
previously untreated, BRAFV600E metastatic melanoma were enrolled in a 
multicentre phase III clinical trial (Chapman et al., 2011). Patients were 
randomized to receive either Vemurafenib (960 mg orally twice-daily) or 
Dacarbazine (1000 mg per square meter of body-surface area intravenously 
every 3 weeks). Vemurafenib achieved an overall response rate of 48% 
compared with 5% for Dacarbazine, and at 6 months the overall survival was 
84% in the Vemurafenib group and 64% in the Dacarbazine group. At the 
interim analysis point, a year after the trial began, the data and safety 
monitoring board recommended that patients being treated with Dacarbazine 
be allowed to cross over to Vemurafenib treatment, due to its greater clinical 
benefit. Overall, the median progression free survival with Vemurafenib was 
5.3 months compared with 1.6 months for Dacarbazine. Toxic side effects 
similar to those in the phase I and II clinical trials were recorded, however, 
few grade 3 or above adverse events were reported. Fewer patients (38%) 
required dose modification than in earlier clinical trials. Keratocanthomas 
were again reported, but at a lower frequency of 18% than in the phase I and 
II trials. At the conclusion of the study Vemurafenib was associated with a 
relative reduction of 63% in the risk of death, and 74% in the risk of tumour 
progression, as compared with Dacarbazine treatment. (Chapman et al., 
2011).  
The pivotal phase III clinical trial confirmed that, as was seen in phase I and II 
studies, Vemurafenib reliably ach
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of patients with advanced, BRAFV600E metastatic melanoma, and across all 
three trials provided a median progression-free survival of ~7 months 
(Chapman et al., 2011; Flaherty et al., 2010; Sosman et al., 2012). As a result of 
these trials Vemurafenib received Food and Drug Administration (FDA) 
approval for use in the USA in August 2011, and subsequently European 
Medicines Agency approval for use in Europe in February 2012. While 
Vemurafenib was the first oncogenic-targeted BRAF inhibitor to be approved, 
other inhibitors have been developed such as Dabrafenib, which received 
FDA approval in 2013 and is currently the only other clinically approved 
mutant-BRAF inhibitor. However, due to the two-year lead Vemurafenib had 
on the market the majority of research surrounding targeted BRAF inhibition 
to date has focussed on Vemurafenib. The success of Vemurafenib is 
compelling, especially when compared with the 10% response rates and ~2-
month progression free survival historically achieved with Dacarbazine 
treatment (Bollag et al., 2012). However, the duration of tumour regression 
with Vemurafenib therapy is limited and continuous treatment is required. 
As a result, nearly all patients relapse eventually due to the development of 
resistance.  
1.3.2 BRAF inhibitor effects on wild-type BRAF cells 
The presentation of squamous cell carcinomas, or keratocanthomas in 18-31% 
of patients involved in the Phase I-III Vemurafenib clinical trials was 
noteworthy, although easily manageable (Chapman et al., 2011; Flaherty et 
al., 2010). These growths indicate that whilst Vemurafenib is highly targeted 
to mutant BRAF, it also has clinically relevant effects on wild-type (WT) 
BRAF cells. These observations led to the discovery that Vemurafenib 
paradoxically activates the MAPK pathway in BRAF wild-type cells, 
promoting cellular growth. In both RAS mutant, and RAS/RAF wild-type 
cells, Vemurafenib induces the formation of BRAF-CRAF heterodimers and 
CRAF-CRAF homodimers. Dimerization results in RAF activation, 
localization to the membrane and interaction with RAS-GTP, triggering 
downstream activation of the pathway, and subsequent MEK/ERK activation 
(Halaban et al., 2010; Hatzivassiliou et al., 2010; Heidorn et al., 2010; 
Poulikakos et al., 2010).  Vemurafenib activation of ERK has been shown to 
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occur in a concentration-dependent manner, in a range of BRAF wild-type 
tumour cells (Joseph et al., 2010; Yang et al., 2010). Furthermore, both 
PLX4720 and Vemurafenib can stimulate the growth of some BRAFWT tumour 
cells in vitro and in vivo (Halaban et al., 2010; Hatzivassiliou et al., 2010). This 
paradoxical activation of the MAPK pathway in BRAF wild-type cells 
accounts for the undesirable effects of Vemurafenib treatment on normal skin 
cells. Additionally, this highlights the need for rigorous testing and selection 
of patients with mutant BRAF for Vemurafenib treatment. 
1.3.3 BRAF inhibitor resistance 
In addition to the unexpected development of keratocanthomas in patients 
involved in the Phase I-III clinical trials of Vemurafenib, a second issue arose 
that is clinically much more significant. The development of acquired therapy 
resistance in the majority of patients who were initially responsive 
compromised successful Vemurafenib treatment.  
There are two types of therapy resistance, inherent or de novo resistance, and 
secondary or acquired resistance, both of which commonly occur with 
targeted therapies. Although the majority of BRAF mutant melanoma patients 
treated with Vemurafenib show some clinical response, approximately 10-
20% of mutant BRAF patients are refractory to initial BRAF inhibitor 
treatment, which is indicative of inherent resistance (Chapman, 2013; 
Chapman et al., 2011). This variation in sensitivity to BRAF inhibition is also 
present in melanoma cell lines, and has been the subject of several 
investigations. The main mechanism of de novo resistance appears to be 
activation of the PI3K pathway, through the loss of PTEN.  PTEN loss has 
been shown to confer resistance to both PLX4720- and Vemurafenib-induced 
apoptosis (Deng et al., 2012; Paraiso et al., 2011; Xing et al., 2012; Ye et al., 
2013). However, loss of PTEN has inconsistent effects on growth inhibition by 
BRAF inhibitors. Some BRAF-mutant PTEN-null cell lines are resistant to 
both apoptosis and growth inhibition, while others retain varying degrees of 
sensitivity to growth inhibition (Deng et al., 2012; Xing et al., 2012; Ye et al., 
2013).  Although PTEN loss plays a significant role in resistance to BRAF 
inhibitor-induced cell death, there is heterogeneity in BRAF-mutant PTEN-
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null melanomas and PTEN loss is not always predictive of BRAF inhibitor 
resistance. This heterogeneity may be a result of the involvement of 
additional factors, which are yet to be fully elucidated. It has been shown that 
concurrent loss of the tumour suppressor RB1 and PTEN abrogates 
melanoma dependence on the MAPK pathway, rendering cells resistant to 
MAPK targeting (Xing et al., 2012).  Whilst PI3K activation has been the main 
focus in studies of de novo resistance, other mechanisms have also been 
implicated. There is evidence that inherent resistance to BRAF inhibitors can 
be a result of ERK activation through RAF signalling-independent 
mechanisms. Expression of COT (a MAP3K8 encoded protein) can reactivate 
the MAPK pathway in the presence of BRAF inhibition and has been shown 
to drive de novo BRAF inhibitor resistance in melanoma cell lines 
(Johannessen et al., 2010). These pathways are potential therapeutic targets in 
patients with inherent BRAF inhibitor resistance, and pre-clinical data 
indicates PI3K and mTOR inhibitors can sensitise inherently resistant 
melanoma to BRAF inhibition (Deng et al., 2012; Paraiso et al., 2011). 
In addition to the issues associated with de novo resistance, acquired 
resistance presents a major hurdle to long-term tumour remission with 
Vemurafenib treatment. Patients who initially benefit from Vemurafenib have 
a limited duration of response, with the majority relapsing within a year 
(Bollag et al., 2012; Chapman et al., 2011). This relapse is indicative of 
acquired resistance, which develops as a result of continuous Vemurafenib 
dosing and despite the persistence of the original BRAFV600 mutation 
(Nazarian et al., 2010; Villanueva et al., 2010). Many investigators are 
exploring the problem of BRAF inhibitor resistance, and numerous 
mechanisms have been proposed and investigated. The most commonly 
described mechanisms to date involve reactivation of the MAPK pathway, 
through a variety of intermediary alterations. The intrinsic negative feedback 
mechanism of the MAPK pathway, active in all tumours, is the first 
mechanism that can result in pathway reactivation. The high levels of ERK-
mediated negative feedback that result from constitutive MAPK signalling 
suppress RAS. When mutant BRAF is inhibited, negative feedback is 
abrogated and RAS activation increases resulting in the formation of BRAF 
dimers (Lito et al., 2012). BRAF dimerization allows Vemurafenib to 
 18 
transactivate RAF and subsequently reactivate MEK and ERK (Poulikakos et 
al., 2010). Inhibition of MEK has been shown to circumvent this pathway 
reactivation in in vitro models (Lito et al., 2012). This resistance arising from 
inherent pathway regulation may be the reason for the majority of clinical 
responses only being partial responses that are not sustained over time 
(Chapman, 2013). Secondary activating mutations in neuroblastoma RAS viral 
oncogene (NRAS), aberrantly spliced hyperactive BRAFV600E and the 
previously described COT1/2 upregulation can also result in reactivation of 
the MAPK pathway through enhanced BRAF dimerization and Vemurafenib 
transactivation of RAF (Johannessen et al., 2010, Nazarian, 2010 #56; Nazarian 
et al., 2010; Poulikakos et al., 2011). Additionally, increased RTK expression 
can lead to BRAF inhibitor resistance, either through reactivation of the 
MAPK pathway or through activation of alternative survival pathways. The 
parallel PI3K pathway is the most commonly implicated alternative survival 
pathway. PI3K/AKT can be activated through PTEN loss as previously 
discussed, as well as by increased expression of the RTKs including insulin-
like growth factor 1 receptor (IGFR) and platelet-derived growth factor 
receptor (PDGFR) (Nazarian et al., 2010; Villanueva et al., 2010), thus rescuing 
melanoma cells from BRAF inhibition. 
The mechanisms of resistance described above only cover those that have 
been shown in melanoma models, and confirmed in clinical specimens. This 
list is far from exhaustive with additional mechanisms of resistance 
constantly emerging. Regardless of the mechanism of secondary resistance, it 
is evident that melanoma cells are highly plastic and capable of adapting to 
extreme selection pressures. Multi-pronged targeted treatments or alternative 
combination therapy approaches will be required to thwart the development 
of resistance.  
 The role of the immune system in tumour biology 1.4
The tumour microenvironment is a fundamental aspect of cancer biology, 
which contributes to tumour development and progression, as well as 
therapy response and resistance. One important component of the 
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microenvironment is the cells of the immune system. The immune system has 
evolved to protect an individual from infection and disease, and as such can 
recognize “danger” from “non-danger” signals. In the same way that the 
immune system can identify viral or bacterial pathogens, and mount a 
response that targets only that pathogen, the immune system is capable of 
specifically recognizing and eliminating tumour cells. Some immune cells are 
particularly important for driving potent anti-tumour immune responses, 
including natural killer (NK) cells, dendritic cells (DCs) and T cells.  
1.4.1 Tumour antigens 
The accumulation of genetic alterations that is characteristic of cancer results 
in tumour expression of proteins not usually present on normal tissues, which 
allow the immune system to distinguish tumour cells from “normal” cells. 
The first evidence of this was reported by Gross in 1943; mice were inoculated 
intradermally with low doses of a syngeneic sarcoma, and in approximately 
18% of animals spontaneous tumour regression was observed. Mice that were 
able to clear the initial tumours were resistant to re-challenge, indicating they 
had developed anti-tumour immunity (Gross, 1943). The ability of the 
immune system to recognize and target tumours in animal models was 
subsequently confirmed by other groups (Boon and Van Pel, 1978; Prehn and 
Main, 1957; Van Pel and Boon, 1982). Following on from the discovery that 
tumours express specific rejection antigens, further work was undertaken 
investigating types of antigens, their corresponding expression profiles and 
immunogenicity. We now know tumour antigens can be split into two main 
classes; neoantigens, also termed tumour-specific antigens (TSAs) and self-
antigens, otherwise designated tumour-associated antigens (TAAs) 
(Heemskerk et al., 2013).  
Neoantigen expression is strictly limited to tumour cells, and these tumour-
specific antigens are most commonly derived from genetic mutations and 
rearrangements, but can also arise from oncogenic viruses. The presence of 
genetic mutations leads to new peptide sequences through amino acid 
changes, alterations in reading frame or altering stop codons. These novel 
peptides are then expressed on the tumour cell surface, and can be recognized 
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by T cells with the appropriate antigen specificities. Neoantigens may also be 
peptides that are displayed at the surface of tumour cells due to mutations 
increasing major histocompatibility complex (MHC) molecule binding 
affinity, allowing for antigen presentation (Heemskerk et al., 2013). As a 
result, neoantigen expression is linked to the mutational profile of the 
tumour. Thus, cancers with a high mutation rate such as lung carcinomas 
resulting from tobacco smoking and ultraviolet radiation-induced melanomas 
are likely to have greater neoantigen expression (Coulie et al., 2014). 
Additionally, in the small subset of virus-associated cancers, such as the 
human papilloma virus (HPV)-triggered cervical cancer, antigens derived 
from viral open reading frames can contribute to the neo-epitope profile. 
However, as the vast majority of tumours lack viral etiology, oncogenic virus 
encoded peptides contribute little to the overall burden of neoantigens 
(Schumacher and Schreiber, 2015). As neoantigens result from somatic 
mutations or viral gene expression they are primarily unique antigens, which 
are patient specific.  
In addition to neoantigens, tumours can also overexpress self-antigens or 
express them in abnormal locations. Self-antigens can be categorized as 
cancer-germline antigens (e.g. cancer-testis antigens), tissue differentiation 
antigens or overexpressed antigens. Cancer-testis antigens are, as their name 
implies, proteins normally found in the male germ cells in the testis but can 
also be expressed on tumour cells. Germ cells represent an immune 
privileged site, and as such do not express MHC molecules, meaning testis-
associated antigens are not normally presented to T cells. On tumours these 
antigens are frequently overexpressed due to epigenetic changes, which 
facilitate gene expression (Chomez et al., 2001). The first cancer germline 
antigen identified was melanoma antigen-1 (MAGE-1) (van der Bruggen et 
al., 1991) which is expressed on spermatogenic cells of the testis as well as on 
44% of tumours including malignant melanomas, breast carcinomas, lung 
adenocarcinomas, glioma and acute myeloid leukaemia (Amaravadi et al.) (Li 
et al., 2015).  
The second class of self-antigens, tissue differentiation antigens, are expressed 
by both tumour cells and their tissue of origin. A well-known example is 
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MART-1 (melanoma antigen recognized by T cells-1), which is expressed both 
on malignant melanoma cells and non-malignant melanocytes (Kawakami et 
al., 1994). Finally, tumours can also overexpress proteins that are found in 
lower levels on non-related, normal tissues. One example of this is human 
epidermal growth factor receptor 2 (HER2), which is essential for embryonic 
development and is normally expressed on multiple tissues including 
epithelium, endometrium, pancreas, liver and lung tissues. HER2 is also 
commonly over-expressed on ovarian and breast cancers, where tumour 
expression is 100-200-fold higher than expression on normal tissues (Fisk et 
al., 1995). 
Although both neoantigens and self-antigens can be recognized by the 
immune system, neoantigens are considered to be more immunogenic. 
Targeting of self-antigens is likely to be fraught with issues surround 
tolerance, which does not apply to neoantigens due to their tumour 
specificity. T cells specific for self-antigens have a high chance of being 
tolerogenic, due to the development of central T cell tolerance, and T cell 
reactivity against self-antigens can only occur when self-tolerance is 
incomplete. In contrast, the tumour specificity of neoantigens means central 
tolerance does not present an issue. Furthermore, successful targeting of self-
antigens is likely to be associated with autoimmune toxicities, which do not 
occur with immune responses targeting tumour-specific antigens.  Despite 
this, at present our knowledge of self-antigens is much more comprehensive. 
Their commonality across multiple tumour types and shared expression 
between patients makes them easier to study, and to generate therapies 
against. Irrespective of the type of antigen expressed, the presence of tumour 
antigens is not sufficient to generate immunogenicity. The context in which 
the antigen is presented to the immune system is of utmost importance for 
generating an active immune response versus immune tolerance.  
1.4.2 Dendritic cells  
DCs are critical players in inducing and coordinating adaptive immune 
responses, and are known as professional antigen presenting cells (APCs) due 
to their efficiency at acquiring and presenting antigen, and at stimulating T 
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cell responses. DCs are widely distributed throughout tissues and are 
regarded as “sentinels” of the immune system, optimally poised to constantly 
sample antigens from their environment and transmit this information back 
to T and B cells of the adaptive immune system. It has been demonstrated in 
mouse models that DCs are essential for the generation of anti-tumour 
immune responses in vivo (Diamond et al., 2011; Fuertes et al., 2011).  
In an immature state DCs are characterized by low surface expression of 
MHC II and T cell-stimulating accessory molecules and are specialized for 
antigen sampling of their environment. Immature DCs can capture antigen 
through a variety of endocytosis mechanisms including phagocytosis, 
macropinocytosis, and receptor-mediated endocytosis (Trombetta and 
Mellman, 2005). Antigens are then processed intracellularly, and peptides are 
presented on MHC I or MHC II molecules. Classically, endogenous cellular 
antigens such as viral proteins are presented on MHC class I, whilst 
exogenous antigens including microbial proteins or proteins from apoptotic 
cells are presented on MHC class II. However, as professional APCs, DCs are 
also capable of “cross-presenting” endogenous antigens on MHC II and 
exogenous antigens on MHC I (Mellman and Steinman, 2001). Additionally, 
lipid antigens undergo alternative processing, and as a result are loaded onto 
the CD1d non-classical MHC molecules (Porcelli and Modlin, 1999). 
Following antigen capture DCs migrate to draining lymph nodes (LN). In the 
absence of ‘danger signals’ DCs remain in an immature state with antigens 
presented to T cells in the absence of co-stimulation. Presentation of antigen 
by immature DCs induces tolerance, through clonal deletion of antigen-
specific T cells or the generation of inducible T regulatory cells (Steinman et 
al., 2003). When DCs acquire antigen in the presence of danger signals, such 
as microbial or viral products, they undergo maturation. Mature DCs have 
decreased antigen uptake and high surface expression of MHC-peptide 
complexes and co-stimulatory molecules (Mellman and Steinman, 2001). 
Additionally, once matured, DCs express elevated levels of the chemokine 
receptors CCR7 and CXCR4, allowing them to home to T cell zones of the LN 
and spleen (Sallusto et al., 1998). This allows the DCs to present antigen to a 
large number of naïve T cells in search of their cognate antigen, and upon 
recognition induce T cell activation to effector phenotype. Therefore, whilst 
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antigen-loaded immature DCs can induce tolerance, mature DCs induce 
immunity through the priming of antigen-specific T cells. 
Although mature DCs are associated with the generation of immunity, not all 
mature DCs are created equal with regard to immunogenicity. The cytokine 
milieu present at the time of DC activation can alter the phenotype of mature 
DCs, resulting in immunogenic, tolerogenic or inflammatory DC populations 
(Palucka and Banchereau, 2012). Furthermore, within the tumour 
microenvironment the continuum of DC activation states is even more 
complex. Tumour cells directly interfere with DC function through 
immunosuppressive signals, as discussed in more detail later. In well-
established tumours cancer cells actively maintain DCs in the favourable 
immature state to promote tolerogenicity (Dudek et al., 2013). A murine 
model of ovarian cancer demonstrated that DCs could undergo phenotypic 
switching from immunogenic to immunosuppressive, which was associated 
with cancer progression (Scarlett et al., 2012). Within early stage tumours DCs 
were shown to be immunocompetent, inducing expansion of tumour-specific 
T cells. However, within advanced tumours T cells were no longer 
responsive, despite tumours remaining antigenic. This was shown to be a 
result of DCs acquiring an immunosuppressive phenotype through 
expression of increased levels of programmed death ligand-1 (PD-L1) and 
strong arginase production, both of which suppress T cell effector functions. 
A similar phenotype was also observed in DCs isolated from advanced 
human ovarian tumours (Scarlett et al., 2012).  
1.4.3 T cells 
1.4.3.1 T cell development  
T cells are derived from common lymphoid progenitors, which originate from 
the bone marrow and migrate to the thymus. Once in the thymus, ‘double 
negative’ T cell precursors undergo germline recombination of the γ and δ or 
β T cell receptor (TCR) genes; the vast majority (> 95%) of cells will develop 
TCR-β expression and go on to express an αβ TCR with a unique specificity 
 24 
(Murphy, 2011). Subsequently, T cells develop expression of both the CD4 
and CD8 co-receptors, rendering them double positive (CD4+ CD8+), followed 
by rearrangement and expression of the TCR-α chain (Lind et al., 2001). 
Double positive T cells with complete TCRs then begin a two round selection 
process (Starr et al., 2003). During the first stage, termed ‘positive selection’, T 
cells are tested for appropriate interactions with MHC molecules, to ensure 
they can recognize peptide in an MHC-restricted manner. T cells which 
recognize MHC with neither too strong nor too weak an affinity receive 
survival signals. The process of positive selection also determines CD4 and 
CD8 expression; cells with affinity for MHC II molecules retain CD4+ 
expression, whilst cells with affinity for MHC I remain CD8+. T cells that 
successfully survive positive selection subsequently migrate to the thymic 
medulla and undergo negative selection, to eliminate T cells with self-
reactivity. T cells specific for self-proteins are induced to apoptose or in some 
cases of intermediate to high affinity for self-antigen, become the immune 
modulating CD4+ natural T regulatory cells (nTregs) (Starr et al., 2003). As a 
result of positive and negative selection a mature T cell repertoire is 
generated, which is MHC-restricted and self-tolerant.  
1.4.3.2 T cell activation 
The relatively few T cells which successfully complete thymic development 
then enter the blood stream and migrate to secondary lymphoid organs. 
These mature, antigen-inexperienced “naïve” T cells recirculate through the 
lymphatics and peripheral lymphoid tissues in search of their cognate antigen 
(Murphy, 2011). Naïve T cell recirculation is facilitated by the expression of 
CCR7 and CD62L, and during migration, naïve T cells bind transiently to 
APCs they encounter, sampling antigen (Sallusto et al., 1999). When the TCR 
binds to antigen with sufficient affinity, TCR signalling induces a 
conformational change that stabilizes the APC-T cell interaction. TCR 
signalling induced by antigen recognition is the first of 3 signals required for 
T cell activation: TCR engagement (or ‘signal 1’) alone is insufficient to 
generate effector T cells. The additional signals required are usually supplied 
by the same APC, and it is for this reason that the conformational change 
which stabilizes the APC-T cell interaction is important. The additional 
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signals required for T cell priming consist of the pro-survival and expansion 
co-stimulatory signal (‘signal 2’), which is delivered through binding of T cell-
expressed CD28 to APC CD80 and CD86 (also known as B7.1/7.2 
respectively) (Boomer and Green, 2010). Finally, the cytokine mediated ‘signal 
3’ is required to direct CD4+ T cell differentiation into one of a number of 
effector subsets or to achieve optimal CD8+ T cell activation (Curtsinger et al., 
1999).  
Following T cell activation a number of proteins are upregulated to sustain or 
modulate ongoing co-stimulation. The first of these is upregulation of IL-2 
production and expression of the α chain of the IL-2 receptor (also known as 
CD25) (Malek, 2008). The IL-2 receptor is composed of three chains: α, β and γ; 
resting T cells express the moderate affinity receptor composed of β and γ 
chains. Addition of the α chain stabilizes the receptor and endows it with 
much higher IL-2 affinity. Costimulation through CD28 also contributes to 
increasing T cell IL-2 production. The production of IL-2 by activated T cells, 
and the expression of the high affinity IL-2 receptor is of utmost importance 
as IL-2 is a survival and growth factor required for the generation of effector 
T cells. In addition to upregulating IL-2 and CD25 expression, activated T 
cells begin to express a number of proteins with co-stimulatory functions, one 
of the earliest expressed activation markers is CD69 (Biselli et al., 1992; Risso 
et al., 1991).   
In addition to the expression of co-stimulatory markers following activation, 
T cells also begin to express surface molecules with negative regulatory 
functions, to control peripheral T cell activation. Cytotoxic T lymphocyte 
antigen-4 (CTLA-4) is a CD28-like molecule, which also binds CD80/86. 
However, CTLA-4 has a much stronger affinity for CD80/86 than CD28 does, 
and its effect is to inhibit rather than activate the T cell (Alegre et al., 2001). 
Upregulation of CTLA-4 on the surface of T cells following activation makes 
them less sensitive to APC stimulation than naïve cells, thereby limiting IL-2 
production and the proliferative responses of activated T cells. Following 
antigen recognition and upregulation of co-stimulatory receptors, activated T 
cells then undergo 4-5 days of rapid proliferation (termed clonal expansion) 
induced by IL-2. Clonal expansion produces large numbers of progeny with 
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the same antigen specificity that will differentiate into effector T cells. The key 
distinction of effector T cells is their ability to perform their effector function 
upon recognition of their target antigen without the requirement for co-
stimulation (Lanzavecchia and Sallusto, 2000). The effector functions of 
different T cell subsets are described in detail below. After acquiring effector 
status T cells alter expression of a number of cell-surface molecules to aid in 
trafficking to sites of infection. One example of this is upregulation of 
expression of the adhesion molecule CD44, which mediates T cell 
extravasation (DeGrendele et al., 1997).  
1.4.3.3 Subsets of effector T cells 
Naïve T cells can be primarily classified into two types: CD4+ and CD8+ T 
cells. Once activated, T cells differentiate into specific subsets related to their 
effector function. CD8+ T cells become cytotoxic CD8+ T cells, also called 
cytotoxic T lymphocytes (CTLs), which acquire the ability to directly kill 
target cells following recognition of antigen expressed on MHC class I. As a 
result, CTLs are particularly important for the control of intracellular 
pathogens such as viruses and in surveillance against tumours. CTLs can 
induce target cells to undergo apoptosis through a number of mechanisms, 
the most common of which is the release of preformed, specialized cytotoxic 
granules (Kagi et al., 1996). Cytotoxic granules are modified lysosomes that 
contain the proteins perforin and granzymes. Perforin is involved in the 
delivery of the contents of cytotoxic granules through target-cell membranes. 
Granzymes are serine proteases, of which there are five subclasses in humans 
and ten in mice. They induce apoptosis in target cells by activating caspases, 
which trigger an intrinsic apoptotic signalling cascade resulting in DNA 
fragmentation. Whilst granzymes are the central apoptotic mediators, 
perforin is required for their delivery into the cell. This was demonstrated by 
the inability of perforin knockout mice to generate a CTL response to many 
viruses (Kagi and Hengartner, 1996; Kagi et al., 1994). A second mechanism of 
inducing apoptosis involves the extrinsic apoptotic pathway. This pathway is 
facilitated by death receptors of the tumour necrosis factor (TNF) family, the 
best characterized of which is Fas. Activated CD8+ T cells upregulate Fas 
ligand (FasL) following TCR engagement, allowing CTLs to induce apoptosis 
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of cells expressing Fas through caspase activation. This mechanism is 
primarily used to regulate lymphocyte numbers; activated lymphocytes 
express Fas allowing CTLs to reduce lymphocyte numbers following 
clearance of infection.  Induction of apoptosis is the primary effector function 
of CTLs, although they can also release a number of cytokines including 
interferon-γ (IFNγ), TNFα and lymphotoxin-α (Fong and Mosmann, 1990). 
IFNγ has roles in controlling viral replication and increasing expression of 
MHC I, which increases the likelihood of target cells being recognized. IFNγ 
and TNFα can also synergize to activate and recruit macrophages.  
CD4+ T cells, also known as T helper (Th) cells, can differentiate into one of a 
number of diverse subsets with distinct functions (Figure 1.2). The activation 
phenotype of a CD4+ T cell is partially determined by the cytokine 
environment in which the cell was activated (Zhu and Paul, 2010). CD4+ T cell 
effector activity primarily involves cytokine secretion, with cytokines acting 
on target cells to direct their function. The first two subsets of T helper cells 
were identified by Mosmann and Coffman in 1986, and were defined by their 
cytokine secretion profiles as being the IFNγ-producing Th1 cells and the IL-
4-producing Th2 cells (Mosmann et al., 1986). As the original T helper subsets, 
a large body of work has been generated describing the roles of Th1 and Th2 
cells in disease and homeostasis. Th1 cells are characterized by production of 
high levels of IFNγ but can also produce TNFα, IL-2 and granulocyte 
macrophage colony-stimulating factor (GM-CSF). Th1 cells are primarily 
associated with inflammatory conditions and play a critical role in the control 
of intracellular bacterial infections by activating macrophages. The cytokine 
signature of Th2 cells is IL-4, IL-5 and IL-13, and these effector cells are 
associated with response to parasite infection, but also promote allergic 
disease. The third subset of T helper cells to be identified was the Treg subset, 
defined by their immunosuppressive function and production of the 
cytokines IL-10 and TGFβ (Gershon and Kondo, 1970; Sakaguchi et al., 1995). 
Additional subsets are now recognized including: IL-17-producing Th17 cells, 
critical in antifungal responses and the autoimmune responses in multiple 
sclerosis (Veldhoen et al., 2006); Th22 cells, which produce IL-22 and play a 
role in the maintenance of mucosal microbial populations and wound repair 
(Trifari et al., 2009); IL-9-producing Th9 cells involved in airway 
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inflammation and anti-helminth responses (Dardalhon et al., 2008); and 
finally T follicular helper cells (Tfh) which reside within the germinal centres 
and promote B cell antibody class switching (Schaerli et al., 2000).  
 
Figure 1.2:  Differentiation phenotypes of activated CD4+ T cells. Upon 
activation CD4+ T cells differentiate into one of seven distinct subsets. The 
cytokine environment at differentiation contributes to the activation 
phenotype developed. Once differentiated the subsets of CD4+ T cells can be 
in part be defined by their cytokine secretion profiles. Adapted from (O'Shea 
and Paul, 2010). 
 
T cells can mediate anti-tumour responses through a number of the effector 
functions described. The most obvious of these is the cytotoxic effects of 
CTLs, which upon recognition of tumour-associated antigens induce direct 
tumour cell killing through the release of cytotoxic granules or through the 
expression of apoptosis-inducing ligands. However, perhaps due to the 
highly destructive capability of CTL responses, CD8+ T cell activation 
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generally requires ‘help’ from CD4+ effector T cells (Zhang et al., 2009). One of 
the major forms of CD4+ T cell help comes in the form of T helper membrane 
expression of CD40L, which interacts with DC expressed CD40. This 
interaction provides an additional signal to further activate DCs and enhance 
MHC and co-stimulatory molecule expression, providing additional co-
stimulation to naïve cells. T helper cells also produce IL-2, which is 
indispensable for the production of CTL responses (Zhang et al., 2009). 
Therefore, the first role of CD4+ T cells in anti-tumour settings (amongst other 
inflammatory settings) is to augment CTL responses, and it is well established 
that a Th1 response is essential for successful anti-tumour immunity 
(Nishimura et al., 2000). CTLs and Th1-differentiated CD4+ T cells can also 
mediate anti-tumour immunity through the production of IFNγ and TNFα. 
These cytokines enhance immune responses by causing the upregulation of 
MHC I expression on tumour cells and increasing MHC II expression by 
tumour-resident APCs and in some cases, on tumour cells (Wang and Lin, 
2008; Zaidi and Merlino, 2011). Additionally, Th1 and Th2 cells can activate 
innate immune mechanisms with anti-tumour activity, including the 
recruitment of macrophages, eosinophils and NK cells (Hung et al., 1998). 
Finally, T helper cells can have direct anti-tumour functions through the 
production of TNFα or by inducing death via the extrinsic receptor-mediated 
apoptotic pathway (Fas-FasL interactions amongst others) (Haabeth et al., 
2014). However, in most models the major contribution of CD4+ T cells 
appears to be in the recruitment of accessory cells (APCs, NK cells) and 
supporting CTL anti-tumour responses.  
1.4.3.4 Resolution of T cell responses and generation of memory T cells 
In a primary immune response, which occurs when a pathogen is 
encountered for the first time, the clonal expansion and differentiation of 
effector cells will take several days from pathogen recognition. In the majority 
of cases the cells of the adaptive immune system will effectively target the 
pathogen, leading to clearance of infection, and downregulation of the 
immune response.  To prevent an overly active immune response from 
developing after the peak of effector T cell expansion, there is contraction of 
the immune response, which results in the elimination of 90-95% of T cells 
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(Kaech et al., 2002). During this phase, 5-10% of effector cells are retained and 
differentiate into long-lasting memory T cells (Kaech and Wherry, 2007). The 
mechanisms that determine which effector T cells undergo apoptosis and 
which become memory cells are still unclear, as are the mechanisms by which 
memory cells maintain long-term survival. Regardless of the mechanisms, 
maintenance of memory T cell populations enables the immune system to 
respond more rapidly and effectively to reinfection. Memory T cells possess 
high proliferative potential and have a lower requirement for antigenic 
stimulation and co-stimulation than naïve T cells (Kaech et al., 2002). 
Following reinfection memory T cells rapidly begin to undergo clonal 
expansion, produce effector molecules and differentiate into secondary 
effector T cells generating a fast and robust antigen-specific immune 
response. Memory T cells are a heterogeneous population consisting of 
effector memory (TEM), central memory (TCM) and tissue-resident memory 
(TRM) cells (Sallusto et al., 1999; Schenkel and Masopust, 2014). These subsets 
can be distinguished by their localization with TEM cells circulating through 
non-lymphoid tissues, TCM homing to secondary lymphoid tissues and TRM 
being found in peripheral tissues with requirements for specific 
chemoattractant and homing receptor expression for T cell recruitment (Shin 
and Iwasaki, 2013).  
1.4.4 Natural killer cells 
In addition to the anti-tumour responses of adaptive immune cells, innate 
lymphoid cells (ILCs), which arise from the same lymphoid progenitors as T 
cells and develop in the bone marrow, can also contribute to anti-tumour 
immunity. NK cells are a subset of cytotoxic ILCs which were initially 
identified through their ability to directly kill tumour cells (Herberman et al., 
1975a; Herberman et al., 1975b) An important feature of NK cells is their 
capacity to identify stressed cells (such as tumour cells) from healthy ones, 
and directly kill either through cytotoxic granule release similar to that used 
by CD8+ T cells, or through death receptor pathways which induce apoptosis 
(e.g. Fas-FasL). Whilst NK cells share a number of similarities with T cells, 
there are also key differences. NK cells recognize conserved motifs of 
“missing-self” and of stress, as opposed to specific antigens. Tumours and 
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virally infected cells commonly downregulate MHC I, and NK cells can 
recognize this “missing self” and become activated. Additionally, NK cells 
express receptors including the NKG2D receptor, which recognizes stress-
induced proteins such as MICA and MICB. Receptor binding to stress ligands 
also results in NK cell activation. Upon activation, NK cells eliminate the 
target cell directly, through the release of cytotoxic granules or surface ligand 
binding, or indirectly through the release of IFNγ and recruitment of other 
immune cells. NK cells were first shown to effectively eliminate tumour cells 
in mouse models (Gorelik et al., 1984; Riccardi et al., 1980), and have since 
been shown to kill MHC I-deficient tumours both in vitro and in vivo (Karre et 
al., 1986; Ljunggren and Karre, 1985). Following these initial investigations 
the anti-tumour effects of NK cells have been demonstrated in a number of 
mouse models and human tumours. NK cells play an important role in anti-
tumour immunity not only through their direct cytolytic killing, but also 
through the release of IFNγ, and shaping of downstream adaptive immune 
responses.  
1.4.5 Invariant natural killer T cells 
A second group of non-T lymphocytes that can play important roles in anti-
tumour immunity are natural killer T cells (NKTs), which bridge the innate 
and adaptive immune systems. NKT cells arise from the same common 
lymphoid progenitors as conventional T cells, and also develop in the 
thymus. There are four different groups of NKT cells, the best studied of 
which is the invariant NKT (iNKT) cell subset, also known as Type I NKT 
cells. Following αβ gene rearrangement and the generation of double positive 
(CD4+ CD8+) T cells, the iNKT cells diverge from T cell development and 
develop a semi-invariant TCR (Vα14-Jα18 in mice and Vα24-Jα18 in humans). 
This receptor recognizes a variety of glycolipids presented on the MHC-like 
molecule CD1d, thus iNKT activation is CD1d-restricted. CD1d is expressed 
on APCs including DCs and B cells, and can also be expressed on tumour 
cells, with CD1d expression documented in renal cell carcinoma, breast 
carcinoma and lymphoma amongst other tumours. When DCs present lipid 
antigens, such as the potent iNKT ligand α-galactosylceramide (αGalCer), on 
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CD1d to iNKTs, they induce cellular activation (Figure 1.3) (Kawano et al., 
1997). Subsequent to activation, iNKTs upregulate expression of CD40, which 
in turn provides a maturation signal to the DC known as “licensing”; 
stimulating DC production of IL-12. IL-12 is a potent Th1 polarizing cytokine, 
and it has been established that Th1 responses are critical for successful anti-
tumour immunity. Additionally, activated iNKT cells can rapidly release 
large amounts of cytokines including IFNγ, which recruits T cells and NK 
cells to directly kill the target cells (Motohashi and Nakayama, 2008). In anti-
tumour immunity, iNKT cells have been shown to exert direct anti-tumour 
killing capacity, including cytotoxic granule release and FasL expression. 
However, when stimulated by αGalCer, anti-tumour effects are the result of 
IFNγ-mediated recruitment of CD8+ T cells and NK cells which mediate 
tumour killing, not a result of direct iNKT killing (Vivier et al., 2012).  
 
Figure 1.3: iNKT cells interact with and modulate DC, NK and T cell 
functions. iNKT cells have bi-directional interaction with DCs; DCs present 
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lipid antigens on CD1d to activate iNKT cells and iNKTs license DCs through 
CD40-CD40L. iNKTs also directly and indirectly modulate the cytokine 
environment recruiting NK and T cells. Adapted from (Cerundolo et al., 
2009). 
1.4.6 Immunoediting and tumour-mediated immune 
suppression 
While the immune system is capable of generating powerful anti-tumour 
responses, the progression of tumours to advanced stages is evidence that 
such responses are not always effective. A large body of work now 
demonstrates that the immune system can have paradoxical, and dynamic 
effects on tumour development, both preventing or facilitating tumour 
growth and impacting tumour immunogenicity.  
Over 50 years ago Burnet originally proposed the ‘immune surveillance 
theory’ hypothesizing that the immune system could recognize and eliminate 
nascent transformed cells, and that adaptive immunity was responsible for 
preventing cancer development in immunocompetent hosts (Burnet, 1970). 
However, Burnet’s immune surveillance theory did not take into 
consideration the immune escape that underpins tumour progression in 
immunocompetent hosts. It is now proposed that there is a cancer 
immunoediting process composed of three distinct phases; elimination, 
equilibrium and escape (Dunn et al., 2002). In the elimination phase the cells 
of the innate and adaptive immune systems effectively target and kill 
developing tumours before they become clinically apparent. A number of the 
mechanisms and molecules employed in this process have been described 
above, and more remain to be elucidated. If the elimination phase is 
successful the host remains tumour free and the immunoediting process is 
circumvented. However, if some tumour cells survive elimination the process 
advances to the equilibrium phase, where tumour growth is prevented but 
tumour cells persist. This phase is mediated by adaptive immune mechanisms 
including T cell responses, and IL-12 and IFNγ involvement (Koebel et al., 
2007). Equilibrium can be the endpoint of immunoediting, with the immune 
system able to restrain outgrowth of tumour cells for the lifetime of the host. 
However, as a consequence of the selective immune pressures placed on 
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genetically unstable tumour cells, the equilibrium phase can result in editing 
of tumour immunogenicity. Over time, this process can generate tumour cell 
variants that either lose antigen expression, are resistant to the immune 
effector mechanisms at play, or are able to create an immunosuppressive 
microenvironment. Due to the emergence of tumour cell variants, or as a 
result of immune exhaustion or inhibition, tumour cells may proceed from 
the equilibrium phase to enter the escape phase. In the escape phase the 
balance between anti-tumour immune responses and the tumour is lost, in 
favour of tumour outgrowth. This results in cancer progression. It is worth 
noting that the three phases of cancer immunoediting are not necessarily 
linear, but rather this is a dynamic process with some tumours skipping 
phases. Overall, the immunoediting hypothesis incorporates dual host-
protective and tumour-promoting roles, and explains the role the immune 
system plays in shaping tumour immunogenicity (Dunn et al., 2002; Dunn et 
al., 2006; Schreiber et al., 2011). Although studies of tumour development in 
mice formed the basis of the cancer immunoediting hypothesis, there is 
increasingly substantive evidence of this process occurring in human tumours 
(Dunn et al., 2004) 
One central mechanism of immune escape is the creation of an 
immunosuppressive tumour microenvironment. Progressive tumour growth 
has been shown to occur despite the retention of tumour antigen expression 
and the presence of effector tumour infiltrating lymphocytes (TILs) with 
tumour antigen specificity (Prevost-Blondel et al., 1998; Rosenberg et al., 2005; 
van der Bruggen et al., 1991). In this setting, progression is likely a result of 
tumour immunosuppressive mechanisms abrogating effector T cell function. 
Tumour cells employ a number of mechanisms to generate a highly immune 
suppressive microenvironment, including expression of suppressive 
cytokines and molecules and the recruitment or induction of regulatory 
immune cells with suppressor functions. Immune suppression can be 
mediated through intrinsic tumour mechanisms or via extrinsic suppression 
facilitated by regulatory cell populations or non-cancerous cells within the 
tumour microenvironment, such as stromal cells and mesenchymal stem cells 
(Le Blanc et al., 2004; Nauta and Fibbe, 2007; Spaggiari et al., 2008). The first 
mechanism of suppression is the production of suppressive factors by tumour 
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or associated cells. Some tumours, and tumour-associated myeloid cells, have 
increased arginase-1 activity and overproduce nitric oxide, both of which 
inhibit T cell function. Additionally, numerous human tumours have been 
shown to produce indoleamine 2,3-dioxygenase (IDO) which catalyzes the 
degradation of tryptophan, an amino acid essential for T cell function. IDO 
catabolism of tryptophan can block CD8+ T cell proliferation (Uyttenhove et 
al., 2003) and promote CD4+ T cell apoptosis (Terness et al., 2002). The tumour 
microenvironment also contains a number of factors, produced by tumour 
cells or stromal cells, which can inhibit the differentiation, maturation and 
function of DCs, including VEGF, IL-6, IL-10, transforming growth factor-β 
(TGFβ), and prostaglandin E2 (PGE2) amongst others (Dudek et al., 2013; 
Zitvogel et al., 2006). Thus, the tumour maintains infiltrating DCs in the 
favourable immature state, with some immature DCs competent to express 
IDO (Munn et al., 2004). As a result, DCs within the tumour 
microenvironment mediate immunosuppressive, not immunostimulatory, 
effects and promote the differentiation of T helper cells into Tregs.  
Tregs are a major extrinsic mediator of immunosuppression within the 
tumour microenvironment. T helper cell differentiation into Tregs is 
supported within the tumour by a number of mechanisms including 
previously described antigen presentation by immature tumour infiltrating 
DCs. Numerous molecules expressed at high levels in the tumour 
microenvironment also support Treg development such as TGFβ and IL-10, 
IDO and CTLA-4. These factors and ligands are commonly expressed by 
tumour cells or associated cells, with several redundant sources ensuring they 
are present in the majority of established tumours. Thus, Tregs are present in 
elevated numbers in many tumours, and inhibit the effector functions of 
tumour-specific T cells through contact-dependent mechanisms involving the 
expression of inhibitory ligands, and through the production of IL-10 and 
TGFβ. Additionally, Tregs with their high expression of CD25 act as sinkholes 
for IL-2 sequestering it away from the IL-2 dependent CTLs, and similarly 
sequestering the amino acids arginine, tryptophan or cysteine which are all 
required for T cell effector function. The tumour microenvironment also 
induces myeloid precursor cells to develop the immunosuppressive 
phenotype of ‘myeloid derived suppressor cells’ (MDSCs). MDSCs promote 
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tumour growth by enhancing angiogenesis and metastasis and inhibit anti-
tumour T cell responses in a similar manner to Tregs by TGFβ production or 
sequestering of amino acids. Additionally, MDSCs reduce effector T cells and 
boost immunosuppression by inducing T cell differentiation into Tregs. 
MDSCs, amongst other cells in the tumour microenvironment, can also 
polarize macrophages towards tumour-promoting ‘tumour associated 
macrophages’ (TAMs). These TAMs can produce high levels of IL-10 and little 
IL-12, promoting immune suppression and can support tumour progression 
by facilitating angiogenesis, invasion and metastasis (Ostrand-Rosenberg et 
al., 2012).  However, there is no singular phenotype associated with TAMs, 
and macrophages in the tumour microenvironment can also have anti-tumour 
functions.  
In tumours, the accumulation and suppressive activity of Tregs, MDSCs and 
TAMs is initiated by factors produced by the tumour and surrounding 
stromal cells. However, interactions between the suppressive cell populations 
exacerbate the development of the immunosuppressive environment.  
Regulatory cells within the tumour microenvironment function not only to 
tolerize the immune system to the tumour and subdue anti-tumour immunity 
but also have supportive functions for tumour development. Many of the 
immunosuppressive factors within the microenvironment are produced by 
multiple cell types in the tumour bed, and have numerous subsequent 
suppressive activities. IL-10 and TGFβ are a prime example – produced by 
tumour cells, stromal cells, Tregs, MDSCs and TAMS, they act on multiple 
immune cell types and promote the development of the same suppressive 
cells which produce them. This regulatory loop, with both redundant 
production of inhibitory factors and redundant downstream actions results in 
the orchestration of a self-promoting immunosuppressive environment, 
which is highly effective at shutting down attempts by the immune system to 
target tumour cells. In order to mount a successful anti-tumour immune 
response the effector cells must be able to overcome this immunosuppression.  
 Melanoma immunotherapy 1.5
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The ability of the immune system to mount anti-tumour responses has been 
outlined. In reality, however, the immune system regularly fails to mount a 
sufficient response and overcome tumour-mediated immunosuppression. The 
underlying basis of immunotherapy, when applied to the treatment of cancer, 
is to potentiate the inherent anti-tumour responses and overcome immune 
suppression. New York surgeon William B. Coley pioneered the first attempt 
at cancer immunotherapy in 1891. After observing complete remission in a 
patient following acute infection with Streptococcus pyogenes Coley began 
treating patients with inoperable soft-tissue sarcomas with a streptococcal 
and bacillus bacterial preparation, which became known as “Coley’s toxin”. 
His results were first published in 1893 (Coley, 1893), and over 40 years he 
treated almost 900 patients with a cure rate of over 10% (Coley, 1910; Parish, 
2003). Despite successes, Coley’s toxin was not widely accepted scientifically 
or in the clinic, likely in part due to the dramatic fevers associated with 
treatment, perceived low cure rates and the lack of immunological 
understanding. Over 100 years have passed since Coley first attempted to 
treat cancer with immunotherapy and a greater understanding of the immune 
system has facilitated changing attitudes in favour of immunotherapy and 
yielded significant immunotherapeutic advancements. Recent clinical 
successes have demonstrated the potential of immunotherapy to change the 
treatment paradigm in many forms of cancer, but particularly in metastatic 
melanoma. The three main approaches to immunotherapy are adoptive cell 
transfer (ACT), immunomodulation through checkpoint blockade and active 
immunization using cancer vaccines. 
1.5.1 Adoptive cell transfer 
ACT involves the treatment of patients with autologous T cell populations 
that have been expanded ex vivo, and are then reinfused to traffic to and 
mediate destruction of the tumour. Traditionally, ACT involves the isolation 
of TILs from tumours, followed by expansion of tumour-specific T cell 
populations ex vivo with IL-2. Prior to the transfer of the expanded tumour-
specific T cells, patients undergo lymphocyte depletion, which enhances 
persistence of the reinfused TILs by reducing systemic immunosuppression 
associated with advanced cancer. Reinfusion of T cells is often accompanied 
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by the administration of exogenous IL-2, to support T cell effector function 
and expansion. This approach has yielded some positive results. In a clinical 
trial of advanced metastatic melanoma patients TIL therapy achieved 
objective response rates of 49-72% and complete tumour regression in 22% of 
patients, which was shown to be durable (Rosenberg and Dudley, 2009; 
Rosenberg et al., 2011). Despite this success, the reasons for variation in 
patient responsiveness remain elusive, and naturally occurring TIL 
populations can currently only be isolated and expanded from melanoma. 
This has motivated the development of ACT approaches employing 
genetically engineered T cells to expand the reach of ACT therapy. 
Genetically engineering T cells has the ability to generate tumour reactive T 
cells with higher affinity and specificity for tumour antigens. A number of 
gene engineering techniques have been employed, with varying success. One 
approach centres on the cloning of TCRs with tumour specificity, and 
insertion of their genes into lentiviral or retroviral vectors, which are used to 
transfer the antigen specificity and avidity to autologous T cells from patients 
(Restifo et al., 2012). A second technique involves chimeric antigen receptors 
(CARs), which incorporate a single chain variable region of an antibody fused 
to intracellular TCR domains, resulting in antibody-like non-MHC-restricted 
specificity with the capability of T cell activation without co-stimulation 
(Rosenberg and Restifo, 2015). Genetic engineering of T cells for ACT therapy 
still faces a number of questions surrounding optimal T cell specificity, and 
which population of T cells to transduce. However, this represents a 
promising, albeit commercially challenging, immunotherapeutic approach.  
1.5.2 Checkpoint blockade  
Checkpoint blockade therapy targets regulatory pathways, known as immune 
“checkpoints”, to unleash T cell responses, and has emerged as one of the 
most promising immunotherapeutic strategies. Immune checkpoint pathways 
maintain self-tolerance in normal tissues, but are hijacked by tumour cells to 
suppress anti-tumour immunity. Inhibitory immune signalling molecules that 
represent checkpoint blockade targets include the previously described 
CTLA-4, as well as programmed death 1 (PD-1) and PD-L1, T cell 
immunoglobulin and mucin-3 (TIM-3) and lymphocyte activation gene 3 
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(LAG-3) amongst others. Agents that block these targets are in various stages 
of preclinical or clinical development, with checkpoint blockade therapies 
targeting CTLA-4 and PD-1 currently approved for use in metastatic 
melanoma.  
The anti-CTLA-4 antibody Ipilimumab was the first checkpoint blockade 
therapy to approved, with approval for use in the treatment of metastatic 
melanoma passed in the United States and Europe in 2011 following phase III 
clinical trials which achieved an overall survival benefit (Hodi et al., 2010; 
Robert et al., 2011). Ipilimumab is a human, monoclonal antibody that blocks 
the engagement of the inhibitory molecule CTLA-4. Clinically this can 
potentiate robust anti-tumour responses, which are durable with some 
responses lasting a decade or more. However, only a small proportion of 
patients respond to anti-CTLA-4 therapy, with tumour regressions (complete 
or partial) observed in 11% of patients (Schadendorf et al., 2015a). 
Interestingly, meta-analysis of Ipilimumab trials revealed durable increases in 
overall survival were achieved in approximately 20% of patients, double the 
number of patients with measurable tumour regression (Schadendorf et al., 
2015b; Topalian et al., 2015).  
Since the approval of Ipilimumab, the PD-1 blocking antibodies Nivolumab 
and Pembrolizumab have both received FDA-approval. Nivolumab is a fully 
human, anti-PD-1 monoclonal antibody, which achieved response rates of 24-
40% and a 1-year survival rate of 62-73% (Robert et al., 2015a; Topalian et al., 
2014). Pembrolizumab is a humanized monoclonal anti-PD-1 antibody and 
has demonstrated response rates of 26-38% in patients with metastatic 
melanoma (Hamid et al., 2013; Robert et al., 2014). The activity of these agents 
in patients pre-treated with Ipilimumab lead to both receiving accelerated 
FDA-approval, with Pembrolizumb approved in September 2014 and 
Nivolumab in December 2014 (Schadendorf et al., 2015a).  PD-1/PD-L1 
blockade has enhanced tumour specificity and reduced toxicity when 
compared to anti-CTLA-4 therapy. This translates into significantly increased 
response rates and overall survival, in addition to decreased adverse events 
when Pembrolizumab was compared head-to-head with Ipilimumab (Robert 
et al., 2015b). However, the majority of patients treated with anti-PD-1/PD-L1 
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only experienced partial tumour regressions and did not achieve objective 
responses (Topalian et al., 2015). The discovery of predictive biomarkers to 
identify cohorts of patients that will respond to checkpoint blockade therapy 
will be critical to treatment optimization and elucidating mechanisms that 
determine responsiveness. There is already some evidence that anti-PD-1 
therapies achieve better responses in patients with tumours expressing PD-L1 
(Topalian et al., 2015). The combination of anti-PD-1 and anti-CTLA-4 also 
appears to achieve increased response rates, although this was accompanied 
by elevated severity of adverse events (Postow et al., 2015). Combination of 
checkpoint blockade is likely to be increasingly favoured going forward, with 
new combinations being generated as new checkpoints are successfully 
targeted. 
1.5.3  Vaccines 
Therapeutic cancer vaccines are active drivers of anti-tumour immune 
responses, which aim to enhance anti-tumour immunity within the patient. 
There are a number of strategies for cancer vaccination including vaccination 
based on specific tumour-expressed antigens, dendritic cells or inactivated 
whole tumour cells.  
1.5.3.1 Peptide vaccines 
Peptide vaccines incorporate one or multiple short or long amino acid 
sequences from defined tumour antigens. One of the most common 
approaches involves the delivery of MHC class I restricted peptides to 
activate CD8+ T cell responses. Peptides can be delivered alone or with 
adjuvants to increase immune responses to the associated antigens 
(Butterfield, 2015). Due to the difficulty in identifying neoantigens, which are 
patient-specific, peptide vaccines usually target more frequently expressed 
self-antigens, such as MAGE-1 and MART-1. Targeting self-antigens requires 
overcoming T cell tolerance and as such has had difficulty in achieving 
tumour responses. Meta-analysis of 323 patients treated with peptide vaccines 
derived from melanoma differentiation antigens or cancer-testis antigens 
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showed nine patients achieved a partial response and two patients a complete 
response, with an overall objective response rate of 2.9% (Rosenberg et al., 
2004). These disappointingly low objective response rates indicate major 
limitations of peptide vaccines as single agent therapies. However, optimal 
adjuvants and peptide combinations are still being identified and such 
optimisation may enhance outcomes in the future. Peptide based approaches 
still hold strong appeal due to the simplicity and low manufacturing costs 
associated with peptide production, as well as the ability for large-scale 
manufacture and ease of transport and storage.  
1.5.3.2 Dendritic cell vaccines 
Vaccination strategies involving dendritic cells cultured and primed ex vivo 
have been developed due to the crucial role DCs play in initiating immune 
responses and their outstanding capacity to induce effective T cells responses. 
DC based cancer vaccines have particular merit when tumour antigens are 
poorly immunogenic and have the advantage of bypassing the induction of 
immune tolerance associated with tumour-mediated immunosuppression. 
Generally, autologous DCs are harvested and cultured ex vivo with adjuvant 
and peptides for known tumour antigens or patient-derived antigens/tumour 
lysate. Matured, immunogenic DCs loaded with tumour antigens are then 
reinfused back in to the patient. The first major success for DC-based vaccines 
was achieved with the 2010 FDA-approval of ‘Sipuleucel-T’ for the treatment 
of metastatic prostate cancer (Palucka and Banchereau, 2012). Dendritic cell 
vaccines have also been trialled rigorously for metastatic melanoma. Analysis 
of several DC vaccine trials in metastatic melanoma, which had a combined 
total of 1250 patients, revealed an 8.5% objective response rate (Anguille et al., 
2014). This objective response rate is comparable to that achieved with 
Ipilimumab treatment for metastatic melanoma. DC vaccines also proffer 
additional advantages such as increasing the diversity of neoantigen-specific 
T cells in melanoma (Carreno et al., 2015). The implementation of next-
generation dendritic cell vaccines with improved immunostimulatory activity 
has improved immunogenicity. The potential to augment efficacy through 
combination of DC vaccines with other cancer therapies is likely to be a focus 
of future DC vaccine development (Anguille et al., 2014). 
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1.5.3.3 Whole tumour cell vaccines 
One of the major challenges associated with anti-tumour vaccines is the 
selection of the appropriate antigen or antigens, to evoke a strong and 
tumour-specific immune response. It has been previously shown that 
neoantigens are more immunogenic than self-antigens, however 
immunotherapeutic targeting of these unique peptides has been difficult as 
they are highly variable between patients (Schumacher and Schreiber, 2015). 
The majority of immunotherapies favour use of conserved tumour associated 
antigens, such as MAGE, which are often poorly immunogenic due to 
peripheral tolerance. Sequencing a tumour sample to identify patient specific 
neo-antigens, performing algorithm based analysis of peptide:MHC binding 
and identifying immunogenic targets is a lengthy and expensive process, 
taking more time than is feasible in the treatment of cancer patients. Using 
whole tumour cells, irradiated or otherwise inactivated, as the basis for anti-
tumour vaccines makes it possible to target neoantigens, circumventing the 
need for identification of antigenic expression and selection of target antigens. 
Instead, whole tumour cell vaccines stimulate the immune system against a 
complement of tumour-expressed antigens, likely including both neoepitopes 
and tumour-associated antigens, with both CD4+ and CD8+ T cell reactivity.  
Autologous whole tumour cell vaccines, including irradiated IFNγ and IFNβ-
treated B16.F10 and irradiated GM-CSF-transfected B16 have demonstrated 
strong anti-tumour efficacy with the induction of CTL responses in mouse 
models of melanoma (Dezfouli et al., 2003; Dranoff et al., 1993; Scheffer et al., 
2003). These are just a few examples of the success of a variety of autologous 
tumour cell vaccine preparations in pre-clinical models of melanoma. To elicit 
strong immune responses, whole-tumour cell vaccines require an adjuvant to 
induce appropriate activation of DCs (Finn, 2003). In clinical trials, several 
whole tumour cell vaccines with different adjuvants have been shown to elicit 
strong anti-tumour immune responses in melanoma patients (Baars et al., 
2000; Berd et al., 2004; Janetzki et al., 2000; Soiffer et al., 1998). Numerous 
patients demonstrated expansion of tumour-specific CTLs as well as tumour 
infiltration with NK cells, DCs and macrophages. However, as a result of the 
single arm trial designs it is difficult to form conclusions about the effects of 
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vaccination on overall survival, due to lack of a control arm. When compared 
to historical controls, whole tumour cell vaccination in the studies by Baars 
and by Berd improved patient 5-year survival rates (de Gruijl et al., 2008). 
Additionally, the use of allogeneic tumour cells as the basis for whole tumour 
cell vaccines has also shown benefit in pre-clinical mouse models (Ward et al., 
2002) and bypasses the difficulty associated with producing personalised 
whole tumour cell vaccines on a patient-by-patient basis. These whole tumour 
cell vaccine approaches represent a promising avenue of immunotherapy 
with strong pre-clinical and early clinical work supporting their efficacy. As 
with other immunotherapies, future use of whole tumour cell vaccines is 
likely to focus on combination therapy approaches. The ability of whole 
tumour cell vaccines to provide positive stimulation of the immune system 
against a complement of tumour antigens is likely to be highly beneficial in 
combination therapy approaches.  
 Rationale for combination of BRAF inhibitor 1.6
treatment with immunotherapy 
The last five years have seen significant advances in treatment of metastatic 
melanoma. The approval of new mechanism-based therapies has shifted the 
treatment paradigm away from non-specific cytotoxics to more targeted, and 
effective treatments. Despite this substantial improvement limitations of the 
new therapeutics have been revealed and the long-term prognosis remains 
poor for many patients. BRAF inhibitor treatment achieves high initial 
response rates with rapid, dramatic responses, but effects are short-lived. In 
contrast, immunotherapies deliver durable responses but only in a small 
subset of patients. To achieve improved clinical outcomes in metastatic 
melanoma it is now widely accepted that it is going to be essential to combine 
therapies. One promising approach is the combination of Vemurafenib and 
immunotherapy.  
Chemotherapy-induced tumour cell death generally occurs via apoptosis, and 
numerous studies have shown that apoptotic tumour cell death can be highly 
immunogenic as determined by calreticulin exposure (Obeid et al., 2007; 
 44 
Zitvogel et al., 2010). Chemotherapy has also been shown to enhance tumour 
immunogenicity and increase the susceptibility of tumour cells to CTL-
mediated killing with immunotherapy (Giampietri et al., 1981; Ramakrishnan 
et al., 2010). This suggests that Vemurafenib-induced apoptosis may play an 
immunostimulatory role. Furthermore, the potential of Vemurafenib to cause 
rapid tumour regression is associated with a window of decreased tumour-
mediated immune suppression, and release of large amounts of tumour 
antigens (Vanneman and Dranoff, 2012). This would generate a favourable 
environment for anti-tumour immunity, providing the opportunity for 
immunotherapy to achieve potent effects. Thus, Vemurafenib is expected to 
be immune-stimulating and, unlike traditional chemotherapies, does not 
induce lymphopaenia, due to its targeted nature. Additionally, the 
combination of Vemurafenib and immunotherapy has the potential to prevent 
the development of acquired BRAF inhibitor resistance by targeting tumour 
cells more broadly and increasing the likelihood of tumour cytotoxicity. The 
complementary strengths and weaknesses in response rates and response 
durability, in addition to the potential for synergy provide a strong rationale 
for combining Vemurafenib and immunotherapy.  
 Impact of BRAF inhibitor treatment on immune 1.7
cells 
To inform optimal combination of BRAF inhibition and immunotherapy, the 
direct effects of BRAF inhibitors on immune cells must first be elucidated. It 
was initially assumed that mutant BRAF-targeted inhibitors would have no 
impact on the function of cells of the immune system. However, the discovery 
that PLX4720 and Vemurafenib interact with wild-type BRAF and CRAF to 
alter the growth characteristics of BRAFWT melanocytes or melanoma cells 
suggests these inhibitors may also modulate immune cell function.    
1.7.1 BRAF inhibitor effects on tumour antigenicity 
BRAF inhibition has been shown to increase the expression of tumour 
differentiation antigens in some pre-clinical models and in patient-derived 
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cell lines and tumour samples. PLX4720 treatment of several BRAFV600E 
human melanoma cell lines, including SK-mel-28, resulted in upregulation of 
MART-1 expression and of MHC Class I expression (Boni et al., 2010). 
Vemurafenib treatment of human BRAFV600E melanoma cell lines enhanced 
MHC I and MHC II expression induced by IFNγ. However, MHC 
upregulation with BRAF inhibitor treatment was specific to BRAFV600E 
homozygous cell lines such as SK-mel-28 and A375 but did not occur in 
BRAFV600E heterozygous cell lines including SK-mel-5 (Sapkota et al., 2013). 
Similar findings were observed in ex vivo patient samples with Vemurafenib 
treatment in vitro of short-term cultured mutant-BRAFV600 cell lines increasing 
tumour-associated antigen expression. Increased antigenicity was correlated 
with upregulation of genes in the MHC I presentation pathway (Donia et al., 
2012b). These effects were confirmed in vivo with patient biopsies showing 
increased MART-1, gp100, Tryp-1 and Tryp-2 expression after 10-14 days of 
Vemurafenib treatment, when compared to baseline biopsies (Frederick et al., 
2013). In contrast, Koya and colleagues demonstrated that Vemurafenib 
treatment had no effect on gp100 antigen expression or MHC I expression in 
the SM1 murine melanoma cell line (Koya et al., 2012). Although it is possible 
SM1 may be heterozygous for the BRAFV600E mutation, no information is 
available detailing this. However, heterozygosity would be consistent with 
SM1 having a relatively high IC50 of 14 µM for Vemurafenib. Thus, these data 
may confirm that BRAFV600E homozygous cell lines are susceptible to BRAF 
inhibitor-induced antigen expression whilst heterozygous cell lines are not. 
The underlying mechanisms of BRAF inhibitor-stimulated upregulation of 
melanoma differentiation antigens remain to be fully elucidated. 
Overexpression of oncogenic BRAF has been demonstrated to suppress MHC 
I expression (Sapkota et al., 2013), accordingly BRAF inhibition directly 
reverses this suppression. It has been postulated that a similar mechanism is 
at play with oncogenic BRAF suppressing antigen expression (Ott and 
Bhardwaj, 2013), however this remains to be confirmed.  
1.7.2 BRAF inhibitor effects on DCs 
The direct effects of mutant BRAF inhibition on human monocyte derived DC 
(moDC) viability and function were investigated in two studies with different 
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inhibitors, Ott and colleagues used Vemurafenib (Ott and Bhardwaj, 2013), 
while Vella et al. used Dabrafenib (Vella et al., 2014). Both inhibitors were 
found to have no DC toxicity, with moDC viability unaffected when treated 
for 24-48 hours at concentrations of up to 2 µM Dabrafenib and 50 µM 
Vemurafenib. Dabrafenib, again at concentrations of up to 2 µM, was shown 
to have no effect on moDC cross-presentation of NY-ESO-1 complexes to 
antigen specific CD8+ T cells, and no significant impact on lipopolysaccharide 
(Fong and Mosmann) activation of moDCs as measured by expression of the 
activation markers CD83, CD86 and human leukocyte antigen (Avruch et al.)-
DR (Vella et al., 2014). Likewise, concentrations of up to 10 µM Vemurafenib 
had no effect on DC expression of CD40, CD83, CD86 or MHC, production of 
IL-12 or TNFα or on DC stimulation of T cell proliferation. However, 
treatment of moDCs with 50 µM Vemurafenib significantly inhibited IL-12 
and TNFα production. The effect of this relatively high concentration of 
Vemurafenib on other read-outs of DC effector function was not assessed, 
with activation marker expression and T cell stimulation assays performed at 
lower Vemurafenib concentrations. Overall, these studies indicate that BRAF 
inhibitors have no impact on human moDC viability or effector function at 
concentrations of up to 10 µM, however at 50 µM there is evidence that 
Vemurafenib can negatively impact DC function. 
In addition to the direct effects of BRAF inhibition on DC viability and 
function, DC function in relation to melanoma-mediated immune 
suppression has been investigated with BRAF inhibitors. The tumour 
microenvironment contains immunosuppressive factors, produced by tumour 
cells or stromal cells, which maintain DCs in the immunosuppressive, 
immature state favourable to tumour progression as shown by Sumimoto and 
colleagues in an in vitro human BRAFV600E melanoma model. Culture of 
immature moDCs with A375 supernatant resulted in reduced IL-12 and TNFα 
production by DCs following LPS maturation. Thus, exposure of immature 
DCs to melanoma-produced factors led to compromised DC maturation. This 
inhibitory effect was attributed to A375 cells producing immunosuppressive 
cytokines VEGF, IL-6 and IL-10. Pre-treatment of the A375 cells with RNA 
interference (RNAi) specific for BRAFV600E reversed the suppressive activity on 
DCs and reduced production of immunosuppressive cytokines (Sumimoto et 
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al., 2006).  These results were supported by a separate study conducted by Ott 
and colleagues, using human melanoma-DC co-cultures (Ott et al., 2013). Both 
BRAFV600E and WT cells were co-cultured with immature moDCs following 
which moDCs were matured with polyI:C. Co-culture with melanoma cells 
inhibited DC production of IL-12 and TNFα, and resulted in reduced 
expression of the activation markers CD80, CD83 and CD86. Similar to the 
Sumimoto study, melanoma inhibition of DC effector function was not cell-
contact dependent. However, the soluble suppressive factor could not be 
identified. Pre-treatment of the melanoma cell lines with Vemurafenib for 24 
hours prior to co-culture partially reversed the inhibitory effects of BRAFV600E 
but not BRAFWT cells, restoring DC cytokine secretion and partially restoring 
activation marker expression (Ott et al., 2013). BRAF inhibition by both RNAi 
and Vemurafenib treatment did not result in melanoma cell death. Therefore, 
abrogation of DC suppression was a direct effect of reduced production of 
suppressive factors by melanoma cells. Together, these data indicate that 
constitutive activation of the MAPK pathway in BRAFV600E melanoma cells can 
suppress DC function through immunosuppressive soluble mediators, which 
can be overcome by inhibition of mutant BRAF.    
1.7.3 BRAF inhibitor effects on T cells 
Increased antigen expression and promotion of immunogenic DC function 
associated with BRAF inhibition will indirectly enhance T cell response to 
tumours. Boni and colleagues investigated the direct and indirect effects of 
BRAF inhibition in vitro using PBMCs isolated from melanoma patients (Boni 
et al., 2010).  At concentrations of up to 10 µM, PLX4720 had no effect on T cell 
viability or proliferation, and did not directly impact T cell secretion of IFNγ 
in response to target antigens. However, treatment of a co-culture of target 
melanoma cells and T cells with PLX4720 resulted in increased T cell IFNγ 
production. This was attributed to a response to the increased expression of 
MART-1 on melanoma cells and not a direct effect on T cells. Similarly, 
Vemurafenib increased tumour recognition by T cells in an in vitro system 
using patient short-term cell lines and autologous TILs. However, this was 
directly attributed to increased MDA expression since melanoma cells were 
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pre-treated with minimal exposure of T cells to BRAF inhibitors (Donia et al., 
2012b). Thus, in an indirect manner, BRAF inhibitors can augment T cell 
recognition of tumour cells. 
BRAF inhibition has also been shown to induce increased tumour infiltration 
by T cells. In xenograft models of human melanoma, PLX4720 has been 
shown to promote tumour infiltration of adoptively transferred antigen-
specific T cells. Enhanced T cell infiltration was specific for BRAFV600E 
tumours, with no increase of TILs in BRAFWT tumours, and was attributed to 
decreased melanoma production of VEGF (Liu et al., 2013). Improved T cell 
infiltration of tumours has also been demonstrated in patients, with tumour 
biopsies showing increased numbers of CD8+ T cells after 10-14 days of 
Vemurafenib treatment when compared to baseline. Increased CD8+ T cell 
infiltration of tumours was accompanied by significantly higher expression of 
markers of cytotoxicity, with T cells demonstrating greater production of 
granzyme B and perforin (Frederick et al., 2013), although as has already been 
described, patient tumour samples exhibited increased melanoma antigen 
expression. Therefore, increased T cell infiltration and augmented effector 
function is potentially a result of both higher melanoma antigen expression 
and improved T cell recognition of tumours. Nonetheless, increases in TILs 
are not consistently observed with BRAF inhibitor treatment. In an inducible 
murine model of BRAFV600E melanoma, a decreased frequency of tumour 
resident T cells, NK cells, macrophages and MDSCs was observed following 
PLX4720 administration (Hooijkaas et al., 2012a). Ho and colleagues 
confirmed this finding in an independent study, which used a similar but 
independently developed mouse model of inducible BRAFV600E melanoma. 
Their results demonstrated no change in the frequency of effector TILs 
following PLX4720 treatment, but revealed increased CD4+ T cell expression 
of the effector molecules CD40L and IFNγ. Although effector T cell infiltration 
remained unaltered with PLX4720, reduced accumulation of Tregs and 
MDSCs was detected making it difficult to delineate if the increased CD4 
effector functionality was a direct result of BRAF inhibition or a product of a 
less suppressive microenvironment (Ho et al., 2014).  
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In addition to these ancillary effects of BRAF inhibitors on T cells, the direct 
impact of BRAF inhibition on T cell function has also been investigated. 
Dabrafenib treatment of human peripheral blood monocytes (PBMCs) in in 
vitro cultures demonstrated no direct cytotoxicity (Vella et al., 2014). There 
was also no effect on CD4+ or CD8+ T cell proliferation or effector functions as 
measured by IFNγ and IL-17 or IFNγ and TNFα production respectively 
(Vella et al., 2014). The effects of Vemurafenib in similar conditions were 
investigated by Comin-Anduix and colleagues, who showed Vemurafenib 
decreased viability of resting PBMCs with an IC50 of between 50 and 150 µM 
(variation in individuals was observed). Activated lymphocytes showed 
increased resistance to cytotoxic effects with no inhibition of viability, no 
effect on cell cycle progression and no induction of apoptosis at 
concentrations of up to 250 µM. At 50 µM increased pERK1/2 was detected in 
both CD4+ and CD8+ T cells but not in CD20+ B cells. IFNγ, IL-5 and IL-10 
release by CD4+ T cells in response to specific antigen recognition were 
unaffected at 1 and 10 µM Vemurafenib but were significantly decreased with 
50 µM treatment, although CTL-mediated killing was unaltered (Comin-
Anduix et al., 2010). Although the variation in drug concentrations makes it 
difficult to directly compare these results, the data indicate there may be a 
differential impact of Dabrafenib and Vemurafenib treatment when directly 
assessing T cell effects.  
The disparity in the effects of Dabrafenib and Vemurafenib on T cells has also 
been observed in vivo. A study by Schilling and colleagues evaluated the 
peripheral lymphocyte populations of 65 Dabrafenib-treated and 277 
Vemurafenib treated patients. Dabrafenib was found to have no effect on 
peripheral lymphocyte numbers, whilst Vemurafenib treatment was 
associated with a significant decrease of 24.3% in the total numbers of 
peripheral lymphocytes. This reduction was related to a selective decrease in 
CD4+ T cells, with CD8+ T cell and B cell numbers remaining unaffected, 
while NK cell numbers increased (Schilling et al., 2014). In contrast, in clinical 
trials of Vemurafenib, no lymphopaenia was observed. It is possible that the 
decrease in lymphocyte numbers measured in the study by Schilling et al. 
may have been subclinical. Alternatively, there may be variation between 
patients, or patient groups. Further confirmation of this study-to-study 
 50 
variation is evident in the effects observed by Gargett and colleagues. In 
contrast to the work by Comin-Anduix and Vella, these authors did not 
report differential effects of Dabrafenib and Vemurafenib treatment. This 
study directly compared the effects of Dabrafenib and Vemurafenib on T cell 
viability, activation and proliferation in vitro using healthy human PBMCs 
and T cells transduced with a tumour-specific CAR (Gargett et al., 2015). Cell 
growth, as measured in an ATP assay of unstimulated PBMCs and CAR T 
cells, was found to be unaffected by both inhibitors, with an IC50 ≥ 150 µM. In 
contrast to the results of Comin-Anduix et al., stimulated PBMCs showed 
increased sensitivity with IC50s ranging from 11-53 µM with Dabrafenib or 6-
42 µM with Vemurafenib, the variation depending on the method of 
stimulation. Both drugs at 50 µM significantly inhibited activation, as 
determined by CD25 expression, and proliferation, and Vemurafenib 
demonstrated some inhibition at 5 µM. Overall, both Vemurafenib and 
Dabrafenib had similar ability to adversely affect T cell viability and 
activation, although T cells may be more sensitive to Vemurafenib (Gargett et 
al., 2015). Collectively, these studies indicate variability in the effects of BRAF 
inhibition on T cells.  It appears Vemurafenib is more likely than Dabrafenib 
to have T cell selective inhibitory effects, which may be specific to CD4+ T 
cells and are highly concentration dependent. 
Despite the detrimental effects to T cells observed at relatively high inhibitor 
concentrations, it appears Vemurafenib and PLX4720 can have paradoxical 
effects with augmentation of T cell responses reported at lower 
concentrations. Callahan and colleagues demonstrated that PLX4720 could 
significantly increase in vitro T cell activation as determined by CD69 
expression. The augmented T cell activation was shown to be a direct result of 
BRAF inhibitor potentiation of MAPK signalling, as indicated by increased 
pERK expression. This PLX4720 enhanced T cell activation was concentration-
dependent, with beneficial effects evident in a dose range of 500 nM to 20 µM, 
with greatest CD69 and pERK expression detected at 5 µM and 2 µM 
respectively (Callahan et al., 2014). These findings were confirmed by Irving 
and colleagues who also demonstrated that PLX4720 enhanced TCR-driven 
proliferation in vitro. The same stimulatory effect was evident in vivo when 
BRAF inhibition was combined with vaccination for the treatment of BRAF 
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wild-type tumours (Irving et al., 2013). Collectively the current literature 
demonstrates that Vemurafenib and PLX4720 treatment can have indirect 
effects, which support anti-tumour T cell immunity, with enhanced tumour 
antigen expression and DC activation stimulating greater T cell recognition of 
tumours. The direct effects of both PLX4720 and Vemurafenib on T cell 
responses appear to be paradoxical, with variation observed between models 
and patients, and concentration dependent effects.  
1.7.4 BRAF inhibitor effects on melanoma-mediated immune 
suppression 
In addition to stimulating anti-tumour immunity, BRAF inhibitors can 
diminish the immune suppression associated with the tumour 
microenvironment. IL-6, IL-10 and VEGF play and immunosuppressive role 
in the tumour microenvironment, and BRAF inhibition has been shown to 
decrease BRAFV600E melanoma production of these factors in vitro (Sumimoto 
et al., 2006). Similar findings have been demonstrated in patients, with 
biopsies following Vemurafenib treatment exhibiting decreased levels of the 
immunosuppressive cytokines IL-6 and IL-8 when compared to pre-treatment 
biopsies, although no change was observed in IL-10 and TGFβ production 
(Frederick et al., 2013). BRAF inhibition not only reduces immune 
suppression by abrogating production of suppressive factors but also 
decreases the frequency of regulatory cell types. This has been demonstrated 
pre-clinically in an inducible model of BRAFV600E melanoma in two 
independent studies. Steinberg and colleagues demonstrated that PLX4720 
selectively decreased numbers and proportions of Tregs within the tumour 
after 10 days of treatment. This reduction in Tregs was not a result of reduced 
recruitment or increased conversion of Tregs to an alternate T helper subset. 
Rather, PLX4720 promoted loss of pre-existing Tregs through the induction of 
apoptosis. The numbers and frequencies of intratumoural MDSCs were also 
depleted with PLX4720 treatment, however this was not attributed to 
apoptosis and the underlying mechanism was not identified. In addition to a 
decreased MDSC population, the myeloid cells isolated from PLX4720-treated 
tumours have diminished suppressive function in vitro when compared to 
those from untreated tumours (Steinberg et al., 2014). Ho et al. demonstrated 
 52 
similar findings with reduced accumulation of Tregs and MDSCs within 
tumours following PLX4720 treatment. However, their data showed the 
decreased frequency of Tregs was a result of reduced recruitment or 
formation of inducible Tregs within the tumour. Likewise, the reduced 
proportions of MDSCs were attributed to decreased recruitment, which was 
IFNγ-dependent (Ho et al., 2014). Furthermore, a decrease in patient MDSCs 
has been reported following BRAF inhibition. Schilling and colleagues 
demonstrated detectable populations of monocytic-MDSCs (moMDSCs) and 
granulocytic-MDSCs (grMDSCs) within the PBMCs of patients with 
progressive melanoma. These peripheral MDSC populations suppressed 
autologous T cell proliferation in vitro. Following Vemurafenib treatment, 
patients had decreased frequencies of MDSCs within the blood, although the 
effect on intratumoural MDSCs could not be assessed (Schilling et al., 2013). 
Collectively, these studies demonstrate that BRAF inhibition ameliorates 
tumour-mediated immune suppression by reducing the production of soluble 
suppressive mediators and neutralizing immunosuppressive cell types.  
 Combining Vemurafenib with immunotherapy 1.8
The improved immune recognition and targeting of tumours evoked by 
BRAF inhibitor therapy, and diminished immunosuppression, suggest it may 
be possible to achieve synergy when combining BRAF inhibition with 
immunotherapies. Enhanced anti-tumour responses with BRAF inhibition 
and immunotherapy have been demonstrated in a number of pre-clinical 
models of melanoma. Koya and colleagues investigated combination of 
Vemurafenib and ACT in the SM1 model, using both C57BL/6 splenocytes 
transduced with the OTI TCR, which is specific for ovalbumin (OVA), in the 
SM1.OVA model and gp100 specific “pmel” in T cells in non OVA-expressing 
SM1. With both types of ACT, combination with Vemurafenib provided 
significantly increased anti-tumour activity and prolonged survival when 
compared to single-agent treatments. The mechanism of synergy was 
investigated using pmel ACT, in combination with Vemurafenib there was no 
change detected in T cell distribution or expansion of adoptively transferred 
cells. Furthermore, no increase in tumour antigen expression was evident. 
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The increased efficacy of combination therapy was attributed to increased 
cytotoxic effector functions of TILs, with Vemurafenib treatment increasing 
antigen-specific IFNγ production by adoptively transferred cells (Koya et al., 
2012). Hu-Lieskovan performed a similar study using the SM1 model and 
pmel ACT with the addition of BRAF inhibition using Dabrafenib. 
Combination of pmel ACT with Dabrafenib improved anti-tumour responses, 
as evidenced by a decrease in tumour growth. This combination therapy was 
associated with improved homing of effector T cells to the tumour and 
increased proportions of TILs. However, increased frequencies of 
intratumoural MDSCs, tumour associated macrophages and Tregs were also 
observed (Hu-Lieskovan et al., 2015). The benefit of Dabrafenib and pmel 
ACT combination was less striking than the synergy observed by Koya et al. 
with Vemurafenib. Perhaps the significant increase in suppressive cells within 
the tumour could have accounted for the sub-optimal efficacy of Dabrafenib 
combination. Combination of pmel ACT with PLX4720 was also investigated 
in xenograft models of human melanoma by Liu and colleagues, as 
previously mentioned. Combined therapy significantly enhanced anti-tumour 
activity resulting in reduced tumour size and prolonged survival. This 
increased efficacy was attributed to PLX4720 decreasing VEGF production by 
melanoma cells and inducing a less suppressive microenvironment. In 
patients, BRAF inhibition has also been demonstrated to cause 
downregulation of VEGF, which correlated with increased CD8+ TIL (Liu et 
al., 2013).  
Pre-clinical studies of BRAF inhibition with immunotherapy have not been 
limited to combination with adoptive T cell therapy: combined therapy with 
checkpoint blockade has also been examined. Cooper and colleagues 
developed a cell line from a tumour in an inducible BRAFV600E model, and 
investigated PLX4720 in combination with anti-PD-1 or anti-PD-L1. Both 
approaches improved therapy responses as measured by slowed tumour 
growth and significantly increased survival, with the benefit more 
pronounced when PLX4720 and anti-PD-L1 were administered together. In 
both combinations there was a significant increase of CD3+ TILs, 
predominantly CD8+ T cells, and this was accompanied by an improved ratio 
of CTLs to Tregs. With PLX4720 combination with anti-PD-1, but not anti-PD-
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L1, increased CTL effector function was detected with increased proportions 
of CD8+ T cells expressing Granzyme B, IFNγ and TNFα (Cooper et al., 2014).  
With pre-clinical evidence suggesting BRAF inhibition may enhance anti-
tumour immunity and independent mechanisms of action with minimal 
overlapping toxicities, Vemurafenib and Ipilimumab combination was 
progressed to a Phase I clinical trial. Initially the first six patients received 
both treatments at their maximum tolerated doses, with 960 mg of 
Vemurafenib given orally, twice daily and Ipilimumab delivered at 3 mg/kg 
every three weeks. However, this first cohort of patients experienced dose-
limiting toxic effects involving grade 3 elevation of hepatic enzymes. The 
second cohort of patients was enrolled on a lower dose of Vemurafenib (720 
mg twice daily, orally), with the Ipilimumab dose remaining the same as the 
original schedule. The first four patients treated in the second cohort also 
developed dose-limiting liver toxicities with grade 2 and grade 3 elevation in 
liver enzymes; thus the remaining two patients received single agent 
Vemurafenib. Following the significant hepatotoxicities associated with 
combination treatment the trial was closed to further patient accrual (Ribas et 
al., 2013). Despite the unanticipated, adverse side effects, there is some 
evidence that the combination of BRAF inhibition and anti-CTLA-4 
synergized to achieve enhanced tumour-specific, immune responses. In 
addition to exploring BRAF inhibitor combination with checkpoint blockade 
in pre-clinical models, Cooper et al. analysed tumour biopsies from a single 
patient who received combination Ipilimumab and Vemurafenib as part of 
the phase I clinical trial. Combination treatment enhanced tumour infiltration 
of CD8+ T cells, and achieved increased intratumoural CD8+ T cell:Treg ratio. 
These parameters of improved anti-tumour immunity were detected out to 
132 days after initiating Vemurafenib therapy, which was the final biopsy 
time point, indicating durable anti-tumour immune responses (Cooper et al., 
2014). The immunological outcome of combination therapy in this patient 
supports the hypothesis that BRAF inhibitors may enhance immune cell 
function to synergize with checkpoint blockade. However, the severe, 
unexpected toxicities reinforce the need for rigorous pre-clinical investigation 
and carefully conducted clinical trials of BRAF inhibitor and immunotherapy 
combinations.  
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 Aims 1.9
Collectively, the literature discussed so far demonstrates that while many 
recent breakthroughs have been made in the treatment of metastatic 
melanoma, further progress is required due to mutant-BRAF inhibitor 
resistance and low response rates to single-agent immunotherapy. Given the 
complementary mechanisms of action there is potential for mutant-BRAF 
inhibitors to synergize with immunotherapy, which provides a strong 
rationale for combination of these approaches. This potential has been 
realized in pre-clinical models combining adoptive cell transfer with BRAF 
inhibition, but has yet to be thoroughly investigated with other 
immunotherapeutic approaches. The unsuccessful attempt to combine 
checkpoint blockade and BRAF inhibition at maximum tolerated doses in 
clinical trial highlights the requirement for comprehensive pre-clinical 
investigation of combination therapies. There is a need for exploration of 
alternative immunotherapeutic approaches to be combined with BRAF 
inhibitors, with optimizing dose and sequence of treatments likely to play a 
pivotal role in the success of combination therapy. The variation reported in 
effects of BRAF inhibitors on T cell viability, proliferation and function also 
indicates the need for further clarification of the direct effects BRAF inhibitors 
have on immune cells.  
1.9.1 Specific Aims 
The research undertaken for this thesis sets out to achieve the following 
specific aims: 
• To assess the effects of mutant BRAF inhibitors on both human and 
murine T cell viability and responses in vitro. 
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• To determine the effects of mutant BRAF inhibition on antigen-specific 
immune responses in vivo, and on anti-tumour immune responses in 
vivo in a BRAF wild-type model of melanoma. 
• To optimize a mouse model of syngeneic, transplantable BRAFV600E 
melanoma, and develop a sub-optimal autologous whole tumour cell 
vaccine. 
• To investigate whether vaccination can complement the anti-tumour 
effects of mutant BRAF-targeted inhibitors in a murine model of 
BRAFV600E melanoma. Subsequently, lymphocyte infiltration of 
tumours and local lymphoid tissues will be explored to determine the 
effects of therapy on immune cell populations.  
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CHAPTER 2: Materials 
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 Materials  2.1
2.1.1 Labware 
Product Supplier/Distributor 
Axygen Micro Tubes 1.7 mL Axygen Scientific Inc., Union City, 
CA, USA 
BD 1 mL tuberculin syringes  BD Biosciences, Bedford, MA, USA 
BD Falcon 5 mL polystyrene 
round-bottom tubes with cell-
strainer caps 
BD Biosciences, Bedford, MA, USA 
BD Falcon polypropylene 15 and 
50 mL conical tubes 
BD Biosciences, Bedford, MA, USA 
BD Falcon tissue culture-treated  
175 cm2 Flasks 
BD Biosciences, Bedford, MA, USA 
BD Falcon Polystyrene tissue 
culture plates: 6, 12, 24 & 96-well 
plates and 96-well U-bottom plate 
BD Biosciences, Bedford, MA, USA 
Corning Costar 50 mL reagent 
reservoirs 
Sigma-Aldrich, St. Louis, MO, USA 
Corning Costar serological pipettes 
(5, 10 and 25 mL) 
Sigma-Aldrich, St. Louis, MO, USA 
Eppendorf tubes (0.5, 1.7 and 2 
mL) 
Sigma-Aldrich, St. Louis, MO, USA 
Feeding needles 18 gauge (G) Thermo Fisher Scientific, Auckland, 
NZ 
NuncTM cell culture-treated 25 cm2 
and 75 cm2 Flasks 
Thermo Fisher Scientific, Auckland, 
NZ 
Nylon Cell Strainers (70 µM) BD Biosciences, Bedford, MA, USA 
Nylon Gauze (70 µM) Sefar Filter Specialist, Nelson, NZ 
Pasteur pipetters (Sterile, 1 mL) Interlab, Wellington, NZ 
PrecisionGlideTM Needles (25 and 
27.5 G)  
BD Biosciences, Bedford, MA, USA 
Disposable carbon steel surgical 
blades 
Swann-Morton, Sheffield, UK 
Plastic 10 mL vaccutainers with 
spray-coated EDTA 
BD Biosciences, Bedford, MA, USA 
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2.1.2  Reagents and Buffers 
2.1.2.1  Cell culture reagents and buffers 
Product Supplier/Distributor 
5-(and-6)-carboxyfluorescein 
diacetate, succinimidyl ester (CFSE) 
Molecular Probes, Invitrogen, 
OR, USA 
Brefeldin A BioLegend, San Diego, CA, USA  
Bovine serum albumin (BSA) ICP Biologicals, New Zealand 
Carboxymethylcellulose (CMC) Sigma-Aldrich, St. Louis, MO, 
USA 
Collagenase Type IV from Clostridium 
histolyticum 
Sigma-Aldrich, St. Louis, MO, 
USA 
CompBead anti-mouse Ig, κ /Negative 
Control Compensation Particles Set 
BD Biosciences, Bedford, MA, 
USA 
CompBead anti-rat/hamster Ig κ 
/Negative Control Compensation 
Particles Set 
BD Biosciences, Bedford, MA, 
USA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, St. Louis, MO, 
USA 
Dimethylformamide (DMF) Thermo Fisher Scientific, 
Auckland, NZ 
DNase I Sigma-Aldrich, St. Louis, MO, 
USA 
UltraPure 0.5 M, pH 8.0 
Ethylenediaminetetraacetic acid 
(EDTA) 
Invitrogen, Life Technologies, 
Auckland, New Zealand 
Foetal Calf Serum (FCS) Sigma-Aldrich, St. Louis, MO, 
USA 
Geneticin® Selective Antibiotic (G418) GIBCO, Life Technologies, 
Auckland, New Zealand 
Glacial Acetic Acid Sigma-Aldrich, St. Louis, MO, 
USA 
GlutaMAXTM GIBCO, Life Technologies, 
Auckland, New Zealand 
Hanks Balanced Salt Solution (HBSS, 
1.4 M NaCl, 5.3 mM KCl, 4.2 mM 
NaHCO3, 0.44 mM KH2PO4, 0.34 mM 
NaH2PO4) 
GIBCO, Life Technologies, 
Auckland, New Zealand 
Human AB Serum – Heat Inactivated GIBCO, Life Technologies, 
Auckland, New Zealand 
Ionomycin Sigma-Aldrich, St. Louis, MO, 
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USA 
Iscove’s Modified Dulbecco’s Medium 
(IMDM) 
GIBCO, Life Technologies, 
Auckland, New Zealand 
Liberase TL Research Grade Roche, Mannheim, Germany 
LymphoPrep Axis-Shield, Norway 
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) 
Sigma-Aldrich, MO, USA 
Mycoplasma PCR Detection Kit Intron Biotechnology, Korea 
M-SolutionTM 1-2 Antibiotics  Intron Biotechnology, Korea 
Ovalbumin (OVA) Sigma-Aldrich, MO, USA 
OVA257-264 peptide (SIINFEKL) GenScript, NJ, USA 
Phorbol myristate acetate (PMA) Sigma-Aldrich, MO, USA 
Penicillin Streptomycin Invitrogen, New Zealand 
Dulbeccos Phosphate Buffered Saline 
(dPBS) 
GIBCO, Life Technologies, 
Auckland, New Zealand 
Red Blood Cell (RBC) lysis buffer Sigma-Aldrich, MO, USA 
RPMI-1640 GIBCO, Life Technologies, 
Auckland, New Zealand 
Sodium Azide (NaN3) Sigma-Aldrich, MO, USA 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, St. Louis, MO, 
USA 
Trypan blue (0.4% v/v) GIBCO, Life Technologies, 
Auckland, New Zealand 
TNFα Peprotech, NJ, USA 
Trypsin-EDTA (0.05%), phenol red GIBCO, Life Technologies, 
Auckland, New Zealand 
 
 
Complete IMDM (cIMDM) 
IMDM was supplemented with 10% FCS, 2 mM Glutamax, 100 U/mL 
penicillin and 100 µg/mL streptomycin. 
Complete RPMI (cRPMI) 
RPMI was supplemented with 10% FCS, 2 mM Glutamax, 100 U/mL 
penicillin and 100 µg/mL streptomycin.  
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SDS lysing buffer 
SDS and DMF were added to ddH2O to concentrations of 10% SDS and 45% 
DMF. The pH was adjusted to 4.7 using glacial acetic acid. Lysing buffer 
solution was stored at room temperature.  
 
Wurzburger buffer 
EDTA, FCS and DNase I were added to 500 mL dPBS to give final 
concentrations of 1% FCS, 0.5 M EDTA and 0.02 mg/mL. Buffer was stored at 
4 °C. 
2.1.2.2  Enzymes 
Collagenase IV 
Lyophilized enzyme was reconstituted at 50 mg/mL in dPBS, aliquoted and 
stored at -20 °C. 
DNase I 
Lyophilized enzyme was resuspended in pre-warmed IMDM and agitated to 
reconstitute to a concentration of 10 mg/mL. Reconstituted enzymes were 
used stored at -80 °C.  
Liberase TL 
Lyophilized enzyme was stored at -20 °C for long-term storage. Prior to use 
enzymes were resuspended in pre-warmed IMDM and agitated to 
reconstitute to a concentration of 1 mg/mL. Reconstituted enzymes were 
used immediately or stored at -80 °C for up to three months.  
2.1.2.3 Peptides/Antigens 
α-Galactosylceramide (αGalCer) 
αGalCer was manufactured by the Ferrier Research Institute, and was 
reconstituted in sterile dH2O at 0.5 mg/mL. Reconstituted αGalCer was 
stored a 4 °C. 
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OVA 
OVA was reconstituted in sterile dH2O, creating a stock concentration of 50 
mg/ml. Reconstituted stocks were stored in aliquots -80 °C. 
 
SIINFEKL 
SIINFEKL was dissolved in DMSO to give a stock concentration of 50 mM. 
Aliquots of reconstituted stocks were stored at -20 °C.  
2.1.2.4 Cytokines 
IFNγ  
IFNγ was harvested from in-house X63-IFNγ hybridoma cultures and used 
neat. 
Human recombinant Interleukin 2 (rIL-2) 
rIL-2 under the brand name Proleukin was sourced from Prometheus 
Laboratories, Inc., San Diego, CA, USA. rIL-2 was aliquoted and stored at -80 
°C. 
TNFα 
TNFα was reconstituted in dH2O containing 0.1% BSA at 100 µg/mL. 
Aliquots were stored at -80 °C. 
2.1.2.5 Purified Antibodies 
Rat anti-mouse CD25 (Clone PC61) 
Anti-mouse CD25 was affinity-purified in house from hybridoma culture 
supernatants using protein G-Sepharose columns. 
Rat anti-mouse CD3 (Clone 2C11) 
Anti-mouse CD3 was affinity-purified in house from hybridoma culture 
supernatants using protein G-Sepharose columns. 
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Rat anti-mouse CD16 (FcεRIII)/CD32 (FcεRII) (Clone 2.4G2) 
!Anti-mouse CD16 (FcεRIII)/CD32 (FcεRII) was affinity-purified in house 
from hybridoma culture supernatants protein G-Sepharose columns. 
 Hamster anti-mouse CD28 (Clone 37.51) 
Anti-mouse CD28 was harvested from in house hybridoma cultures and used 
neat.  
Mouse anti-human CD3ε 
Lyophilized mouse anti-human CD3 epsilon MAb, clone UCHT1 (R&D 
systems, MN, USA) was reconstituted at 0.5 mg/mL in sterile dPBS and 
aliquoted. Aliquots were stored at 4 °C for short-term use (up to 1 month), or 
at -20 °C for long-term storage.  
Mouse anti-human CD28 
Lyophilized mouse anti-human CD28 MAb, clone 37407 (R&D systems, 
MN, USA) was reconstituted at 0.5 mg/mL in sterile dPBS and aliquoted. 
Aliquots were stored at 4 °C for short-term use (up to 1 month), or at – 20 
°C for long-term storage.  
2.1.2.6 Inhibitors 
Etanercept 
Etanercept (Enbrel®, Pfizer, NY, USA) was resuspended at 25 mg/mL in 
sterile water and stored at 4 °C in the dark. 
PLX4720 
PLX4720 was generously provided by Gideon Bollag, Plexxikon. PLX4720 
powder was stored in the dark at room temperature long-term. For in vitro 
applications PLX4720 was dissolved in DMSO to give a stock solution of 100 
mM, and aliquots were stored at -80 °C. 
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Sorafenib 
Sorafenib (Sorafenib Tosylate, Selleck, TX, USA) was reconstituted in DMSO 
to give a stock solution of 100 mM and aliquots of stock were stored at -80 °C. 
Vemurafenib 
Vemurafenib was generously provided by Gideon Bollag, Plexxikon. 
Vemurafenib powder was stored in the dark at room temperature. For in vitro 
applications Vemurafenib was dissolved in DMSO to give a stock solution of 
100 mM, aliquots were stored at -80 °C.  
2.1.2.7 Flow cytometry reagents 
Annexin V staining buffer 
Annexin V 10x binding buffer (BD Biosciences, Bedford, MA, USA) was 
stored at 4 °C and diluted immediately prior to use 1:10 in dH2O. 
CFSE 
CFSE was reconstituted at 10 mM in DMSO and stored at -20 °C. 
DAPI 
DAPI was reconstituted at 2 µg/mL in deionised (MilliQ) water, and vortexed 
to dissolve. DAPI was then aliquoted and stored at -20 °C for long-term 
storage, and at 4 °C for short-term storage. 
Flow buffer (with Sodium Azide) 
FCS, NaN3 and EDTA were added to 500 mL dPBS to give final 
concentrations of 1% FCS, 0.01% NaN3 and 2 mM EDTA. The buffer was 
stored at 4 °C. 
Flow buffer (Sodium Azide free) 
FCS was added to 500 mL dPBS to give a final concentration of 1%. The buffer 
was stored at 4 °C. 
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FoxP3 Transcription Factor Staining Set 
The FoxP3 transcription factor staining set (Affymetrix, eBioscience San 
Diego, CA, USA) was stored at 4 °C. 4x Fixation/Permeabilization 
Concentrate was diluted 1:4 in Fixation/Permeabilization Diluent 
immediately prior to use. 10x Permeabilization Buffer was diluted 10-fold in 
dH20 immediately prior to use, or diluted and stored at 4 °C. 
2.1.2.8 Human flow cytometry antibodies 
Specificity Fluorophore Clone Supplier 
CD3ε APC-H7 SK7 BD Pharmingen 
CD3 PE-Cy7 HIT3a BioLegend 
CD4 APC RPA-T4 BioLegend 
CD8 PE HIT8a BioLegend 
CD69 AlexaFluor700 
(AF700) 
FN50 BioLegend 
IgG isotype - - Invitrogen 
2.1.2.9 Murine flow cytometry antibodies 
Specificity Fluorophore Clone Supplier 
Annexin V APC -  BD Pharmingen 
CD1d PE 1B1 BioLegend 
CD3ε BUV395 145-2C11 BD Horizon 
CD3ε FITC 145-2C11 BioLegend 
CD3ε PE 145-2C11 BD Horizon 
CD3ε PE-Cy7 145-2C11 EBioScience 
CD4 APC-Cy7 GK1.5 BD Pharmingen 
CD8α Pacific Blue 53-6.7 BD Pharmingen 
CD8α PE-CF594 53-6.7 BD Horizon 
CD11b APC M1/70 BioLegend 
CD44 APC IM7 BD Pharmingen 
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CD45 BV786 30-F11 BD Horizon 
CD45.1 PE A20 BioLegend 
CD62L PE MEL-14 BD Pharmingen 
CD279 (PD-1) BV421 J43 BD Horizon 
F4/80 BV605 BM8 BioLegend 
FoxP3  FITC FJK-16s eBioscience 
IFNγ PE XMG1.2 BioLegend 
IgG1, κ, 
isotype control 
BV421 RTK2071 BioLegend 
I-A/I-E (MHC 
II) 
PE-Cy7 M5/114.15.2 BioLegend 
Ly6C BV421 AL-21 BD Horizon 
Ly6G PE 1A8 BD Horizon 
NK1.1 BV650 PK136 BD Horizon 
PD-L1 BV711 MIH5 BD Horizon 
TNFα BV421 MP6-XT22 BioLegend 
Vα2 APC B20.1 BioLegend 
 
2.1.2.10 Flow viability dyes 
Name Source 
4',6-diamidino-2-phenylindole 
(DAPI) 
Invitrogen, New Zealand 
Live Dead Fixable Blue (LDFB) Life Technologies 
 
2.1.3 Cell lines 
2.1.3.1 Human cell lines 
The melanoma cells lines A375, SK-mel-5, LM-mel-15, LM-mel-34 and LM-
mel-62 were obtained from frozen stocks of the Cancer Cell and Molecular 
Biology group, Malaghan Institute of Medical Research.  
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The LM-mel cell lines were originally obtained courtesy of the Ludwig 
Institute, Melbourne, Australia. 
2.1.3.2 Murine cell lines 
The melanoma cell lines B16 and B16.Ova were obtained from frozen stocks 
of the Cancer Cell and Molecular Biology Group, Malaghan Institute of 
Medical Research.  
The primary murine melanoma cell lines YUMM1.1 and YUMM1.7 were 
generously provided by Associate Professor Marcus Bosenberg, Yale School 
of Medicine. 
2.1.4 Mice 
2.1.4.1 Maintenance and ethical approvals 
Mice were either ordered from the Jackson Laboratory (Bar Harbour, ME, 
USA) or bred in the Biomedical Research Unit at the Malaghan Institute of 
Medical Research.    
All mice were maintained in the Biomedical Research Unit of the Malaghan 
Institute of Medical Research.  
Experimental procedures were performed with the approval of the Victoria 
University Animal Ethics Committee, and carried out according to 
institutional guidelines. 
2.1.4.2 Mouse Strains 
C57BL/6 mouse strain 
C57BL/6 mice were from breeding pairs originally obtained from the Jackson 
Laboratory (Bar Harbour, ME, USA). 
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FoxP3 GFP mouse strain 
The B6x(Foxp3GFP-g2) mice, commonly referred to as FoxP3 GFP mice, have the 
eGFP construct knocked in to the first coding frame of the Foxp3 gene. As a 
result this allele encodes a chimeric GFP-FoxP3 fusion protein (FoxP3GFP) 
(Fontenot et al., 2005). These mice were from breeding pairs originally kindly 
provided by Prof. A Rudensky, University of Washington, USA. 
B6.SJ-OTI mouse strain 
The transgenic OTI mice (OT-I x B6.SJL-PtprcaPepcb/BoyJ) express the Vα2 
Vβ5 T cell receptor designed to recognize OVA residues 257-264, rendering 
the majority of CD8+ T cells in the periphery OVA-specific (Hogquist et al., 
1994). The breeding pairs for these mice were originally obtained with 
permission from of F. Carbone, Melbourne University, Australia.  
B6Aa0 mouse strain 
MHC Class II-deficient B6Aa0/Aa0 (B6Aa0) mice initially generated by 
Köntgen and colleagues (Kontgen et al., 1993), were from breeding pairs 
originally obtained from the Biological Research Laboratories Ltd. 
Wolferstrasse 4, Switzerland.  
TAP-/- mouse strain 
TAP1 deficient (TAP-/-) mice, which lack peptide transport to MHC Class I 
and thus are deficient in CD8+ T cell responses, were also used, and were 
initially generated by Van Kaer and colleagues (Van Kaer et al., 1992). 
NOD/Scid mouse strain 
NOD/Scid (severe combined immune deficiency on a non-obese diabetic 
background) mice, which have impaired T and B cell development (Schultz et 
al., 1995), were from breeding pairs initially obtained from the Hercus-Taieri 
Research Unit, University of Otago, New Zealand.  
Mice strains were maintained by brother x sister mating. Mice between 6-14 
weeks of age with gender-matched controls were used for all experiments.  
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 Methods 2.2
2.2.1 Cell culture techniques 
2.2.1.1 General cell culture 
Cell culture took place in PC2 facilities at the Malaghan Institute of Medical 
Research, Wellington. Cell work was carried out in Class II (HERAsafe, 
Heraeus, Germany) biological safety cabinets with HEPA air filters. Cells 
were incubated in a humidified environment at 37 °C in 5% CO2 (HERAcell 
incubator, Heraeus, Germany).  
All tumour cell lines were grown cRPMI, except B16.Ova. B16.Ova cells were 
cultured in cIMDM containing 0.5 mg/mL Geneticin.	  
Tumour cells were passaged once they reached 70-80% confluence. Medium 
was removed and cells washed with sterile dPBS. To detach cells Trypsin-
EDTA was added and cells were incubated for 2-4 minutes at 37 °C. 
Following detachment 7 mL complete medium was added to stop proteolysis 
and cells were washed and replated. 
2.2.1.2 Harvesting adherent tumour cells 
To harvest adherent tumour cells medium was removed from cultures and 
cells were washed with sterile dPBS. Trypsin-EDTA was added and 
incubated for 2-4 minutes at 37 °C. After cell detachment 7 mL medium was 
added to stop proteolysis. Cells were washed with complete medium and a 
single cell suspension was generated for subsequent use. 
2.2.1.3 Mycoplasma testing 
Cultured cells were tested every 3-6 months for mycoplasma contamination 
using the Intron Mycoplasma PCR Detection Kit, as per the manufacturer’s 
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instructions. Cells were also tested for mycoplasma prior to freezing down to 
ensure frozen stocks were mycoplasma-free. 
2.2.1.4 Mycoplasma treatment 
Cell lines that tested positive for mycoplasma were treated with the M-
SolutionTM 1-2 Antibiotics, if no mycoplasma free stocks were available.  
Cells were cultured in the presence of cRPMI containing M1 antibiotic (a 
Tiamutin-like antibiotic) for 4 days. Cells were then harvested, washed and 
replated in M2 antibiotic (a Minocycline derivative) for 3 days. This cycle was 
repeated twice. Cells were then cultured in antibiotic free media for a week 
before being re-tested. All contaminated cells were cleared through this 
process. 
2.2.2 Cell isolation/purification 
2.2.2.1 Isolation of human peripheral blood mononuclear cells (PBMCs) 
from whole blood 
Blood was taken from healthy volunteers by a trained phlebotomist under the 
Malaghan Institute of Medical Research ethics approval. Blood was diluted 
1:1 with sterile dPBS. Overlaying 8-10 mL of the diluted blood admixture on 
to 5 mL of Lymphoprep, in 50 mL conical tubes, isolated PBMCs. These 
overlays were centrifuged at 300 xg for 25 minutes with no brake at room 
temperature. The buffy coat was collected using transfer pipettes and 
transferred to 50 mL conical tubes. The buffy coat was washed by the 
addition of 20-40 mL serum-free RPMI (sfRPMI), after which it was 
centrifuged at 500 xg at room temperature for 5 minutes. The pellet was then 
washed twice with 10 mL sfRPMI. 
PBMCs were frozen down in a 10% DMSO and 90% FCS solution, in a 
Nalgene® Mr. Frosty at -80 °C. PBMCs were then stored in liquid nitrogen. 
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2.2.2.2 Preparation of murine lymphocyte single cell suspensions 
Blood 
Lateral tail vein bleeding was performed on mice and 6-8 drops of blood were 
collected into 1.7 mL Eppendorf tubes containing 200 µL of dPBS with 10 mM 
EDTA. RBC lysis was performed; 500 µL of RBC lysis buffer was added and 
samples were incubated for 10-15 minutes at 37 °C. Samples were centrifuged 
at 400 xg for 5 minutes and washed once with dPBS. 
Lymph Nodes (LN) 
LN were harvested into cIMDM, then mashed through a 70 µM filter using a 1 
mL syringe plunger. Cells were washed with dPBS if processing for flow 
cytometry or with Wurzburger buffer for sterile applications and centrifuged 
at 400 xg for 5 minutes. LN cells were then resuspended in the appropriate 
buffer or media for their application and kept on ice until further use.   
Spleen 
Spleens were harvested into cIMDM, then mashed through a 70 µM filter 
using a 1 mL syringe plunger. Cells were washed with dPBS if processing for 
flow cytometry or with Wurzburger buffer for sterile applications and 
centrifuged at 400 xg for 5 minutes. Splenocytes were resuspended in 2 mL of 
RBC lysis buffer and incubated at 37 °C for 5-10 minutes, RBC lysis was 
quenched with 8 mL cold cIMDM and washed once. Cells were resuspended 
in the appropriate buffer or media for their application, and kept on ice until 
further use.  
2.2.2.3 Magnetic Cell Separation (MACs) 
Lymphocyte suspensions were prepared from OTI spleens and lymph nodes 
(2.2.2.2) and enriched for CD8+ T cells using the MACs Dynabead system.  
Cells were resuspended at 1 x 108/mL in Wurzburger buffer and 50 µL of 
FlowComp anti-CD8 Antibody was added per 108 cells. The cell-antibody 
mixture was incubated at 4 °C for 10 minutes. Cells were washed with 
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Wurzburger buffer and resuspended in 1 mL of buffer. 150 µL of FlowComp 
Dynabeads was added per 108 cells and incubated at 4 °C for 15 minutes, 
mixing every 5 minutes. The tube was placed in the Dynabead magnet for at 
least 1 minute before removing the negative fraction. The cells were 
resuspended in 1 mL of buffer and the magnet step was repeated. The 
positive fraction was then resuspended in 1 mL FlowComp Release Buffer 
and incubated for 10 minutes at room temperature. The tube was again 
placed in the Dynabead magnet for at least 1 minute, following which the 
cells were collected. 
2.2.3 Viability assays 
2.2.3.1 Trypan blue exclusion 
Cells were harvested as described in 2.2.1.2 to assay for viability. Following 
harvest cells were resuspended in complete media and 10 µL of cell 
suspension was mixed with 10-90 µL of Trypan blue. Within 5-10 minutes of 
mixing 10 µL of the cell and trypan blue mixture was loaded in a Neubauer 
haemocytometer (Hawksley, Lancing, UK). The cell numbers were counted 
using an inverted microscope (CK2; Olympus, PA, USA). To determine 
viability unstained (viable) and stained (dead) cells were counted, and 
percentage viability was calculated.  
2.2.3.2 Annexin V apoptosis assays 
Exponentially growing cells were harvested (2.2.1.2). Cells were then seeded 
at a density of 1 x 105 cells per well in a 12-well plate and were incubated at 37 
°C in 5% CO2 for 6 hours to adhere. BRAF inhibitors were added at a range of 
concentrations and the plates were incubated for a further 12-36 hours at 37 
°C in 5% CO2 for inhibitor action to take effect. 6 hours prior to harvesting 
plates 5 µM Staurosporine (diluted in cRPMI) was added to a control well, to 
provide a positive control for apoptosis. 
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Following drug treatment supernatant was collected from wells, and cells 
were harvested as described above. The supernatant and cells were 
combined, and centrifuged at 400 xg for 5 minutes. Annexin V staining for 
phosphatidylserine expression was undertaken (2.2.7.2) and cell expression 
was measured by flow cytometry (2.2.7.7). 
2.2.4 MTT dye reduction assay 
The colourimetric MTT assay was used to measure enzymatic reduction of  
MTT. The yellow MTT dye is reduced to blue formazan crystals by 
metabolically active cells, therefore the intensity of the blue colour was used 
as an indication of the number of live cells (Berridge et al., 1996). 
Exponentially growing cells were harvested (2.2.1.2). Cells were then seeded 
at a density of 0.5-1 x 104 cells per well in a 96-well, flat-bottom plate and were 
incubated overnight at 37 °C in 5% CO2 to adhere. Inhibitors were added at a 
range of concentrations and the plates were incubated for a further 48 hours 
at 37 °C in 5% CO2 for inhibitor action to take effect. Dye reduction was 
initiated by adding 20 µL of 2.5 mg/mL MTT dissolved in HBSS to each well, 
plates were then incubated for 2 hours. Cells were lysed with 100 µL of SDS 
lysing buffer added to each well and incubated for 24 hours. MTT reduction 
was measured at an absorbance of 570 nm using a multi-well plate reader 
(FLUOstar Optima, BMG, Labtech, Australia). 
2.2.5 Characterization of tumour cell surface markers 
2.2.5.1 CD1d expression 
Exponentially growing cells were harvested as described in 2.2.1.2. After 
generating a single cell suspension extracellular staining with α-CD1d-PE was 
performed (2.2.7.1) and expression was assessed by flow cytometry (2.2.7.7). 
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2.2.5.2 IFNγ and TNFα exposure and cell-surface marker expression 
Exponentially growing cells were harvested (2.2.1.2) and seeded at a density 
of 5 x 104 cells per well in a 24-well plate. IFNγ was added to give final 
concentrations of 500 U/mL to 31.25 U/mL, or TNFα was added to give final 
concentrations of 100 ng/mL to 6.25 ng/mL. Control wells received complete 
medium alone. Cells were incubated in the presence or absence of cytokines 
for 48 hours. Subsequently, cells were again harvested (2.2.1.2) and 
extracellular staining with α-PDL1-BV711 and α-MHCII-PE-Cy7 was 
performed (2.2.7.1). Marker expression was assessed by flow cytometry 
(2.2.7.7). 
2.2.6 Proliferation assays 
2.2.6.1 One-way Mixed Lymphocyte Reaction  
One-way mixed lymphocyte reactions combine allogeneic PBMCs, with the 
PBMCs from one donor sub-lethally irradiated to serve as stimulator cells 
while the other donor’s PBMCs are labelled to allow proliferative responses to 
be measured. 
PBMCs were either used fresh following isolation (2.2.2.1) or frozen PBMCs 
were thawed at 37 °C in the waterbath and transferred to 15 mL conical tubes 
containing pre-warmed cRPMI with 20% FCS. PBMCs were washed, 
resuspended in cRPMI and rested for 4 hours or overnight at 37 °C in 5% CO2. 
Stimulator PBMCs were washed and resuspended in serum-free RPMI then γ-
irradiated with 30 Gray (Scheffer et al.) (Gammacell® 1000 Elite irradiator, 
Best Theratronics, Canada). Following irradiation cells were centrifuged at 
500 xg for 5 minutes and resuspended at 4 x 106 cells/mL in cRPMI 
supplemented with 100 U/mL rIl-2. 
Responder PBMCs were stained with 0.4 µM CFSE (2.2.7.3) before being 
washed twice with cRPMI and resuspended at 4 x 106 cells/mL in cRPMI 
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supplemented with 100 U/mL rIL-2. In a 96-well U-bottom tissue culture 
plate, 50 µL of responder and stimulator cells were added to each well to give 
2 x 105 each cell type/well. PLX4720 or Vemurafenib was diluted to 2x the 
final desired concentration in cRPMI, and 100 µL of inhibitor or 0.2% DMSO 
control was plated out. 
The plate containing PBMCs, a range of concentration of inhibitors, vehicle 
and unstimulated controls was incubated at 37 °C in 5% CO2 for 7 days. Cells 
were then harvested and extracellular staining with α-CD3 PE-Cy7, α-CD4 
APC and α-CD8 PE was performed (2.2.7.1). T cell proliferation was measured 
by flow cytometry (2.2.7.7). 
2.2.6.2 α-CD3/28 assays 
Human 
PBMCs were either used fresh following isolation (2.2.2.1) or frozen PBMCs 
were thawed at 37 °C in the waterbath and transferred to 15 mL conical tubes 
containing pre-warmed cRPMI with 20% FCS. PBMCs were washed, 
resuspended in cRPMI and rested for 4 hours or overnight at 37 °C in 5% CO2. 
Antibodies to human CD3ε and CD28 were diluted to 3-5 µg/mL and 0.5 
µg/mL respectively in dPBS. The diluted antibody mixture was distributed to 
the wells of a 96-well U bottom plate in 50 µL aliquots. Control wells for 
unstimulated samples received 50 µL of dPBS. The plate was incubated at 37 
°C for 2-3 hours to facilitate antibody binding to the plate.  
Following resting the PBMCs were washed and a small number were 
reserved on ice as unstained controls. The remaining PBMCs were stained 
with 0.4 µM CFSE (2.2.7.3). CFSE-stained PBMCs were resuspended in cRPMI 
supplemented with 40 U/mL rIL-2 at 1 x 106 cells/mL. The pre-coated 96-well 
plate was removed from the incubator and the antibody suspension 
discarded. α-CD3/28 coated wells were washed twice with dPBS to remove 
unbound antibody. PBMCs were plated out at 1 x 105 cells per well. PLX4720 
 76 
or Vemurafenib was diluted to 2x the final desired concentration in cRPMI, 
and 100 µL of inhibitor or 0.2% DMSO control was plated out. 
The plate containing PBMCs treated with a range of concentrations of 
inhibitors, as well as vehicle and unstimulated controls was incubated at 37 
°C in 5% CO2 for 3 days. Cells were then harvested, and extracellular staining 
with α-CD3 PE-Cy7, α-CD4 APC, α-CD8 PE and α-CD69 AF700 was 
performed (2.2.7.1). T cell proliferation and activation was measured by flow 
cytometry (2.2.7.7). 
Murine 
Murine CD3 antibody was diluted to 1 µg/mL in dPBS and distributed to the 
wells of a 96-well U bottom plate in 50 µL aliquots. Control wells for 
unstimulated samples received 50 µL of dPBS. The plate was incubated for 4 
hours at 37 °C or overnight at 4 °C to facilitate antibody binding to the plate.  
C57BL/6 mice were euthanized by CO2 asphyxiation and spleens were 
harvested into 3mL IMDM and kept on ice. Single cell splenocyte suspensions 
were prepared from C57BL/6 spleens as described in 2.2.2.2.  Splenocytes 
were then counted and 4 x 106 cells were resuspended in 2 mL cIMDM and 
kept on ice to be plated out as unstained, or single stained controls.  
Splenocytes were stained with 0.4µM CFSE (2.2.7.3). Following CFSE staining 
splenocytes washed with cIMDM and counted. 2 x 106 cells were resuspended 
in 1 mL cIMDM as unstimulated controls. The remaining CFSE positive cells 
were resuspended at 2 x 106 cells/mL in cIMDM supplemented with murine α-­‐CD28 at 1:50 and rIL-2 at 400 U/mL.  
The pre-coated 96-well plate was removed from the incubator and the 
antibody suspension discarded. α-CD3 coated wells were washed twice with 
dPBS to remove unbound antibody. Splenocytes were plated out at 2 x 105 
cells per well. PLX4720 or Vemurafenib was diluted to 2x the final desired 
concentration in cIMDM, and 100 µL of inhibitor or 0.2% DMSO control was 
plated out. 
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The plate containing splenocytes treated with a range of concentrations of 
inhibitors, as well as vehicle and unstimulated controls was incubated at 37 
°C in 5% CO2 for 3 days. Cells were then harvested and extracellular staining 
with α-CD3 PE-Cy7 and α-CD69 PE was performed (2.2.7.1). T cell 
proliferation and activation was measured by flow cytometry (2.2.7.7). 
2.2.7 Fluorescent labelling of cells and analysis by flow 
cytometry 
2.2.7.1 Staining for extracellular marker expression 
Human 
Single cell suspensions were prepared or harvested, washed once with flow 
buffer and resuspended in 50–200 µL flow buffer. The cell suspension was 
then distributed to the wells of a 96-well U bottom plate. Plates were 
centrifuged at 400 xg for 4 minutes and supernatants were tipped off by 
flicking once. Pellets were resuspended in residual volume by vortexing. 25 
µL of flow buffer containing FC receptor blocking IgG antibody was added 
and samples were incubated on ice for 20 minutes. Following FC receptor 
blocking samples were again centrifuged, supernatants discarded and pellets 
resuspended as described above. 25 µL of flow buffer containing 
fluorescently-conjugated antibodies at the appropriate dilutions was added to 
samples and the plate was again vortexed, then incubated on ice for 20 
minutes. After staining cells were washed once, then resuspended in 200 µL 
of flow buffer containing DAPI at 0.1 µg/mL for analysis by flow cytometry. 
Murine 
Single cell suspensions were prepared or harvested, washed once with flow 
buffer and resuspended in 50–200 µL flow buffer. The cell suspension was 
then distributed to either the wells of a 96-well U bottom plate or FACS tubes 
for staining. Samples were centrifuged at 400 xg for 4 minutes, and 
supernatants were tipped off plates by flicking once or aspirated from tubes. 
Pellets were resuspended in residual volume by vortexing. 50 µL of flow 
buffer containing FC receptor blocking 2.4G2 antibody at 10 µg/mL was 
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added, and samples were incubated on ice for 20 minutes. Samples were 
again centrifuged, supernatants discarded and pellets resuspended as 
described above. Cells were resuspended in 50 µL of flow buffer containing 
fluorescently-conjugated antibodies at the appropriate dilutions. Samples 
were incubated on ice for 20-30 minutes. Cells were then washed once with 
200 µL flow buffer, then resuspended in 200 µL of flow buffer containing 
DAPI at 0.1 µg/mL, for analysis by flow cytometry, or progressed to 
intracellular staining.  
Antibody titrations 
All antibodies were titrated prior to use. Antibody titrations were performed 
on the cells or tissues that would be used experimentally, and under 
experimental conditions.  
 
2.2.7.2 Detection of apoptosis markers  
Cells were harvested (2.2.1.2 for adherent cells) and washed once with 
Annexin V Binding Buffer (binding buffer). The cell pellet was resuspended 
in 50 µL of Annexin V APC diluted at 1:100 in binding buffer, and cells were 
stained for 15 minutes at room temperature in the dark. After staining cells 
were washed once with binding buffer, then resuspended in 200 µL of flow 
buffer containing DAPI at 0.033 µg/mL, and transferred to FACS tubes for 
flow cytometry (2.2.7.7). 
2.2.7.3 Labelling of cells with CFSE 
CFSE is a non-toxic, fluorescent dye that readily crosses intact cell membranes 
and binds to intracellular proteins in live cells. As cells proliferate the CFSE is 
divided equally between daughter cells, and the resulting halving of 
fluorescence can be used to measure generations of cell division (Lyons and 
Parish, 1994). 
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Single cell suspensions were prepared, washed once with dPBS and 
resuspended in 2 mL of dPBS. 10 mM CFSE was thawed and diluted 1:20,000 
in cold dPBS. 8 mL of diluted CFSE was added to the cell suspension and 
vortexed to ensure even staining with a final concentration of 0.4 µM CFSE. 
Cells were stained for 8 minutes in the dark at room temperature. The 
labelling reaction was then stopped with the addition of 10 mL of pre-
warmed FCS and cells were centrifuged at 500 xg for 4 minutes. Following 
labelling cells were washed twice with complete media, counted and 
resuspended at the required concentration for the specific assay.  
2.2.7.4 Intracellular transcription factor staining 
Cells were stained with the viability dye Live Dead Fixable Blue (LDFB) at 
1:1000 and blocked with 2.4G2 antibody at 10 µg/mL in 50 µL dPBS on ice for 
30 minutes. 100-500 µL of flow buffer was then added and samples were 
centrifuged at 400 xg for 4 minutes. Surface staining was performed as 
described in 2.2.7.1, and cells were washed in flow buffer. Fixing and 
permeabilisation was performed using the FoxP3 Transcription Factor 
Staining Buffer Set to allow for intracellular staining. Cells were fixed by 
incubating in 200-500 µL of 1x Fix/Perm for 60 minutes to 18 hours at 4 °C in 
the dark. Without washing 200-500 µL of 1 x Perm Buffer was added and 
samples were centrifuged at 300-400 xg for 5 minutes. The cell pellet was 
resuspended in 50 µL of flow buffer containing anti-mouse FoxP3 FITC at 
1:250. 
2.2.7.5 Ex vivo restimulation 
Prior to staining for intracellular cytokines, cells were plated out in 96- or 24-
well plates at approximately 5 x 106 cells/mL in cIMDM. PMA and ionomycin 
were added to give final concentrations of 50 ng/mL PMA and 500 ng/mL 
Ionomycin. Cells were incubated at 37 °C, and after 2 hours 3 µg/mL of 
Brefeldin-A was added to prevent cytokine secretion. Cells were incubated 
for a further 2 hours after the addition of Brefeldin-A, then harvested, 
transferred to FACS tubes and washed in dPBS. 
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2.2.7.6 Detection of intracellular effector molecules 
After re-stimulation, cells were stained with the viability dye LDFB at 1:1000 
and blocked with 2.4G2 antibody at 10 µg/mL in 50 µL dPBS on ice for 30 
minutes. 100-500 µL of flow buffer was then added and samples were 
centrifuged at 400 xg for 4 minutes. Cells were stained with antibodies to 
extracellular markers as described in 2.2.7.1, and then washed in flow buffer. 
Fixing and permeabilisation was performed using the FoxP3 Transcription 
Factor Staining Buffer Set to allow for intracellular staining. Cells were fixed 
by incubating in 200-500 µL of 1x Fix/Perm for 60 minutes to 18 hours at 4 °C 
in the dark. Without washing 200-500 µL of 1 x Perm Buffer was added and 
samples were centrifuged at 300-400 xg for 5 minutes. The cell pellet was 
resuspended in 50 µL of flow buffer containing fluorescently-conjugated 
antibodies against intracellular markers at the appropriate dilutions. 
Following staining cells were washed once with flow buffer, and then 
resuspended for acquisition.  
2.2.7.7 Acquisition  
Samples were analysed on an LSR-II special order product (BD) with BD 
FACS Diva software. Cytometer set-up and tracking was performed daily to 
ensure calibration.  
The LSR-II was equipped with the following lasers and detectors: Ultraviolet 
laser (355 nm) UV740/35, UV450/50 and UV379/28.  Violet laser (405 nm) 
V780/60, V720/40, V660/20, V605/40, V560/40, V525/50 and V450/50. Blue 
laser (488 nm) B705/70, B515/20 and B488/10. Green laser (532 nm) G780/60, 
G610/20 and G575/26. Red laser (640 nm) R780/60, R710/50 and R670/14. 
All fluorophores were detected using laser and detector combinations that 
best matched their emission and excitation profile. 
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2.2.7.8 Compensation 
To allow accurate compensation, single stain controls were stained under the 
same conditions as experimental samples. Compensation beads were singly 
stained with the antibody-fluorophore conjugates used in the experimental 
staining panel. Unstained samples consisted of cells that had been cultured or 
isolated in the same conditions as experimental samples, and viability dye 
single stains were also performed on such cells. Compensation was 
automatically calculated and applied using the compensation wizard in FACS 
Dive software and manually checked at the time of analysis.  
2.2.7.9 Flow cytometric data analysis 
Following acquisition FCS files were analysed using the FlowJo software 
(Tree Star, San Carlos, CA, USA). Compensation was manually reviewed by 
observing single stain controls against all other channels used in the panel 
and confirming there was no under or over compensation applied. 
Samples were always gated on singlet cells by gating on the diagonal in SSC-
area against SSC-height and subsequently FSC-area against FSC-height. For 
the majority of gating strategies dead cells were excluded by gating on DAPI- 
or LDFB- cells, with the exception being in viability assays where data for 
both DAPI- and DAPI+ populations were included. In multi-colour panels 
when gating on populations with no clear division between negative and 
positive cells fluorescence minus one (FMO) controls were used to determine 
background fluorescence, and thus confirm where gates should be set. For 
intracellular cytokine staining isotype controls were also used to confirm the 
validity of positive populations.  
2.2.8 In vivo T cell assays 
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2.2.8.1 Adoptive T cell transfer 
OTI T cells were isolated and adoptively transferred to C57BL/6 mice. B6.SJ-
OTI mice were euthanized by CO2 asphyxiation and LN and spleens were 
collected and processed to single cell suspensions (2.2.2.2). The CD8+ T cell 
population was the enriched by MACs Dynabead separation (2.2.2.3). 
Following enrichment the OTI T cells were washed with dPBS, and 
resuspended at 5 x 104 cells/mL in dPBS. C57BL/6 mice were then injected 
intravenously (IV) in to the lateral tail vein with 1 x 104 OTI T cells. 
2.2.8.2 PLX4720 preparation and dosing 
PLX4720 was dissolved in DMSO to give a 10x stock. For 20 mg/kg dosing at 
8 mL/kg, 20 mg of PLX4720 was dissolved in 800 µL of DMSO. For 50 mg/kg 
dosing at 8 mL/kg, 50 mg of PLX4720 was dissolved in 800 µL of DMSO. 10x 
stocks were stored in the dark at room temperature for up to 7-10 days. 
A solution of 1% CMC was prepared for use as the vehicle control. CMC was 
added to dH2O at a ratio of 1 gram per 100 mL, the solution was agitated on a 
magnetic stirring platform for several hours until dissolved and solution was 
clear. 1% CMC was then stored at room temperature long term.  
10x PLX4720 stock was added to 1% CMC at a 1:9 ratio and vortexed to 
produce a uniform suspension. This suspension was delivered intra-
gastrically (IG) by oral gavage (IG) using a 1 mL syringe and feeding needle 
shortly after preparation. Fresh suspensions were prepared daily no more 
than 1 hour prior to delivery.  
Control mice received a suspension of DMSO added to 1% CMC in a 1:9 ratio, 
also prepared fresh daily.  
Mice were gavaged with control suspension or PLX4720 suspension daily, 
treatment was commenced on the day of OTI T cell transfer and continued 
until experiment completion.  
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2.2.8.3 Vaccination 
OTI T cells were stimulated with the peptide OVA and the iNKT ligand 
αGalCer 7 days after adoptive transfer. OVA and αGalCer were resuspended 
at 500 µg/mL and 250 ng/mL respectively. C57BL/6 mice were injected IV 
with either 200 µL of OVA and αGalCer or with 200 µL of dPBS for control 
mice. 
2.2.8.4 Analysis 
The proportion of OTI T cells in the CD8+ T cell compartment was analysed 7 
days following vaccination. C57BL/6 mice were bled from the lateral tail vein 
and lymphocyte suspensions were isolated (2.2.2.2). Lymphocytes were 
stained for expression of the extracellular markers CD3, CD8, Vα2 and CD45.1 
(2.2.7.1), and flow cytometry acquisition and analysis was performed (2.2.7.7). 
OTI T cells were identified as being Vα2+ CD45.1+. 
2.2.9 Tumour challenge experiments 
2.2.9.1 Tumour challenge 
Mice were injected subcutaneously (SC) in the left flank with 1-4 x 105 
YUMM1.1 cells, or 0.5-1 x 105 YUMM1.7 cells, or 1 x 105 B16.Ova cells. All 
YUMM1.1 and YUMM1.7 tumour experiments were performed in male mice, 
due to spontaneous tumour rejection observed in some female C57BL/6 mice 
(a phenomena also observed at Yale University; Katrina Meeth, personal 
communication). 
Tumours in untreated control mice were palpable from approximately 4-7 
days following tumour challenge. Once tumours were palpable they were 
measured every 2-3 days. Bisecting diameters were measured using Mitutoyo 
callipers. Mice were euthanized when tumour size reached 150 mm2 or when 
tumours ulcerated. 
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2.2.9.2 Vaccine generation and delivery 
Autologous tumour cells (YUMM1.1 or YUMM1.7) were passaged as 
previously described (2.2.2.1), and replated with cRPMI containing αGalCer at 
200 ng/mL. Cells were incubated with αGalCer overnight, and then media 
was removed and cells were washed twice with dPBS. The αGalCer-loaded 
tumour cells were harvested (2.2.2.2), resuspended in serum free RPMI and 
delivered 150 Gy γ-irradiation (Gammacell®. 1000 Elite irradiator, Best 
Theratronics, Canada). Irradiated, αGalCer-loaded tumour cells were washed 
with dPBS and resuspended at 1 x 106 cells/mL. Mice were injected IV with 
100-200 µL of vaccine, and control mice received 100-200 µL dPBS. 
2.2.9.3 PLX4720 preparation and dosing 
PLX4720 stocks were prepared as described in 2.2.8.2, with an additional 100 
mg/kg 10 x stock prepared. For dosing at 8 mL/kg 100 mg of PLX4720 stock 
was dissolved in 800 µL DMSO. 
10x PLX4720 was diluted with 1% CMC or DMSO with 1% CMC for control 
mice (2.2.8.2), and suspensions were prepared no more than 1 hour prior to 
delivery. Drug or control solution was delivered intra-gastrically using a 1mL 
syringe and feeding needle daily from 5 or 7 days post-tumour challenge.  
2.2.9.4 Analysis of tumour infiltrating lymphocytes (TIL)  
Mice were euthanized by CO2 asphyxiation 14, 21 or 25 days post-tumour 
challenge.  Tumours were harvested and transferred in to 3 mL IMDM in 15 
mL falcon tubes on ice. Tumours were then manually disassociated in to 
roughly even sized small fragments, following which tumours were digested 
in IMDM containing 200 µg/mL of DNase and 1 mg/mL Collagenase IV at 37 
°C for 60 minutes. After incubation in digestion media 0.5 M EDTA was 
added to give a final concentration of 10 µM and tissues were incubated for a 
further 5 minutes at 37 °C. Single cell tumour suspensions were then 
prepared by passing tissue fragments through an 18 G needle on a 5 mL 
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syringe approximately ten times. Tumour suspensions were then mashed 
through a 70 µM filter using a 1 mL syringe plunger. Tumour cells were 
resuspended in 2 mL RBC lysis buffer and incubated at 37 °C for 5-10 
minutes; RBC lysis was quenched with 8 mL cold cIMDM and washed once. 
Following red blood cell lysis, cells for phenotyping were resuspended in 
flow buffer and extracellular and intracellular staining was performed as in 
2.2.7.1 and 2.2.7.4 respectively. For cytokine analysis, cells were re-stimulated 
as described in 2.2.7.5 prior to extracellular and intracellular staining as 
detailed in 2.2.7.1 and 2.2.7.6. 
2.2.9.5 Analysis of immune cell populations in peripheral lymphoid 
tissues 
As described above, mice were euthanized 14, 21 or 25 days post-tumour 
challenge. Spleens and tumour draining inguinal lymph nodes were 
harvested and transferred in to 1-3 mL IMDM in 24- or 12-well plates on ice. 
Spleens were then manually disassociated into roughly even sized small 
fragments, following which tissues were digested in IMDM containing 100 
µg/mL of DNase and 0.1 mg/mL Liberase at 37 °C for 30 minutes. After 30 
minutes incubation in digestion media 0.5 M EDTA was added to give a final 
concentration of 10 µM, and tissues were incubated for a further 5 minutes at 
37 °C. Single cell lymph node and splenocyte suspensions were then prepared 
as described in 2.2.2.2. Following the generation of single cell suspensions and 
red blood cell lysis of splenocytes, cells for phenotyping were resuspended in 
flow buffer and extracellular and intracellular staining was performed as in 
2.2.7.1 and 2.2.7.4 respectively. For cytokine analysis, cells were re-stimulated 
as described in 2.2.7.5 prior to extracellular and intracellular staining as 
detailed in 2.2.7.1 and 2.2.7.6. 
2.2.10  Statistical analyses 
Statistical analysis and graphing of data was performed using Prism software 
(Graphpad Prism Version 5.0f for MacIntosh, GraphPad Software 
Incorporated, USA). Statistical analyses used are stated in figure legends and 
p < 0.05 was considered the threshold for significance. Analyses examining a 
 86 
single parameter of two groups were performed using an unpaired T-test. 
Analyses examining a single parameter of three or more groups were 
undertaken using a one-way analysis of variance (ANOVA) with Bonferroni 
post-test. For experiments examining two or more parameters of three or 
more groups, two-way ANOVA with Bonferroni post-test was performed. 
MTT results were analysed to calculate the IC50 and generate a dose-response 
curve, using a non-linear regression model plotting log(inhibitor) versus 
normalised dose response. The number of experimental repeats performed is 
detailed in figure legends. Experimental data was not pooled across 
experiments using human cells due to individual-to-individual variation or 
for experiments with large flow cytometry panels due to slight changes to 
flow panels and machine set-up.   
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CHAPTER 3:  
Characterizing 
BRAFV600E melanoma 
models  
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 Introduction 3.1
This thesis investigates the immunological effects of targeted BRAF inhibition 
and aims to optimize combination of BRAF inhibitors with immunotherapy. 
To undertake this research an in vivo model of BRAFV600E melanoma needs to 
be established, and the relevance of this model to human melanoma assessed.  
Several different types of murine in vivo tumour models exist. Traditionally 
the most commonly used are xenograft models, which involve the 
transplantation of human tumour cells into severely immunocompromised 
mice (Budhu et al., 2014). Immune deficient mice are unable to reject non-
autologous cells, allowing study of human tumour biology in vivo and 
providing the opportunity to generate patient-derived tumour models. 
However, the immune deficiencies that are essential to these models are also 
a key limitation, discounting the considerable contribution of the immune 
system to tumourigenesis and limiting the relevance of xenograft systems. 
Several immune competent alternatives have been developed, including 
transplantable models using syngeneic mouse cancer cell lines. 
Transplantable tumour models can be orthotopic with cells implanted directly 
into the tissue of origin, or ectopic most commonly with transplantation to a 
subcutaneous site. Of the two, orthotopic models are considered more 
clinically relevant, recapitulating the appropriate tumour microenvironment. 
However, they can be technically challenging and generally require imaging 
technology such as magnetic resonance imaging or fluorescent reporter 
imaging to assess tumour growth (Troiani et al., 2008).  In contrast, 
subcutaneous models are widely used for their simplicity, reproducibility and 
ease of tumour measurement despite the disadvantage of not representing an 
appropriate tumour site (Killion et al., 1998). The most frequently used 
syngeneic, transplantable melanoma model is the B16 model, however this 
model lacks the genetic lesions found in many human melanomas, making it 
unsuitable for investigation of targeted therapies (Becker et al., 2010). 
Advances in the understanding of the genetic basis of tumour types and in 
genetic engineering have led to the derivation of transgenic mice with 
conditional, tissue specific oncogene expression or tumour suppressor 
inactivation modelled on human tumours. Of the mouse models available, 
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transgenic systems most faithfully recapitulate human cancers, but the caveat 
of this is phenotypic variability, lengthy experiments (a single experiment can 
take upwards of 6-12 months) and the need for expansion of the unique 
mouse colonies (Budhu et al., 2014).  
For the research undertaken in this thesis the BRafV600E, Pten-/-; CDKN2a-/-  
‘YUMM1.1’ and ‘YUMM1.7’ cell lines were generously made available by 
Prof Marcus Bosenberg of Yale University. Whilst transgenic tumour models 
best exemplify human tumours, the lack of available imaging technology at 
the Malaghan Institute and lengthy experiment times make the inducible 
tumours of Tyr::CreER; BRafCA; Ptenlox5/lox5 mice unsuitable for use in this 
research. However, the transplantable cell lines developed from induced 
tumours recapitulate a mutational profile common to human melanoma 
tumours and have been derived from a C57BL/6 background. These tumours 
can be transplanted into fully immunocompetent, syngeneic mice. This makes 
the YUMM1.1 and YUMM1.7 tumour models good candidates for the study 
of the immunological effects of BRAF inhibitors and combination therapy. 
These are novel BRAFV600E tumour lines, and effects of BRAF inhibition in 
these models will be assessed in comparison with human BRAFV600E 
melanoma cells and BRAFWT models. This will allow characterisation of the 
novel BRafV600E; Pten-/-; CDKN2a-/-  cell lines to be performed in the context of 
more widely used models. 
Targeted mutant-BRAF inhibition will be investigated using the clinical 
compound Vemurafenib and the structural analogue PLX4720, which have 
kindly been provided by Dr Gideon Bollag of Plexxikon. The effects of these 
two inhibitors will be compared in vitro. In vivo experiments will be 
undertaken using PLX4720, which is the more appropriate compound for use 
in rodents as its pharmacokinetic profile is analogous to that of Vemurafenib 
in humans (Bollag et al., 2012). PLX4720 will be delivered by oral gavage in 
vivo, to accurately model the oral delivery of Vemurafenib to human patients. 
Additionally, targeted mutant-BRAF inhibitor profiles will be compared with 
those of the pan-RAF inhibitor Sorafenib to confirm mutant-BRAF specificity.  
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3.1.1 Aims 
The experiments described in this chapter were performed to characterize 
novel BRAFV600E tumour lines and determine the relevance of these cell lines 
to human melanoma models, with overall aim of setting up an 
immunocompetent BRAFV600E melanoma model in vivo. 
Specific aims were to: 
• Determine the sensitivity of BRAFV600E and BRAFWT human and murine 
tumour cell lines to targeted BRAF inhibition and pan-RAF inhibition 
• Examine the cytotoxicity of targeted BRAF inhibitors on BRAFV600E 
melanoma cell lines and establish the mechanism of cell death 
• Characterize the effects of targeted BRAF inhibition on BRAFV600E 
melanoma-mediated immunosuppression 
• Optimize in vivo models of BRAFV600E tumour growth in syngeneic 
C57BL/6 mice and determine PLX4720 sensitivity 
 Results 3.2
3.2.1 In vitro sensitivity of a range of human and murine 
cancer cell lines to BRAF inhibition  
Initial experiments were performed to characterize the in vitro sensitivity of a 
range of human and murine cell lines to BRAF inhibition. Cells were treated 
with the targeted mutant-BRAF inhibitors PLX4720 and Vemurafenib 
(Figures 3.1 and 3.2), and the pan-RAF inhibitor Sorafenib (Figures 3.3 and 
3.4). Inhibitor effects on cell viability were measured indirectly using MTT 
assays. Metabolically active cells will reduce the MTT tetrazolium salt to an 
insoluble formazan in a colourimetric reaction. This dye reduction is 
generally proportional to the number of viable cells in the exponential growth 
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phase, and thus can be used as an indirect measure of cell proliferation 
(Berridge et al., 2005). MTT reduction was plotted as a percentage of the 
DMSO (vehicle) treated controls, and the half maximal inhibitory 
concentration (IC50) was determined for each experimental repeat. The mean 
IC50 values for PLX4720 and Vemurafenib treatment of each cell line are 
detailed in Table 3.1, whilst IC50 values for Sorafenib treatment are 
summarized in Table 3.2. The MTT assay was subsequently validated as a 
measure of cell viability in Sections 3.2.2 and 3.2.3. 
3.2.1.1 Human cell lines 
Of the human cell lines profiled, the BRAFV600E homozygous A375 cells 
demonstrated the greatest sensitivity to targeted BRAF inhibition (Figure 3.1), 
with IC50 values of 333 nM for PLX4720 treatment and 82 nM for 
Vemurafenib treatment. However, these cells were approximately 10-fold less 
sensitive to pan-RAF inhibition, with Sorafenib treatment achieving an IC50 
of 2.31 µM (Figure 3.2). In contrast, a second BRAFV600E human melanoma cell 
line, SK-mel-5, was relatively resistant to targeted BRAF inhibition. SK-mel-5 
cells had IC50s of 10.82 µM with PLX4720 treatment and 48.37 µM with 
Vemurafenib treatment. Despite this insensitivity to targeted BRAF inhibition, 
SK-mel-5 cells were sensitive to broad-spectrum RAF inhibition, with an IC50 
of 4.77 µM when treated with Sorafenib. 
By way of comparison, the sensitivity of the human BRAFWT leukaemia cell 
line HL-60 was determined. HL-60 cells were shown to be insensitive to 
targeted BRAF inhibition with IC50s of greater than 20 µM. This cell line was, 
however, highly sensitive to inhibition with Sorafenib with a mean IC50 of 
640 nM. These data demonstrate that HL-60 cells are susceptible to MAPK 
pathway blockade but as expected, not to selective inhibitors of mutant-
BRAF.  
Susceptibility to both targeted and broad-spectrum RAF inhibition was also 
established for human melanoma cell lines of unknown BRAF mutation 
status, with the aim of identifying a second cell line highly sensitive to mutant 
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BRAF inhibition. The cell lines LM-mel-15, LM-mel-34 and LM-mel-62 all 
demonstrated a lack of sensitivity to PLX4720 treatment with IC50s ranging 
from 23.32 µM to 59.8 µM, despite being relatively sensitive to Sorafenib. 
These results suggest that the three cell lines are likely BRAF wild-type, or 
heterozygous for the BRAF mutation and de novo resistant. Therefore, these 
cells were not included in any further work on targeted BRAF inhibition. 
 
 
Figure 3.1: BRAF mutation status determines human melanoma cell line 
sensitivity to highly targeted BRAF inhibitors in vitro. Cells were treated 
with a range of concentrations (1nM-100µM) of PLX4720 or Vemurafenib for 
48 hours. MTT reduction is shown as a percentage of DMSO treated control. 
Each symbol represents the mean of the triplicate; error bars are± S.D. Curves 
generated by non-linear regression analysis. Graphs are representative of at 
least two independent experiments. 
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Figure 3.2: Human melanoma cell line sensitivity to broad spectrum RAF 
inhibition in vitro is not determined by BRAF mutation status.  Cells were 
treated with a range of concentrations (10 nM-100 µM) of Sorafenib for 48 
hours. MTT reduction is shown as a percentage of DMSO treated control. 
Each symbol represents the mean of the triplicate; error bars are ± S.D. Curves 
generated by non-linear regression analysis. Graphs are representative of at 
least two independent experiments. 
 
3.2.1.2 Murine cell lines 
Next, the sensitivities of murine BRAFV600E and BRAFWT melanoma cell lines 
were examined with both targeted BRAF inhibition (Figure 3.2 and Table 3.1) 
and broad-spectrum RAF inhibition (Figure 3.4 and Table 3.2).  
The BRAFV600E YUMM1.1 and YUMM1.7 cells were moderately sensitive to 
targeted BRAF inhibition and had similar sensitivity to both PLX4720 and 
Vemurafenib. YUMM1.1 cells had an IC50 of 880 nM with PLX4720 and 1.53 
µM with Vemurafenib treatment, while YUMM1.7 cells had IC50s of 1.44 µM 
and 1.26 µM with PLX4720 and Vemurafenib respectively. Despite the similar 
responses of both cell lines to targeted BRAF inhibition, YUMM1.1 cells were 
less sensitive to Sorafenib (mean IC50 of 16.75 µM) than YUMM1.7 cells 
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(mean IC50 of 5.58 µM). This discrepancy in sensitivity to broad spectrum 
MAP kinase inhibition may be related to differential proliferation rates, with 
YUMM1.7 cells proliferating more rapidly than YUMM1.1 (data not shown). 
As expected, the BRAF wild-type B16 cell line was highly resistant to targeted 
BRAF inhibition with IC50s of greater than 80 µM for both inhibitors. B16 
cells were also one of the least sensitive cell lines to Sorafenib treatment, with 
an IC50 of 11.16 µM. 
In summary, these data demonstrate that sensitivity to targeted BRAF 
inhibitors is dependent on BRAF mutation status, and confirms that PLX4720 
and Vemurafenib have specificity for mutant BRAF. The human melanoma 
cell line A375 exemplified a highly sensitive BRAFV600E cell line, whilst SK-
mel-5 cells showed de novo resistance to targeted BRAF inhibition. In 
comparison to the human melanoma cell lines, the murine BRAFV600E 
YUMM1.1 and YUMM1.7 cells were moderately sensitive to targeted BRAF 
inhibition. As expected, the response to broad-spectrum MAPK blockade 
with Sorafenib was not dependent on BRAF mutation status, and the cell lines 
assayed exhibited a narrower range of sensitivities to Sorafenib with IC50s 
ranging from 640 nM (HL-60 cells) to 17 µM (YUMM1.1 cells). 
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Figure 3.4: Murine melanoma cell line sensitivity to broad spectrum RAF 
inhibition in vitro is not determined by BRAF mutation status. Cells were 
treated with a range of concentrations (10 nM-100 µM) of Sorafenib for 48 
hours. MTT reduction is shown as a percentage of DMSO treated control. 
Each symbol represents the mean of the triplicate; error bars are ± S.D. Curves 
generated by non-linear regression analysis. Graphs are representative of at 
least two independent experiments 
  
Figure 3.3: BRAF mutation status determines murine melanoma cell line 
sensitivity to highly targeted BRAF inhibitors treatment. Cells were treated 
with a range of concentrations (12 nM-200 µM) of PLX4720 or Vemurafenib for 
48 hours. MTT reduction is shown as a percentage of DMSO treated control. 
Each symbol represents the mean of the triplicate; error bars are ± S.D. Curves 
generated by non-linear regression analysis. Graphs are representative of at 
least two independent experiments. 
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Table 3-1: BRAF mutation status determines human and murine melanoma 
cell line sensitivity to targeted mutant BRAF inhibitors 
 
Table 3-2: Tumour cell line sensitivity to broad spectrum RAF inhibition in 
vitro is not determined by BRAF mutation status. 
Cell line BRAF 
mutation 
Number 
of tests 
Average IC50 
HL-60 WT 3 639.67 nM 
A375 V600E 4 2.31 µM 
LM-mel-34 Unknown 2 3.86 µM 
LM-mel-62 Unknown 4 4.29 µM 
LM-mel-15 Unknown 2 4.35 µM 
SK-mel-5 V600E 2 4.77 µM 
YUMM1.7 V600E 2 5.58 µM 
B16 WT	   3 11.16 µM 
YUMM1.1 V600E 2 16.75 µM 
 
  
Cell line BRAF 
mutation 
PLX4720 Vemurafenib 
Number 
of tests 
Average 
IC50 
Number 
of tests 
Average 
IC50 
A375 V600E 4 333.15 nM 3 81.61 nM 
YUMM1.1 V600E 3 880.23nM 2 1.53 µM 
YUMM1.7 V600E 3 1.44 µM 4 1.26 µM 
SK-mel-5 V600E 2 10.82 µM 2 48.37 µM 
LM-mel-34 Unknown 2 23.32 µM - - 
HL-60 WT 2 32.55 µM 2 20.92 µM 
LM-mel-62 Unknown 4 48.65 µM - - 
LM-mel-15 Unknown 2 59.8 µM - - 
B16 WT 3 85.40 µM 2 80.91 µM 
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3.2.2 BRAF inhibitors induce cell death in sensitive BRAFV600E 
cell lines in a time and concentration dependent manner 
Having established that the BRAFV600E cell lines A375, YUMM1.1 and 
YUMM1.7 are susceptible to growth inhibition by targeted BRAF inhibitors in 
vitro as determined by MTT assay, direct effects on viability were 
investigated. To confirm that PLX4720 and Vemurafenib induce cell death 
rather than decreased metabolic activity, effects on viability were confirmed 
by fluorescent dye staining using flow cytometry. Cells were stained LDFB, a 
blue fluorescent stain which is excluded by live cells but can enter the 
compromised membranes of dead cells to irreversibly bind amines. This 
technique allowed cells to be fixed following staining, preventing ongoing cell 
death from occurring during processing and data acquisition. Melanoma cells 
were treated with a range of concentrations of PLX4720 or Vemurafenib for 12 
to 72 hours. Following drug treatment cells were collected and the percentage 
of viable cells was determined, as shown in Figure 3.5 for A375, Figure 3.6 for 
YUMM1.1 and Figure 3.7 for YUMM1.7 cells. As expected, exposure to BRAF 
inhibitors resulted in cell death in all three cell lines, which occurred in a time 
and concentration dependent manner. 
 
Figure 3.5: A375 sensitivity to PLX4720 and Vemurafenib is time and 
concentration dependent. Cells were treated with a range of concentrations 
(10 nM-100 µM) of PLX4720 or Vemurafenib for 12-72 hours. Cell viability 
was examined by flow cytometry.  Each symbol represents the mean of the 
triplicate; error bars are ± S.D. Graphs are representative of two independent 
experiments. 
  
 99 
More than 12 hours exposure to PLX4720 or Vemurafenib was required to 
induce A375 cell death (Figure 3.5A and B), with 20-40% loss of viability 
evident after 24 hours treatment with 100 µM PLX4720 or Vemurafenib. 
Treatment for 36 to 72 hours with PLX4720 induced up to 40% cell death at a 
concentration of 200 nM, and 50-95% cell death at 100 µM. While 
Vemurafenib treatment for 36 to 72 hours with 10 µM inhibitor resulted in 
20% cell death. The highest concentration of Vemurafenib, 100 µM, induced 
40% cell death at 36 and 48 hours, and close to 100% cell death with exposure 
of 60 hours or longer. Overall, A375 cells showed slightly increased 
susceptibility to PLX4720 treatment than Vemurafenib, with cell death 
observed at lower PLX4720 concentrations.  
Similar to A375 cells, a concentration and time dependent effect was evident 
with PLX4720 treatment of YUMM1.1 cells (Figure 3.6A). Following 12 hours 
of exposure to PLX4720 YUMM1.1 cells remained viable at all drug 
concentrations used. Cell death was observed at concentrations of 10 µM with 
24-36 hours exposure, at 2.5 µM after 48-60 hours and at 1 µM after 72 hours. 
Therefore, with increased treatment length YUMM1.1 cells were more 
sensitive to low concentrations of PLX4720. Additionally, increased cell death 
was observed at high drug concentrations with longer treatment times. After 
24-36 hours treatment 100 µM PLX4720 induced 60% cell death, while 48 to 72 
hours exposure to 100 µM resulted in 80-100% cell death.   
This time dependent effect was less evident when YUMM1.1 cells were 
treated with Vemurafenib (Figure 3.6B).  Following 12 hours exposure less 
than 10% cell death was observed at concentrations up to 25 µM, and 60% of 
cells died with 100 µM Vemurafenib treatment. However, with 24 to 72 hours 
treatment, Vemurafenib induced similar responses. Concentrations of 1 to 10 
µM caused less than 20% cell death, at 25 µM approximately 60% cell death 
was evident and at 100 µM 90-100% of cells were dead. Largely, YUMM1.1 
cells have similar sensitivity to both PLX4720 and Vemurafenib, however 
PLX4720 effects appear to be more closely linked to length of drug exposure. 
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Figure 3.6: YUMM1.1 sensitivity to PLX4720 and Vemurafenib is time and 
concentration dependent. Cells were treated with a range of concentrations 
(1 µM-100 µM) of PLX4720 or Vemurafenib for 12-72 hours. Cell viability was 
determined by LDFB exclusion using flow cytometry.  Each symbol 
represents the mean of the triplicate; error bars are ± S.D. Graphs are 
representative of at least two independent experiments. 
 
 
 
Of the three cell lines analysed YUMM1.7 cells were the least sensitive to 
PLX4720 treatment. Concentrations of up to 25 µM PLX42720 failed to induce 
cell death of greater than 10% even after 72 hours of inhibitor exposure, and 
substantial cell death was not observed until YUMM1.7 cells were exposed to 
100 µM PLX4720. Following 24 and 36 hours of 100 µM treatment around 30-
40% cell death was evident, and after 48-72 hours exposure to 100 µM 
PLX4720 80-100% cell death was observed. In comparison, YUMM1.7 were 
slightly more sensitive to Vemurafenib. Treatment with 25 µM Vemurafenib 
for 24 to 72 hours caused 30-50% cell death. At 100 µM Vemurafenib induced 
40-60% cell death after 12-24 hours, and greater than 90% cell death with 
treatment of 36 hours or longer.  
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Figure 3.7: YUMM1.7 sensitivity to PLX4720 and Vemurafenib is time and 
concentration dependent. Cells were treated with a range of concentrations 
(1 µM-100 µM) of PLX4720 or Vemurafenib for 12-72 hours. Cell viability was 
examined by flow cytometry.  Each symbol represents the mean of the 
triplicate; error bars are ± S.D. Graphs are representative of at least two 
independent experiments. 
 
Collectively, these data confirm that BRAF inhibitors induce cell death of 
BRAFV600E cells, corroborating the conclusions drawn from the MTT assays 
(Section 3.2.1). All three cell lines showed a concentration and time dependent 
effect of targeted BRAF inhibitors on cell viability, although the length of 
inhibitor exposure had greater impact on A375 and YUMM1.7 cells. Overall, 
the cell lines had similar sensitivity to the two inhibitors, but A375 and 
YUMM1.1 cells showed slightly increased susceptibility to PLX4720 treatment 
while YUMM1.7 cells were slightly more sensitive to Vemurafenib.  
3.2.3 BRAFV600E melanoma cells die by apoptosis following 
BRAF inhibitor treatment 
In order to determine the mechanism by which targeted BRAF inhibitors 
induce BRAFV600E melanoma cell death, apoptosis assays were performed on 
A375, YUMM1.1 and YUMM1.7 cells following PLX4720 or Vemurafenib 
exposure. One of the earliest indications of apoptosis is loss of plasma 
membrane symmetry; this results in molecules such as phosphatidylserine 
being translocated from the inner to the outer surface of the cell membrane. 
Expression of phosphatidylserine was used a marker of apoptosis, and was 
detected with high-affinity fluorescently-conjugated Annexin V (AV) staining. 
Cell viability was determined using the nucleic acid binding dye DAPI, which 
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is excluded by live cells but can enter the compromised membranes of dead 
cells. Co-staining with AV and DAPI was used to resolve live, early apoptotic 
and late-stage apoptotic/necrotic cell populations. Live cells present as 
double negative for both AV and DAPI, while early apoptotic cells are AV 
positive and DAPI negative. As apoptosis progresses membrane integrity is 
lost and late-stage apoptotic cells present as double positive. Although double 
positive cells are often regarded as apoptotic, it is worth noting that due to the 
loss of membrane integrity with cell death necrotic cells may also appear 
double positive with AV labelling intracellular phosphatidylserine.  
Exposure of A375 cells to PLX4720 or Vemurafenib for 18 or 24 hours resulted 
in minimal phosphatidylserine translocation or cell death, with greater than 
90% of cells remaining viable (Figure 3.8). Treatment with 100 µM 
Vemurafenib for 18-24 hours induced early apoptosis in a small population of 
cells, and cell death in approximately 20% of cells. Following 36 hours of 
treatment, 25 µM PLX4720 or Vemurafenib resulted in approximately 20-30% 
early apoptosis and dead cells. The greatest proportion of apoptosis and cell 
death was detected with 100 µM inhibitor exposure for 36 hours. At this 
concentration it was evident that Vemurafenib induced apoptosis more 
effectively than PLX4720, with 20% and 70% of cells remaining viable 
respectively.  
Overall, the distinct populations of AV+ DAPI- A375 cells that were detected 
(Appendix A1) clearly demonstrate that PLX4720 and Vemurafenib induce 
A375 death through apoptosis. However, targeted BRAF inhibition caused 
fewer A375 cells to undergo early apoptosis or cell death than expected for a 
highly sensitive cell line. This discrepancy may be due to time dependent 
effects, with A375 cells requiring longer exposure to inhibitors to initiate 
apoptosis and undergo cell death, or passing through early apoptosis rapidly.  
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Figure 3.8: PLX4720 and Vemurafenib induce A375 cell death by apoptosis. 
Cells were treated with a range of concentrations of PLX4720 and 
Vemurafenib (1 µM-100 µM) for 18-36 hours. Cell viability and 
phosphatidylserine expression was then analysed by flow cytometry, with 
gating performed as shown in representative dot plots (A). Proportion of live 
(DAPI-, AV-), early apoptotic (DAPI-, AV+) and late apoptotic/necrotic (DAPI+, 
AV+) cells are shown with PLX4720 treatment (B) or Vemurafenib treatment 
(C). Each bar represents the mean of the triplicates and error bars are ± S.D. 
Data are representative of two independent experiments. 
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Similar results were obtained with YUMM1.1 cells (Figure 3.9). Treatment of 
YUMM1.1 cells with either PLX4720 or Vemurafenib for 18 hours resulted in 
little to no cells undergoing early apoptosis, and less than 20% cell death. This 
shows that generally YUMM1.1 cells require longer than 18 hours exposure to 
targeted BRAF inhibition for induction of apoptosis to occur. Furthermore, 
exposure of YUMM1.1 cells to 1 µM PLX4720 or Vemurafenib caused few 
cells to enter early apoptosis; even with 36 hours of treatment cell viability 
remained greater than 80%. However, at the higher concentrations of 25 and 
100 µM PLX4720 and Vemurafenib induced early apoptosis and death when 
cells were exposed to inhibitors for 24-36 hours, with very similar effects 
observed with both inhibitors. 
Comparatively, YUMM1.7 cells were more sensitive to BRAF inhibitor 
induced apoptosis. Unlike A375 or YUMM1.1 cells a 24 or 36 hour exposure 
to 1 µM PLX4720 or Vemurafenib treatment induced early apoptosis in 
YUMM1.7 cells. Additionally, Vemurafenib induced approximately 20% of 
YUMM1.7 cells to enter early apoptosis after only 18 hours of inhibitor 
treatment. Treatment with 25 and 100 µM PLX4720 or Vemurafenib for 18-36 
hours clearly induced early apoptosis and death of YUMM1.7 cells, with 20-
50% of cells shown to be AV+ DAPI- and 20-40% of cells AV+ DAPI+. At all 
concentrations PLX4720 and Vemurafenib treatment results in greater 
apoptosis and death of YUMM1.7 cells than the other cell lines. Analogous to 
the effects seen with A375 cells, Vemurafenib was more effective than 
PLX4720 at inducing both YUMM1.1 and YUMM1.7 cell death. 
Collectively, these data demonstrate that the targeted BRAF inhibitors 
PLX4720 and Vemurafenib induce death by apoptosis of both murine and 
human BRAFV600E melanoma cells. The proportion of cells undergoing 
apoptosis is time and concentration dependent, increasing with drug 
concentration and length of exposure. In all three cell lines Vemurafenib is 
more effective at inducing apoptosis than PLX4720, although both inhibitors 
showed similar trends.  
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Figure 3.9: PLX4720 and Vemurafenib induce YUMM1.1 cell death by 
apoptosis. Cells were treated with a range of concentrations of PLX4720 and 
Vemurafenib (1 µM-100 µM) for 18-36 hours. Cell viability and 
phosphatidylserine expression was then analysed by flow cytometry, with 
gating performed as shown in representative dot plots (A). Proportion of live 
(DAPI-, AV-), early apoptotic (DAPI-, AV+) and late apoptotic/necrotic (DAPI+, 
AV+) cells are shown with PLX4720 treatment (B) or Vemurafenib treatment 
(C). Each bar represents the mean of the triplicates and error bars are ± S.D. 
Data are representative of two independent repeats. 
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Figure 3.10 PLX4720 and Vemurafenib induce YUMM1.7 cell death by 
apoptosis. Cells were treated with a range of concentrations of PLX4720 and 
Vemurafenib (1 µM-100 µM) for 18-36 hours. Cell viability and 
phosphatidylserine expression was then analysed by flow cytometry, with 
gating performed as shown in representative dot plots (A). Proportion of live 
(DAPI-, AV-), early apoptotic (DAPI-, AV+) and late apoptotic/necrotic (DAPI+, 
AV+) cells are shown with PLX4720 treatment (B) or Vemurafenib treatment 
(C). Each bar represents the mean of the triplicates and error bars are ± S.D. 
Data are representative of two independent repeats. 
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3.2.4 Melanoma production of soluble immunosuppressive 
factors can be partially reversed by BRAF inhibition 
The preceding experiments characterized the dynamics and mechanism of 
BRAF inhibitor induced cell death. Following on from this, the effects of 
BRAF inhibition on melanoma cells at non-cytotoxic concentrations were 
explored. Of particular interest was the effect of BRAF inhibition on 
melanoma-mediated immunosuppression. Initial experiments examined the 
ability of A375 cells to produce soluble immunosuppressive factors, and 
subsequently the effect of PLX4720 treatment on A375 immune suppression 
was investigated. Conditioned media was collected from A375 cell cultures 
(Figure 3.11A), and the effects of this conditioned media on human T cell 
proliferation in vitro were assessed. Peripheral blood mononuclear cells 
(PBMCs) were extracted from the blood of healthy human donors and were 
stimulated in a one-way mixed lymphocyte reaction with IL-2 (Figure 3.11B). 
T cell proliferation was determined by CFSE dilution as measured by flow 
cytometry (Figure 3.11C). The proportion of control T cell proliferation in the 
absence of conditioned media was determined, and T cell proliferation in 
presence of conditioned media was presented as a percentage of this control. 
A375 conditioned media suppressed T cell proliferation significantly, with the 
proportion of cells proliferating reduced by approximately 50% (Figure 
3.11D). Pre-treatment of A375 cells with 200 nM PLX4720 for 18 hours 
partially abrogated immunosuppression, with T cell proliferation increased 
by approximately 20-30%. Similarly, if A375 cells were exposed to 200 nM 
PLX4720 for 18 hours, then thoroughly washed and subsequently cultured in 
the absence of drug for 18 hours, the resulting conditioned media was also 
less immunosuppressive than that of untreated cells. These results 
demonstrate that PLX4720 was acting directly on the A375 cells, and the 
increased proliferation was not a result of residual drug in the conditioned 
media affecting T cell proliferation. Whilst PLX4720 abrogation of A375 
mediated immunosuppression did not reach statistical significance this trend 
was consistent across five independent experiments performed using 
different donor PBMCs.  
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Figure 3.11: A375 supernatant suppression of T cell proliferation is partially 
reversed by PLX4720 treatment. A. Supernatants were collected from A375 
cells treated with PLX4720 as described. B. Suppressive activity of these 
supernatants was then evaluated in a one-way mixed lymphocyte reaction. C. 
T cell proliferation was examined by flow cytometry, representative dot plots 
show the gating strategy used to identify T cells and measure proliferation. D. 
T cell proliferation is shown as a percentage of DMSO treated control. Each 
bar represents the mean of the triplicate. Error bars are ± S.D. NS = not 
significant, *** p < 0.001, **** p <0.0001, one-way ANOVA with Bonferroni 
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post-test. Data are representative of 5 independent experiments, with 
concordant results. 
 
 
Having established that PLX4720 abrogates immunosuppression mediated by 
BRAFV600E melanoma cells sensitive to targeted BRAF inhibition, the effect on 
de novo resistant SK-mel-5 cells was investigated. Similar to the experiments 
performed with A375 cells, SK-mel-5 production of immunosuppressive 
soluble factors in the presence and absence of BRAF inhibition was 
investigated. Conditioned media was collected from SK-mel-5 cells after 48 
hours of culture with DMSO or varying concentrations of PLX4720 from 1 to 
20 µM. PBMCs from healthy human donors were stimulated with anti-CD3, 
anti-CD28 and IL-2, and T cell proliferation was determined by CFSE dilution 
as measured by flow cytometry (Figure 3.12A and B). Again, T cell 
proliferation was presented as percentage of the untreated, control T cells 
(Figure 3.12C).  
Similar to A375 cells, SK-mel-5 conditioned media suppressed T cell 
proliferation significantly (Figure 3.12C). Treatment of SK-mel-5 cells with 1 
or 5 µM PLX4720 decreased the suppressive effects of the conditioned media. 
However, neither 10 nor 20 µM PLX4720 treatment reduced the 
immunosuppression of SK-mel-5 conditioned media. Direct treatment of T 
cells with 5 and 10 µM PLX4720 had no effect on T cell proliferation (as 
shown in Chapter 4). These data indicate that PLX4720 treatment of SK-mel-5 
cells directly reduced SK-mel-5 production of soluble immunosuppressive 
factors, and that this effect only occurs at optimal drug concentration.   
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Figure 3.12: SK-mel-5 production of soluble immunosuppressive factors is 
abrogated by PLX4720 treatment. Conditioned media (CM) was harvested 
from SK-mel-5 cells following 48 hours of culture with DMSO or 1–5 µM 
PLX4720. A. Suppressive activity of CM was assessed with anti-CD3, anti-
CD28 and IL-2 stimulation of PBMCs from healthy human donors. B. T cell 
proliferation was examined by flow cytometry, representative dot plots show 
the gating strategy used to identify T cells and measure proliferation. D. T cell 
proliferation is shown as a percentage of DMSO treated control. Each bar 
represents the mean of the triplicate. Error bars are ± S.D. NS = not 
significant, ** p < 0.05, **** p <0.0001, one-way ANOVA with Bonferroni post-
test. Data are representative of 2 independent experiments. 
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Finally, the immunosuppressive properties of YUMM cells were examined. 
Conditioned media was collected from YUMM1.1 or YUMM1.7 cells cultured 
at cell concentrations of 1 x 104 – 1 x 105 cells per well for 12 – 48 hours. 
C57BL/6 splenocytes were stimulated with anti-CD3, anti-CD28 and IL-2, 
and T cell proliferation was determined by CFSE dilution and activation by 
CD69 expression as measured by flow cytometry (Figure 3.13A and B). The 
proportion of T cells proliferating in control wells was determined, and T cell 
proliferation was presented as a percentage of control T cell proliferation. 
YUMM1.1 and YUMM1.7 conditioned media did not significantly suppress T 
cell proliferation or activation (Figure 3.13C and D). Experimental 
optimization was performed with cell numbers titrated, culture times varied 
and finally the addition of different dilutions of conditioned culture medium 
was tested (diluting from 1:1 to 1:4). None of these culture conditions or 
dilutions of conditioned media resulted in suppression of T cell proliferation 
or activation (data not shown). Therefore, it was concluded that the 
YUMM1.1 and YUMM1.7 cell lines did not produce soluble factors that 
directly suppressed T cell proliferation. With respect to this finding, the effect 
of PLX4720 on YUMM1.1 and YUMM1.7 production was unable to be 
assessed in these assays. 
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Figure 3.13: YUMM1.1 and YUMM1.7 cells do not produce soluble factors 
that suppress T cell proliferation. A. Conditioned media (CM) was 
harvested from YUMM1.1 or YUMM1.7 cells following 48 hours of culture at 
with varying cell numbers per well (1 x 104-1 x 105). Suppressive activity of 
CM was assessed with anti-CD3, anti-CD28 and IL-2 stimulation of C57BL/6 
splenocytes. B. T cell proliferation was examined by flow cytometry with 
populations defined as shown, samples pre-gated on single and live cells. 
Neither YUMM1.1 (C) nor YUMM1.7 (D) conditioned media affected T cell 
proliferation. 
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3.2.5 PX4720 treatment slows YUMM1.1 and YUMM1.7 growth 
in vivo and increases survival 
In order to investigate YUMM sensitivity to BRAF inhibitor treatment in vivo, 
the number of cells delivered during tumour challenge was optimized. Cell 
numbers for injection were based on a reported tumour growth rate of 1 cm3 
tumours 6 weeks after subcutaneous injection of 1 x 105 YUMM1.1 cells 
(personal communications; Katrina Meeth, Yale University), and the 
knowledge that YUMM1.7 cells have a faster doubling time in vitro (data not 
shown). Mice were injected subcutaneously with 2-4 x 105 YUMM1.1 cells, or 
1-2 x 105 YUMM1.7 cells and tumour growth was monitored (Appendix B1). 
Similar rates of YUMM1.1 and YUMM1.7 tumour growth were seen with 
both cell numbers tested. YUMM1.1 growth was less variable with 2 x 105 
cells, while YUMM1.7 tumours were less likely to ulcerate with 1 x 105 cells. 
Therefore, these cell numbers were used for tumour injections in the ensuing 
experiments.  
Next, the effect of PLX4720 treatment on YUMM1.1 tumour growth and 
mouse survival was determined. C57BL/6 mice were challenged with 2 x 105 
YUMM1.1 cells and seven days post-tumour challenge daily treatment with 
PLX4720 delivered by oral gavage was initiated (Figure 3.14A). Mice received 
doses of PLX4720 ranging from 5 mg/kg to 100 mg/kg with control mice 
receiving a vehicle solution, and tumour size was measured every two to 
three days. All PLX4720 treatments decreased average tumour growth, with a 
highly significant reduction in tumour size evident at Day 21 post tumour-
challenge (the point at which the first control mouse had to be culled due to 
tumour size) (Figure 3.14B). Despite PLX4720 slowing tumour growth, 
delivery of the highest recommended drug concentration of 100 mg/kg (Dr 
Gideon Bollag, personal communications) did not result in tumour regression 
(Figure 3.14B and C). In addition to slowing tumour growth 5-100 mg/kg 
PLX4720 treatment significantly increased mouse survival relative to vehicle 
control treated mice (Figure 3.14D). The effects on tumour growth and 
survival were clearly dose dependent with increasing anti-tumour effects 
correlating with increased PLX4720 dose.  
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Figure 3.14: PLX4720 treatment slows YUMM1.1 growth in vivo and 
increases survival, but does not induce tumour regression.  A. C57BL/6 
mice were injected subcutaneously in the left flank with 2 x 105 YUMM1.1 
cells. Daily drug treatment was begun 7 days post-tumour challenge with 5-
100 mg/kg PLX4720 given by oral gavage. Tumour growth was monitored 
and size recorded. Mice were culled when tumours reached 150 mm2, or 
when tumours ulcerated. **** P ≤ 0.0001, 2-way ANOVA with Bonferroni 
post-test, statistics are shown for Day 21. B. Individual tumour growth is 
shown. Each symbol represents the mean growth of groups of 4-5 mice; error 
bars are ± SEM. C. Tumour growth for each treatment group. Each symbol 
represents one mouse.  Graphs are representative of at least two independent 
experiments. D. Percent survival shown for groups of 4-5 mice. Treatment 
groups are compared to the vehicle treated control mice ** P < 0.01, Mantel-
Cox test. 
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YUMM1.7 sensitivity to PLX4720 treatment in vivo was also examined using a 
similar experimental design. C57BL/6 mice were challenged with 1 x 105 
YUMM1.7 cells and mice either received 5 or 20 mg/kg PLX4720 from seven 
days post-tumour challenge, while control mice received a vehicle solution 
(Figure 3.15A). Both 5 and 20 mg/kg PLX4720 significantly slowed tumour 
growth, relative to the vehicle treated control group, with statistics shown for 
Day 26 post-tumour challenge, when the first control mouse was culled due 
to tumour size (Figure 3.15B). A greater reduction in tumour growth was 
evident with 20mg/kg PLX4720 treatment than 5 mg/kg PLX4720, and 20 
mg/kg also appeared to induce a more consistent response in tumours 
(Figure 3.15C). PLX4720 significantly increased survival at both doses, again 
the beneficial effect was more apparent at the higher dose of 20 mg/kg 
(Figure 3.15D). Comparable to the results observed in YUMM1.1 tumours, 
PLX4720 effects on YUMM1.7 tumour growth and mouse survival were also 
dose-dependent. However, YUMM1.7 tumours appear to be a lot more 
sensitive to PLX4720 treatment with 20 mg/kg dosing inducing a greater 
reduction in YUMM1.7 tumour growth than YUMM1.1 and proffering a 
greater survival advantage to mice with YUMM1.7 tumours. 
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Figure 3.15: PLX4720 treatment slows YUMM1.7 growth in vivo and 
increases survival, but does not induce tumour regression.  A. C57BL/6 
mice were injected subcutaneously in the left flank with 1 x 105 YUMM1.7 
cells. Daily drug treatment was begun 7 days post-tumour challenge with 5 or 
20 mg/kg PLX4720 given by oral gavage. Tumour growth was monitored and 
size recorded. Mice were culled when tumours reached 150 mm2, or when 
tumours ulcerated. **** P ≤ 0.0001, 2-way ANOVA with Bonferroni post-test, 
statistics are shown for Day 26. B. Individual tumour growth is shown. Each 
symbol represents the mean growth of groups of 4-5 mice; error bars are ± 
SEM. C. Percent survival shown for groups of 4-5 mice. Treatment groups are 
compared to the vehicle treated control mice * P ≤ 0.05 ** P < 0.01, Mantel-Cox 
test. D. Tumour growth for each treatment group. Each symbol represents 
one mouse.  Graphs are representative of two independent experiments. 
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 Discussion 3.3
In this chapter I have characterised novel BRafV600E; Pten-/-; CDKN2a-/- murine 
melanoma cell lines. Both cytotoxic and non-cytotoxic effects of BRAF 
inhibition were investigated in these models, and responses were compared 
and contrasted with those of the widely used human BRAFV600E A375 and SK-
mel-5 cell lines. Additionally, responses of BRAF mutant cell lines have been 
compared with those of BRAF wild-type cell lines.  
The mutant-BRAF targeted inhibitors PLX4720 and Vemurafenib were clearly 
demonstrated to be specific for cell lines with BRAF mutations, as expected. 
BRAF wild-type cell lines including B16 murine melanoma and HL-60 human 
leukaemia were resistant to PLX4720 and Vemurafenib, despite being 
sensitive to broad-spectrum MAP kinase blockade. The human BRAFV600E cell 
line A375 was highly sensitive to BRAF inhibition, while human BRAFV600E 
SK-mel-5 melanoma cells were relatively insensitive. These findings 
complement a previously published study showing SK-mel-5 cells to be de 
novo resistant to PLX4720 (Deng et al., 2012). Identification of two cell lines 
that represented different ends of the spectrum of BRAFV600E melanoma 
sensitivity to PLX4720 and Vemurafenib provided a good framework for 
comparison of the novel BRafV600E; Pten-/-; CDKN2a-/- YUMM1.1 and YUMM1.7 
cell lines. These were demonstrated to be moderately sensitive cell lines in 
vitro. PLX4720-induced death of both these cell lines and of A375 cells was 
shown to occur by apoptosis.  
Traditionally, immunogenic cell death has been associated with necrosis 
while apoptosis has been considered to be less immunostimulatory, or even 
tolerogenic (Zitvogel et al., 2008). However, it has become increasingly clear 
that this assumption does not always hold true. Under certain conditions, 
apoptosis of tumour cells can be immunostimulatory (Feng et al., 2002; Obeid 
et al., 2007; Restifo, 2000). Apoptosis is a non-uniform process that can occur 
either in a tolerogenic or immunogenic manner. Immunogenic apoptosis 
occurs when phagocytes engulf apoptotic cells in the presence of a danger 
signal (Steer et al., 2010). Commonly, in chemotherapy-induced immunogenic 
apoptosis this danger signal is the expression of calreticulin (Obeid et al., 
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2007; Zitvogel et al., 2010). Vaccines using tumour cells have been shown to 
induce potent anti-tumour immune responses only if tumour cells were 
apoptotic, not necrotic (Scheffer et al., 2003). This study supports the idea that 
apoptotic tumour cell death is immunogenic in a context relevant to 
immunotherapy. Thus chemotherapy-induced apoptosis may be able to 
stimulate immune responses in vivo.  
Unexpectedly, induction of YUMM1.1 and YUMM1.7 apoptosis by BRAF 
inhibition in vitro did not predict the outcome of BRAF inhibitor treatment of 
tumours in vivo. PLX4720 treatment in vivo significantly decreased tumour 
outgrowth, but did not cause tumour regression, implying a lack of 
significant tumour cell death. Irrespective of the absence of obvious tumour 
cell death in vivo, PXL4720 treatment of YUMM1.1 and YUMM1.7 tumours 
likely still generated an immunogenic phenotype. Previous studies have 
demonstrated that broad-spectrum chemotherapies do not necessarily need to 
induce cell death to render tumour cells more immunogenic. Sub-lethal 
chemotherapy has been shown to increase tumour cell immunogenicity, 
MHC class I expression and granzyme B permeability resulting in increased 
susceptibility to CTL-mediated killing  (Fisk and Ioannides, 1998; Kaneno et 
al., 2011; Ramakrishnan et al., 2010). Furthermore, non-cytotoxic 
chemotherapy can cause downregulation of tumour anti-apoptotic genes and 
increased Fas expression, rendering cells more receptive to CTL-mediated 
Fas-dependent CTL lysis (Gameiro et al., 2011). Targeted BRAF inhibitors are 
likely to have similar effects, with non-cytotoxic concentrations of 
Vemurafenib and PLX4720 previously shown to enhance MHC expression, 
tumour antigenicity and decrease melanoma-mediated immunosuppression 
(Donia et al., 2012a; Frederick et al., 2013; Sapkota et al., 2013; Sumimoto et al., 
2006).  
There are several possible mechanisms that may underlie resistance to 
tumour cell death in vivo. This could be attributable to the PTEN-deficiency of 
the model, which has been strongly associated with resistance to BRAF 
inhibitor treatment (Deng et al., 2012; Paraiso et al., 2011; Xing et al., 2012; Ye 
et al., 2013). Although, there is variability in the degree of resistance conferred 
by PTEN loss. Resistance mediated by PTEN-loss may explain the decreased 
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sensitivity of YUMM cell lines compared with the highly sensitive, and PTEN 
wild-type, A375 cells (Chen et al., 2012).  However, loss of PTEN alone would 
not account for the disparity between in vitro and in vivo cell death in the 
YUMM models. These contradictory findings may be reconciled by the 
presence of factors or interactions within the tumour microenvironment in 
vivo, which may confer a protective phenotype.  
There is considerable evidence that tumour-associated fibroblasts, immune 
cells and vasculature can mediate a BRAF inhibitor resistant phenotype 
(Junttila and de Sauvage, 2013). Hepatocyte growth factor (HGF), produced 
by stromal cells, has been shown to induce BRAFV600E melanoma resistance to 
both Vemurafenib and PLX4720 (Filitis et al., 2015). In patients, both increased 
expression of the HGF receptor cMET by melanoma cells and stromal cell 
expression of HGF have been correlated with BRAF inhibitor resistance  
(Straussman et al., 2012). Additionally, Vemurafenib induced melanoma cells 
to produce TGFβ, causing fibroblast differentiation, and stimulating 
differentiated fibroblasts to produce HGF. This resulted in fibroblast- and 
HGF-mediated resistance to Vemurafenib treatment (Fedorenko et al., 2015). 
Independently, TGFβ was shown to induce Vemurafenib resistance through 
EGFR and PDGFRβ upregulation (Sun et al., 2014). Fibroblast-mediated 
resistance has also been demonstrated to occur through production of focal 
adhesion kinase (FAK) and integrinβ1, driving ERK activation and BRAF 
inhibitor resistance (Hirata et al., 2015). Finally, TNFα has been implicated in 
BRAF inhibitor resistance, through activation of nuclear factor-κB (NFκB), and 
macrophages are a likely source of TNFα within the tumour 
microenvironment (Gray-Schopfer et al., 2007; Menon et al., 2013; Shao et al., 
2015). Therefore, a multitude of resistance mechanisms mediated by the 
tumour microenvironment can play a role in BRAF inhibitor resistance, some 
of which may be relevant to the YUMM1.1 and YUMM1.7 models.  
In addition to effects of the tumour microenvironment, intra-tumoural 
heterogeneity is a well-established mechanism of resistance in vivo, where 
targeted drug treatment selects for the outgrowth of resistant phenotypes (Shi 
et al., 2014; Somasundaram et al., 2012). YUMM1.1 and YUMM1.7 are 
primary cell lines, containing a variety of distinct cell morphologies. 
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Treatment with PLX4720 in vivo may stimulate the outgrowth of drug-
resistant populations, as shown previously in tumours with cell populations 
of mixed drug sensitivity (Obenauf et al., 2015). BRAFV600E melanomas 
sensitive to BRAF inhibition in vitro but refractory to treatment in vivo are 
becoming increasingly recognized. These models may represent the subset of 
patient BRAF-mutant melanomas that exhibit only limited, or short-term 
responsiveness to targeted BRAF inhibitors. With significant variability in the 
initial response of patients to BRAF inhibition, it is essential that research be 
carried out in models representing less responsive patients as well as in 
highly sensitive models  (Chapman et al., 2011; Sosman et al., 2012). 
PLX4720 induced reduction in A375- and SK-mel-5-mediated 
immunosuppression demonstrated in this chapter supports previously 
published data. Whilst the mediators of A375 and SK-mel-5 suppression were 
not investigated in this thesis, other studies using these cell lines have 
implicated the soluble factors TGFβ, IL-6, IL-10, VEGF, MICA/B and CCL22 
as being key mediators of immunosuppression (Diaz-Valdes et al., 2011; Groh 
et al., 2002; Sumimoto et al., 2006; Yaguchi et al., 2011). These findings 
support the role for non-cytotoxic effects of BRAF inhibitors in creating a 
more favourable immune microenvironment in both BRAF inhibitor-sensitive 
and resistant melanoma cells. These effects were unable to be assessed in the 
YUMM1.1 and YUMM1.7 models, due to an absence of soluble factors that 
suppressed T cell proliferation. However, these cell lines likely generate an 
immunosuppressive microenvironment through one of a number of 
alternative mechanisms. Some melanoma cells have been previously shown to 
express immunosuppressive molecules on the cell surface, such as CD200 or 
members of the B7 family (such as PD-L1) (Yaguchi et al., 2011). Alternatively, 
YUMM cells may express molecules or produce soluble factors that induce 
the differentiation and migration of regulatory immune cell phenotypes. 
3.3.1 Conclusions 
In this chapter I have demonstrated that targeted BRAF inhibition induces 
both murine and human BRAFV600E melanoma cell death via apoptosis. At 
non-cytotoxic concentrations, BRAF inhibitors can partially abrogate 
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melanoma-mediated immune suppression, reducing the production of 
soluble immunosuppressive factors by melanoma cells. These findings 
support the hypothesis that BRAF inhibition will generate a tumour 
microenvironment more favourable to anti-tumour immunity and strengthen 
the justification for combining targeted BRAF inhibition with 
immunotherapy.  
Two immunocompetent in vivo models of BRafV600E; Pten-/-; CDKN2a-/- murine 
melanoma have been optimized for further work. I have demonstrated that 
these models are only moderately sensitive to BRAF inhibition, and in vivo 
PLX4720 treatment reduced tumour growth but did not achieve tumour 
regression. This work has established a valuable model, which possesses key 
mutations genetically similar to many human melanomas and represents 
patients who are less sensitive to BRAF inhibition. This is a useful tool for 
further research into the combination of targeted BRAF inhibition and 
immunotherapy. 
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CHAPTER 4:  
Direct effects of BRAF  
inhibitors on immune 
cells 
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 Introduction 4.1
The previous chapter established that the targeted BRAF inhibitors PLX4720 
and Vemurafenib had cytotoxic effects on BRAFV600E melanoma cells, inducing 
cell death via apoptosis, which is potentially immunogenic. In addition, 
targeted BRAF inhibition reversed BRAFV600E melanoma-mediated 
immunosuppression. These findings support investigation into combination 
of PLX4720 with immunotherapy. However, prior to attempting to combine 
BRAF inhibitors with T cell-mediated immunotherapy it is crucial that any 
direct immunological effects are elucidated. Therefore, this chapter examines 
the direct effects of targeted BRAF inhibitors on T cell responses. 
When experimental research for this thesis commenced in 2012, it was widely 
assumed that targeted BRAF inhibitors would have no effect on immune cell 
viability or function due to their exceptional specificity for mutant BRAF over 
wild-type BRAF. Recently, several studies have investigated the effects of 
targeted BRAF inhibition on immune cells in vitro and in vivo, and the results 
have been contradictory (Callahan et al., 2014; Comin-Anduix et al., 2010; 
Gargett et al., 2015; Irving et al., 2013; Schilling et al., 2014). Both inhibitory 
and stimulatory effects of PLX4720 and Vemurafenib have been reported, and 
differential effects on T cell activation and function were observed. Despite 
study-to-study variation, clear detrimental effects of targeted BRAF inhibitors 
have been shown, questioning initial assumptions that PLX4720 and 
Vemurafenib would not affect immune cells. A major limitation of the studies 
published to date has been the concentration range of Vemurafenib and 
PLX4720 tested. Predominantly, doses of 50 µM or lower were tested, while 
patient plasma concentrations of Vemurafenib are often well in excess of this. 
Studies of patients receiving Vemurafenib have reported concentration ranges 
in patient plasma of 50-200 µM (Flaherty et al., 2010; Funck-Brentano et al., 
2015). The mean plasma concentration in the Vemurafenib phase I clinical 
trial was 80 µM (Flaherty et al., 2010). Furthermore, meta-analysis of 
Vemurafenib clinical trials revealed that patient plasma concentrations often 
reached 300 µM, which was determined to be the optimally effective 
concentration for tumour regression (Bollag et al., 2012). Therefore, it is 
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essential that the effects of BRAF inhibitors on immune cells are assessed at 
concentrations of greater than 50 µM. In addition to the variability reported in 
in vitro studies, there also appears to be a discrepancy in the immunological 
effects of BRAF inhibitors observed between in vitro and in vivo studies. In 
vivo studies have reported less significant inhibitory effects and more 
commonly beneficial effects of targeted BRAF inhibitor treatment on immune 
cells compared with in vitro studies (Frederick et al., 2013; Ho et al., 2014; 
Irving et al., 2013; Schilling et al., 2014). This variability is likely a product of 
the considerable differences in in vitro and in vivo microenvironments, in 
particular the difference in drug bioavailability when considering serum 
binding proteins. While the absolute bioavailability of Vemurafenib is 
unknown, it is highly bound by human plasma proteins (in excess of 99% 
binding), possibly altering drug availability in vivo (da Rocha Dias et al., 
2013).  
To validate findings reported in the literature, the effects of PLX4720 and 
Vemurafenib on both human and murine T cells in vitro was assessed at 
physiologically relevant concentrations. Immunological effects were also 
established in in vivo models to determine the translational applicability of in 
vitro findings.  
4.1.1 Aims 
The following series of experiments were undertaken to determine the direct 
effects of targeted BRAF inhibitors on T cell responses. In particular, these 
experiments aimed to: 
• Characterise the effects of targeted BRAF inhibition on human and 
murine T cells in vitro 
• Determine the consequences of PLX4720 treatment on antigen-specific 
T cell responses in vivo 
• Assess the relevance of BRAF inhibitor effects on T cell-mediated anti-
tumour responses in vivo 
 127 
 Results 4.2
4.2.1 Human and murine T cells are susceptible to inhibition 
by targeted BRAF inhibitors in vitro 
In order to establish the effects of targeted BRAF inhibitors on human T cell 
responses in vitro, PBMCs from healthy human donors were stimulated in a 
one-way mixed lymphocyte reaction and exposed to varying concentrations 
of PLX4720 or Vemurafenib (Figure 4.1A). Following seven days of 
stimulation and drug exposure cells were harvested and T cell viability and 
proliferation was assessed by flow cytometry. Unexpectedly, dose dependent 
effects were observed (Figure 4.1C). Below 1 µM neither PLX4720 nor 
Vemurafenib affected T cell proliferation or viability. However, at 
concentrations of greater than 1 µM inhibitory effects of drug treatment were 
evident with both viability and proliferation significantly reduced. 
Proliferative responses of T cells were more susceptible than viability to the 
detrimental effects of PLX4720 and Vemurafenib. Treatment with 12.5 µM 
PLX4720 reduced T cell proliferation by ~20% and viability by ~10% relative 
to controls. While 10 µM Vemurafenib had similar effects on viability (~10% 
reduction), the anti-proliferative effect was more substantial with a reduction 
in T cell proliferation of 60% relative to controls. Complete inhibition of T cell 
proliferation was observed with 200 µM PLX4720 or 100 µM Vemurafenib 
treatment, accompanied by decreases in viability of around 80% and 60% 
respectively.  
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Figure 4.1: PLX4720 and Vemurafenib inhibit human T cell proliferation 
and viability in vitro in mixed lymphocyte cultures. A. PBMCs from healthy 
autologous donors were combined in a one-way mixed lymphocyte reaction. 
Stimulator cells received 30 Gy γ-irradiation and responder cells were CFSE 
labelled. Cells were combined and treated with a range of concentrations (24 
nM-200 µM) of PLX4720 or Vemurafenib for 7 days. B. T cell proliferation was 
examined by flow cytometry. Representative dot plots show the gating 
strategy used to identify T cells and measure proliferation. C. Each symbol 
represents the mean of triplicates; error bars are ± S.D. Graphs are 
representative of at least 5 independent experiments using different donors, 
with similar results. 
 
Results from the mixed lymphocyte reactions revealed a clear detrimental 
effect of targeted BRAF inhibitor treatment on both T cell viability and 
proliferation. However, with mixed cell populations present within the assay 
it is possible that impaired T cell proliferation resulted from diminished 
stimulatory capacity of antigen presenting cells rather than direct inhibitory 
effects on T cells. To determine if PLX4720 and Vemurafenib directly affect T 
cells, human PBMCs were stimulated for three days with anti-CD3 and anti-
CD28 and treated with PLX4720 or Vemurafenib (Figure 4.2A). As seen in 
mixed lymphocyte reactions, T cell viability and proliferation were reduced 
with BRAF inhibitor treatment in a concentration dependent manner (Figure 
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4.2B). Trends were similar to those observed in previous experiments, with 
proliferation more sensitive than viability to both PLX4720 and Vemurafenib 
treatments. Concentrations of up to 6.75 µM PLX4720 and Vemurafenib did 
not effect T cell responses. However, treatment with 12.5 µM Vemurafenib 
reduced proliferation by approximately 25%, with viability remaining 
unaffected. Interestingly, PLX4720 treatment at the same concentration had 
no effect on T cells, again indicating a stronger inhibitory effect of 
Vemurafenib. At 50 and 100 µM both inhibitors almost completely abrogated 
T cell proliferation. PLX4720 had little effect on viability at 50 µM, but at 100 
µM resulted in 20% reduction in viability. Vemurafenib reduced viability by 
approximately 20% and 50% with 50 µM and 100 µM treatments respectively.  
The relative sensitivity of the two major subsets of T cells (CD4+ and CD8+) 
was then addressed by assessing the responses of sub-populations with anti-
CD3/28 stimulation (Figure 4.3A). Both CD4+ and CD8+ T cells were equally 
inhibited by treatment with PLX4720 and Vemurafenib, and showed similar 
response profiles to those seen in previous experiments (Figure 4.3B). 
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Figure 4.2: High concentrations of PLX4720 and Vemurafenib inhibit 
human T cell proliferation and viability in vitro with strong anti-CD3 and 
anti-CD28 stimulus. A. PBMCs from healthy human donors were stimulated 
for 3 days with 5 µg/mL anti-CD3, 0.5 µg/mL anti-CD28 and 20 U/mL IL-2. 
B. T cell proliferation was examined by flow cytometry. Representative dot 
plots show the gating strategy used to identify T cells and measure 
proliferation. C. Proliferation and viability are displayed as a percentage of 
DMSO control. Each symbol represents the mean of the triplicates. Error bars 
are ± S.D. Graphs are representative of 6 independent experiments using 
different donors, with similar results. 
 
 
 
 
 
 
 
Figure 4.3: PLX4720 and Vemurafenib inhibit human CD4 and CD8 T cell 
proliferation following strong anti-CD3 and anti-CD28 stimulation. PBMCs 
were stimulated with anti-CD3, anti-CD28 and IL-2 as described in Figure 
4.2A. A. T cell proliferation was examined by flow cytometry. Representative 
dot plots show the gating strategy used to identify CD4+ and CD8+ T cells and 
measure proliferation. B. Proliferation is displayed as a percentage of DMSO 
control. Each symbol represents the mean of the triplicates. Error bars are ± 
S.D. Graphs are representative of 3 independent experiments using different 
donors, with concordant results. 
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Having established the effects of BRAF inhibitors on human T cells, the effects 
on murine T cells in vitro were determined to allow direct comparison with 
human T cell responses. Splenocytes from naïve C57BL/6 mice were 
stimulated with anti-CD3 and anti-CD28, and treated with a range of 
concentrations of PLX4720 or Vemurafenib. (Figure 4.4A).  After three days 
cells were harvested and T cell viability and proliferation assessed by flow 
cytometry (Figure 4.4B). Murine T cells showed dose-dependent inhibition 
following both PLX4720 and Vemurafenib exposure (Figure 4.4C). Again, 
with inhibitor treatment at low concentrations (up to 6.75 µM) T cell 
proliferation and viability remained unaffected. Exposure to PLX4720 and 
Vemurafenib at concentrations of 12.5 µM and above inhibited proliferation, 
with complete inhibition observed at 25 µM PLX4720 and 100 µM 
Vemurafenib. Again, effects on viability were observed at higher 
concentrations with PLX4720 reducing viability at concentrations of 50 µM or 
higher and Vemurafenib reduced viability at 100 and 200 µM. In contrast to 
human T cells, murine T cells appeared more susceptible to treatment with 
PLX4720.  
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Figure 4.4: High concentrations of PLX4720 and Vemurafenib inhibit 
murine T cell proliferation and viability in vitro following strong anti-CD3 
and anti-CD28 stimulation. A. Splenocytes from C57BL/6 mice were 
stimulated for 3 days with 1 µg/mL anti-CD3, 1:50 anti-CD28 and 100 U/mL 
IL-2. B. T cell proliferation was examined by flow cytometry. Representative 
dot plots show the gating strategy used to identify T cells and measure 
proliferation. C. Proliferation and viability are displayed as a percentage of 
DMSO control. Each symbol represents the mean of triplicates and error bars 
are ± S.D. Graphs are representative of 6 independent experiments using 
different donors, with similar results. 
 
4.2.2 Serum protects T cells against detrimental effects of 
BRAF inhibitors in vitro 
Previous experiments demonstrated that targeted BRAF inhibitors 
significantly impair both T cell proliferation and viability. Despite this, 
lymphopaenia is not an adverse event commonly associated with 
Vemurafenib treatment in patients. This suggests there is some protective 
mechanism in vivo, with sequestration of drug by plasma binding proteins a 
likely explanation.  
To investigate the role of serum in sequestering BRAF inhibitors, human 
PBMCs were stimulated with anti-CD3/28 and exposed to PLX4720 at 
concentrations previously determined to inhibit T cell proliferation. 
Experiments were designed to assess the effects of PLX4720 on T cell 
proliferation in conditions of low serum (5%), normal serum (10%) or high 
serum (25-50%). Initial experiments were performed titrating FCS, to allow 
comparison with earlier data where FCS was the serum component used in 
cIMDM. These experiments revealed a clear role for serum concentration in 
modulating T cell susceptibility to PLX4720 inhibition of proliferative 
responses (Figure 4.5A). Increasing FCS concentrations provided protection 
against the detrimental effects of PLX4720 treatment. In low serum culture 
conditions, 25 µM PLX4720 impaired T cell proliferation, whilst in normal or 
high serum conditions 25 µM PLX4720 had less impact. The protective effects 
of higher serum culture conditions were observed at each drug concentration 
(Figure 4.5B).  
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To confirm the relevance of FCS findings to patients, similar experiments 
were performed using human AB serum. Again, human PBMCs were 
stimulated and the effects of PLX4720 treatment were assessed in conditions 
of low serum (5%), normal serum (10%) or high serum (25-50%).  T cells 
exposed to PLX4720 in the presence of human AB serum exhibited strikingly 
reduced sensitivity to inhibition of T cell proliferation, with protection 
directly associated with serum concentration (Figure 4.6A).  When compared 
with cultures containing FCS, all concentrations of human AB serum 
provided better protection against the detrimental effects of PLX4720 (Figure 
4.6B). High human AB serum culture conditions were completely protective 
against PLX4720 effects. Interestingly, in the presence of 50% human AB 
serum 25 µM and 50 µM PLX4720 consistently stimulated T cell proliferation.  
These data show that in high serum conditions the T cell inhibitory effects of 
PLX4720 are abrogated. This finding may explain the discrepancy between 
the severe inhibitory effects observed in vitro and the lack of clinical grade 
lymphopaenia reported in patients. Interestingly, there may be some capacity 
for PLX4720 to stimulate T cell proliferation, which is examined further in the 
next section. 
 
 
Figure 4.5: Increasing concentrations of foetal calf serum (FCS) are partially 
protective against the inhibitory effects of PLX4720 in vitro. PBMCs from 
healthy human donors were stimulated for 3 days with 1 µg/mL anti-CD3, 0.1 
µg/mL anti-CD28 and 20 U/mL IL-2 as described in Figure 4.2A. Cells were 
cultured in cIMDM with a range of FCS concentrations (5-50% FCS).  Cells were 
treated with DMSO vehicle control or PLX4720 ranging from 10-100 µM. T cell 
proliferation was examined by flow cytometry as described in Figure 4.2B. A. 
Proliferation is shown relative to DMSO control. Each symbol represents the mean 
of triplicate. B. Representative dot plots illustrating T cell CFSE staining are 
shown. Data are representative of 3 independent experiments using different 
donors, with similar results. 
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4.2.3 BRAF inhibitor treatment has paradoxical effects on 
sub-optimally stimulated human and murine T cells  
To establish the capacity of BRAF inhibitors to stimulate T cell proliferation 
experiments were performed investigating the effects of PLX4720 and 
Vemurafenib on sub-optimally-stimulated T cells. Initial experiments were 
aimed at confirming the ability of BRAF inhibitors to stimulate human T cell 
proliferation in vitro. As with previous experiments healthy human PBMCs 
were stimulated with anti-CD3 and anti-CD28. Sub-optimal stimulation was 
achieved by decreasing the concentration of anti-CD3 from 5 µg/mL to 3 
µg/mL. Both T cell proliferation, as measured by CFSE dilution, and T cell 
activation as determined by upregulation of CD69 expression were assessed 
by flow cytometry (Figure 4.7A). Treatment with Vemurafenib significantly 
augmented T cell proliferation at low concentrations, and some increased 
expression of the activation marker CD69 was also detected (Figure 4.7B and 
C). Conversely, at high concentrations, significant inhibition of T cell 
proliferation and non-significant decreases in CD69 expression were 
observed. These results confirm the concentration dependence of BRAF 
inhibitor effects on T cell functional parameters. Differential effects on 
proliferation compared with CD69 expression were observed. The strongest 
augmentation of T cell proliferation was seen at Vemurafenib concentrations 
between 50-500 nM, whilst concentrations of 5 µM and above clearly inhibited 
proliferation (Figures 4.7B and D). In contrast, concentrations of less than 500 
nM Vemurafenib had little impact on CD69 expression, with optimal drug-
Figure 4.6: Increasing concentrations of human AB serum abrogate the 
inhibitory effects of PLX4720 in vitro. PBMCs from healthy human donors were 
stimulated for 3 days with 1 µg/mL anti-CD3, 0.1 µg/mL anti-CD28 and 20 
U/mL IL-2 as described in Figure 4.2A. Cells were cultured in cIMDM with a 
range of human AB serum (Scheffer et al.) concentrations (5-50%).  Cells were 
treated with DMSO vehicle control or PLX4720 ranging from 10-100 µM. T cell 
proliferation was examined by flow cytometry as described in Figure 4.2B. A. 
Proliferation is shown relative to DMSO control. Each symbol represents the 
mean of triplicates, and error bars are ± S.D. B. Representative dot plots 
illustrating T cell CFSE staining are shown. Data are representative of 4 
independent experiments using different donors, with similar results. 
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induced augmentation seen with 2 µM treatment (Figure 4.7C). Detrimental 
effects of Vemurafenib treatment on CD69 expression were also less marked. 
The discrepancies between the inhibitory effects on CD69 expression and 
proliferation may be a result of differences between temporal kinetics of both 
measures. 
Subsequently, the stimulatory effects of BRAF inhibitors on murine T cells 
were assessed with a similar experimental design (Figure 4.8A). As with 
human T cells, murine T cell proliferation was increased with exposure to low 
concentrations of PLX4720 while high concentrations inhibited proliferation 
(Figure 4.8B). Stimulatory effects were most clearly observed between 50 nM 
and 2 µM PLX4720, and inhibition was evident at concentrations of greater 
than 5 µM (Figures 4.8B and D). No significant upregulation of CD69 
expression was observed at low concentrations of PLX4720, although a 
consistent trend of small increases was observed and activation was clearly 
decreased with exposure to 5 and 20 µM (Figure 4.8C). 
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Figure 4.7: Low concentrations of Vemurafenib boost human T cell 
proliferation in vitro with sub-optimal anti-CD3 and anti-CD28 
stimulation.PBMCs from healthy human donors were stimulated for 3 days 
with 3 µg/mL anti-CD3, 0.5 µg/mL anti-CD28 and 20 U/mL IL-2 as depicted 
in Figure 4.3A. A. T cell proliferation and activation (CD69 expression) was 
examined by flow cytometry. Representative dot plots show the gating 
strategy used to identify T cells. B. Proliferation is shown relative to the 
DMSO control. Each bar represents the mean of triplicates. Error bars are ± 
S.D. C. Each bar represents CD69 AlexaFluor700 average median fluorescence 
intensity (MFI) of triplicates. Error bars are ± S.D. D. Representative dot plots 
illustrating T cell CFSE staining are shown. NS = not significant, * p < 0.05, ** p 
< 0.01, *** p < 0.001, **** p <0.0001, by one-way ANOVA with Bonferroni 
post-test. Data are representative of 3 independent experiments using 
different donors, with concordant results. 
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Figure 4.8: Low concentrations of PLX4720 and Vemurafenib boost murine 
T cell proliferation in vitro with sub-optimal anti-CD3 and anti-CD28 
stimulation. Splenocytes from C57BL/6 mice were stimulated for 3 days with 
0.6 µg/mL anti-CD3, 1:50 anti-CD28 and 100 U/mL IL-2 as shown in Figure 
4.7A. A. T cell proliferation and activation (CD69 expression) was examined 
by flow cytometry. Representative dot plots show the gating strategy used to 
identify T cells. B. Proliferation is shown relative to the DMSO control. Each 
bar represents the mean of triplicates. Error bars are ± S.D. C. Each bar 
represents the average CD69 PE median fluorescence intensity (MFI) of 
triplicates. Error bars are ± S.D. D. Representative dot plots illustrating T cell 
CFSE staining are shown. NS = not significant, * p < 0.05, ** p < 0.01, **** p 
<0.0001, one-way ANOVA with Bonferroni post-test. Data are representative 
of 4 independent experiments.  
 
 
Building on the finding that BRAF inhibitors can stimulate T cell proliferation 
in vitro, the capacity of BRAF inhibitors to enhance antigen specific T cell 
proliferation in vivo was investigated. CD8+ T cells specific for the ovalbumin 
peptide SIINFEKL (‘OTI’ T cells) were adoptively transferred to syngeneic 
C57BL/6 mice. PLX4720 treatment was initiated on the day of T cell transfer, 
with mice receiving either the recommended dose of 20 mg/kg PLX4720 or 
vehicle control by oral gavage daily (Dr Gideon Bollag, personal 
communication). BRAF inhibitor treatment was performed for seven days to 
allow plasma drug levels to stabilise prior to the intravenous challenge with 
OVA and αGalCer to stimulate OTI T cell expansion (Figure 4.9A). PLX4720 
treatment continued following challenge and seven days later, at the expected 
peak of effector T cell responses, OTI T cell expansion was assessed by flow 
cytometry (Figure 4.9B). Without OVA and αGalCer challenge, OTI T cells 
were undetectable 14 days following adoptive transfer (Figures 4.9 C and D). 
Two different doses of OVA and αGalCer were delivered to achieve optimal 
and sub-optimal stimulation of OTI T cells. Previous work at the Malaghan 
Institute had identified that 200 µg OVA and 200 ng αGalCer optimally 
stimulates OTI T cell proliferation (Dr Taryn Osmond, personal 
communication). This was reduced to 100 µg OVA and 50 ng αGalCer to 
achieve sub-optimal stimulation. The lowered dose of antigen and adjuvant 
conferred an approximately two-fold reduction in the proportion of 
peripheral OTI T cells (Figures 4.9 C and D). PLX4720 treatment of mice that 
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received OTI T cells and 200 µg OVA with 200 ng αGalCer did not affect OTI 
T cell expansion, with a comparable proportion of OTI T cells detected seven 
days following challenge (Figure 4.9C). However, when OTI T cells were sub-
optimally stimulated with 100 µg OVA and 50 ng αGalCer, PLX4720 
treatment significantly increased the proportion of OTI T cells detected seven 
days following challenge (Figure 4.9D).  
These in vivo results support the in vitro findings that targeted BRAF 
inhibitors can stimulate T cell proliferation. In addition to the concentration 
dependence of stimulatory effects observed in vitro, there also appears to be a 
role for stimulus strength in determining stimulatory capacity. This could be 
explained by the fact that maximally stimulated T cells are unable to 
proliferate further despite BRAF inhibitor treatment. The lack of inhibitory 
effects observed with strong stimulus of the OTI T cells supports the in vitro 
finding that a high serum environment (such as the blood) may be protective 
against the negative effects of BRAF inhibitors observed in vitro. 
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Figure 4.9: PLX4720 boosts sub-optimal, but not optimal, antigen specific 
stimulation of OTI T cells in vivo. A. 1 x 104 CD8+ OTI T cells were 
adoptively transferred to naïve C57BL/6 mice. On the same day BRAF 
inhibitor treatment was initiated with 20 mg/kg PLX4720 given daily by oral 
gavage. 7 days post-adoptive transfer mice received 100-200 µg OVA + 50-200 
ng αGalCer intravenously. 7 days later mice were bled via the lateral tail vein. 
B. The proportion of OTI T cells in the peripheral blood was analysed by flow 
cytometry. C. OVA was delivered at 200 µg and αGalCer at 200ng, deemed 
“maximal stimulus”. D. Mice received 100 µg OVA and 50 ng αGalCer, 
deemed “sub-maximal stimulus”.  C and D. Each bar represents the mean of 
the group (5 mice), N.D. = non-detectable. Error bars are ± SEM. NS = not 
significant, ** p < 0.01, **** p <0.0001, one-way ANOVA with Bonferroni post-
test. Data are representative of 3 independent experiments, with concordant 
results. 
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4.2.4 Anti-tumour vaccination is unaffected by BRAF 
inhibition, while tumour growth is enhanced in a BRAF 
wild-type mouse model 
Having established that BRAF inhibitors can stimulate T cell proliferation, 
experiments were designed to investigate the relevance of this finding to anti-
tumour T cell responses. This required a melanoma tumour model insensitive 
to targeted BRAF inhibition, to allow inhibitor effects on T cell-mediated anti-
tumour responses to be assessed without BRAF inhibition affecting tumour 
growth. Having previously established that the BRAF wild-type B16 
melanoma cell line was highly resistant to PLX4720 and Vemurafenib 
treatment in vitro (Chapter 3), this tumour model was deemed suitable. It was 
also necessary to be able to induce effective anti-tumour T cell responses to 
investigate drug effects on tumour-specific T cells. Therefore, the B16.OVA 
tumour model was selected for these experiments; this model is derived from 
the B16 cell line and has been stably transfected to express ovalbumin as a 
model antigen (Moore et al., 1988).  
Anti-tumour T cell responses were generated using a vaccine of 200 µg OVA 
with 200 ng of the adjuvant αGalCer to stimulate endogenous ovalbumin-
specific T cells. Mice were injected with tumours and seven days later, at 
which point tumours were palpable, daily treatment with 20 mg/kg PLX4720 
was initiated. The following day vaccination was delivered intravenously. 
Vaccination significantly slowed B16.OVA tumour growth (Figure 4.10B and 
C), which corresponded to significantly increased survival (Figure 4.10D) 
indicating effective anti-tumour T cell responses were elicited. As a control 
mice with B16.OVA tumours were treated with single agent 20 mg/kg 
PLX4720. Unexpectedly, PLX4720 treatment significantly increased tumour 
growth (Figure 4.10B), appearing to push tumours towards a more aggressive 
phenotype (Figure 4.10C). This increased growth rate of tumours 
corresponded with significantly decreased survival of mice treated with 
PLX4720 (Figure 4.10D).  
The increased tumour growth seen with PLX4720 treatment confounded the 
experimental design. As a result of this, too many variables were affected by 
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PLX4720 treatment, which made it difficult to assess the direct effects of 
PLX4720 treatment on anti-tumour T cell responses. In an attempt to further 
elucidate the effects of PLX4720 on anti-tumour vaccine efficacy, survival 
benefit with vaccine or vaccine/PLX4720 combination was plotted relative to 
the appropriate control group, which were taken to be tumour only or 
PLX4720 only respectively (Figure 4.10E). In this way, the contribution of 
PLX4720 treatment to tumour growth could be assessed. Analysis showed no 
significant impact of PLX4720 on vaccine, and a non-significant but consistent 
trend towards increased vaccine efficacy across experimental repeats. 
However, due to the unexpected increase in tumour growth with single agent 
PLX4720 robust conclusions are unable to be drawn from these experiments. 
 
To confirm the effects of targeted BRAF inhibition on BRAF wild-type 
melanoma growth, B16.OVA cells were treated with PLX4720 and 
Vemurafenib in vitro. Cellular reduction of MTT was used as an indirect 
measure of cell number, and thus proliferation. Concentration dependent 
effects of BRAF inhibitor treatment were observed (Figure 4.11). Low 
concentrations of ≤ 360 nM had no effect on B16.OVA tumour growth. 
However, at concentrations of 780 nM–1.56 µM, a stimulatory effect of 
PLX4720 treatment was repeatedly observed, which was not present with 
Vemurafenib treatment. PLX4720 at 6.25–50 µM significantly stimulated 
growth, and comparable concentrations of Vemurafenib reliably achieved 
small increases in B16.OVA growth. Growth was inhibited with 200 µM 
PLX4720 and 100–200 µM Vemurafenib.  
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Figure 4.10: PLX4720 has no effect on anti-tumour vaccination in a BRAFWT 
B16.Ova tumour model, but directly stimulated BRAFWT tumour growth. A. 
C57BL/6 mice were injected subcutaneously in the left flank with 1 x 105 
B16.Ova cells. Daily drug treatment was initiated 7 days post-tumour 
challenge with 20 mg/kg PLX4720 given by oral gavage. The day after 
beginning drug treatment mice were vaccinated intravenously with 200 µg 
OVA + 200 ng αGalCer. Tumour growth was monitored and size recorded. 
Mice were culled when tumours reached 150 mm2, or when tumours 
ulcerated. B. Average tumour growth is shown and each symbol represents 
the mean growth of 4-5 mice. Error bars are ± SEM. C. Individual tumour 
growth is shown. Each symbol represents one mouse. D. Percent survival 
shown for groups of 4-5 mice. Treatment groups are compared to vehicle-
treated control mice * P ≤ 0.05, ** P < 0.01, Mantel-Cox test. E.  Overall 
survival shown relative to the survival of the appropriate control group, NS = 
not significant, unpaired t-test with Welch’s correction. Graphs are 
representative of two independent experiments. 
 
 
 
 
Figure 4.11: PLX4720 stimulates BRAFWT B16.Ova melanoma growth in 
vitro. Cells were treated with a range of concentrations (24 nM-200 µM) of 
PLX4720 or Vemurafenib for 48 hours. Cell proliferation was measured by 
MTT reduction, and shown as a percentage of DMSO treated control. Each 
symbol represents the mean of the triplicates. Error bars are ± S.D. Curves 
were generated by non-linear regression analysis. Drug treated triplicates 
were compared to DMSO control by one-way ANOVA with Bonferroni post-
test. Points for which no stars are shown differences were non-significant, * P 
≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Graphs are representative of at 
least four independent experiments.  
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 Discussion 4.3
The focus of this chapter was to elucidate the effects of targeted BRAF 
inhibitors on T cell responses. I demonstrated that BRAF inhibition can either 
augment or inhibit T cell proliferation, depending on the setting and the 
inhibitor concentration. These results confirmed previously published work 
(Callahan et al., 2014; Comin-Anduix et al., 2010; Gargett et al., 2015). 
However this is the first time the contradictory effects have been reported 
together, indicating that the difference between inhibitory and stimulatory 
effects is not solely due to different inhibitors or culture conditions, as was 
previously suggested (Callahan et al., 2014). Furthermore, I have shown that 
high serum environments are protective against the detrimental effects of 
targeted BRAF inhibitors. This novel finding reconciles the contradictory 
effects observed in in vitro and in vivo studies. 
The concentrations at which inhibitory effects on T cells were demonstrated in 
vitro fall within the range of patient plasma concentrations, which averaged 
80 µmol/L in phase I clinical trial (Bollag et al., 2010; Flaherty et al., 2010). 
However, because Vemurafenib is more than 99% protein bound in serum, 
the free concentration of Vemurafenib should be less than 1% of the total 
plasma concentration (FDA, 2011). On this basis, immune cells within the 
circulation will be protected from inhibitory concentrations of free drug. This 
is supported by the protection I have demonstrated under high serum 
conditions in vitro. Nevertheless, the intratumoural concentration of 
Vemurafenib in patients, or mice, has not been well defined, and increased 
free drug concentrations may be possible. Daily dosing of mice with 100 
mg/kg Vemurafenib generated peak plasma concentrations of greater than 
100 µmol/L, and corresponding intratumour concentrations of 15 µmol/L 
(Yang et al., 2010). If this is free drug, intratumoural concentrations of 
inhibitors may approach concentrations at which growth inhibition and 
decreased viability of T cells have been observed in vitro in this study. 
However, both the data presented in this chapter and in the study by Comin-
Anduix and colleagues show highly activated lymphocytes are more resistant 
to detrimental effects of BRAF inhibitors (Comin-Anduix et al., 2010). Thus, 
activated T cells within the tumour microenvironment are more likely to be 
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unaffected by high inhibitor concentrations, which would have significant 
effects on BRAFV600E melanoma cells. Collectively, these findings may explain 
the lack of clinical grade lymphopaenia observed in patients. However, the 
study by Schilling and colleagues reported decreased numbers of peripheral 
lymphocytes with Vemurafenib treatment, indicating that inhibitory effects 
may be occur in vivo and need to be considered when clinical dosing is being 
determined (Schilling et al., 2014).  
The paradoxical stimulatory effects of BRAF inhibitors on T cell responses 
were demonstrated within a unique, and lower, dose range. Additionally, 
these effects were more apparent in settings of sub-maximal T cell 
stimulation. It is well established that activation of BRAFWT cells occurs due to 
inhibitor transactivation of RAF dimers, resulting in downstream ERK 
signalling (Callahan et al., 2014; Halaban et al., 2010; Hatzivassiliou et al., 
2010; Heidorn et al., 2010; Poulikakos et al., 2010). Having demonstrated these 
effects in vivo with antigen-specific T cell proliferation highlights a possible 
capacity for augmentation of anti-tumour T cell responses. Unfortunately, as 
PLX4720 also increased wild-type BRAF melanoma proliferation the effects 
on anti-tumour T cell responses were unable to be fully assessed. The growth 
promoting consequences of BRAF inhibition in the BRAFWT B16.Ova tumours 
highlights the importance of rigorous tumour typing, and the risk of treating 
tumours with heterogeneous expression of BRAFV600E. This represents a 
significant clinical problem, as both intratumour and intertumour 
polyclonality of the BRAF mutation has been shown in metastatic melanoma 
specimens. In two small but independent studies, heterogeneity of BRAF 
alleles was reported in 67-80% of primary tumour samples, whilst 26% of 
metastases were shown to have BRAF status discordant with the primary 
tumour type (Lin et al., 2011; Yancovitz et al., 2012). Therefore, it is likely that 
in a large proportion of patients who develop BRAF inhibitor resistance, 
initial treatment with a targeted BRAF inhibitor is selecting for BRAFWT 
tumour cell outgrowth. This strengthens the rationale for combination of 
targeted therapy with immunotherapy, which will target melanoma cells 
irrespective of their mutation status. 
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4.3.1 Conclusions 
The results presented in this chapter have confirmed and extended previous 
studies demonstrating the paradoxical effects targeted BRAF inhibitors exert 
on T cell responses. I have provided strong evidence that PLX4720 can 
stimulate antigen-specific T cell responses in vivo, although it remains 
uncertain if anti-tumour T cell responses could be similarly augmented with 
targeted BRAF inhibitors. It is critical for success of combination BRAF 
inhibitor and immunotherapy that the direct effects of BRAF inhibitors on T 
cells are considered. Optimal combination therapy approaches may be able to 
harness the T cell stimulatory effects of BRAF inhibition, to achieve maximal 
augmentation of anti-tumour T cell responses. However, further elucidation 
of patient intratumoural inhibitor concentrations at clinically relevant doses 
would be required. This will also be necessary to ensure the elimination of 
detrimental effects on TILs. 
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CHAPTER 5: Developing  
an autologous vaccine 
for BRAFV600E tumours 
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 Introduction 5.1
Recent advances in immunotherapy have transformed the treatment of 
metastatic melanoma. These breakthroughs have been driven by the 
development and clinical progression of antibodies against the checkpoint 
molecules CTLA-4 and PD-1. Targeting of immune checkpoints generates 
anti-tumour effects by blocking immunoinhibitory signals and unleashing 
existing tumour-specific immune responses. However, many patients do not 
respond to checkpoint blockade therapy. Meta-analysis of Ipilimumab (anti-
CTLA-4) trials revealed approximately 20% of patients responded to 
treatment (Schadendorf et al., 2015b; Topalian et al., 2015), while the phase III 
clinical trial of Nivolumab (anti-PD-1) achieved responses in around 30% of 
patients (Robert et al., 2015a). Amongst the unresponsive patient cohort, it is 
likely that there are individuals who lack pre-existing anti-tumour immune 
responses (Delamarre et al., 2015). In these patients active immunization 
approaches, which promote the development of anti-tumour immune 
responses, may be more effective. Furthermore, when considering 
immunotherapy for combination with targeted BRAF inhibitors, checkpoint 
blockade may not represent the best immunotherapeutic strategy, as 
demonstrated by the unsuccessful phase I clinical trial combining Ipilimumab 
and Vemurafenib (Ribas et al., 2013). Other immunotherapeutic approaches 
may be more suitable for combination with BRAF inhibitors.  
Autologous tumour cell vaccination is a form of active immunization that 
aims to generate anti-tumour immune responses. This approach delivers a 
full complement of tumour specific antigens, including undefined 
neoantigens, to stimulate cells of the innate and adaptive systems. The ability 
to stimulate responses to undefined neoantigens, which have been shown to 
drive potent anti-tumour effector T cell responses, is a major benefit of this 
approach (Carreno et al., 2015; Schumacher and Schreiber, 2015). To be 
effective the fundamental requirement of active immunotherapy is the 
stimulation of strong anti-tumour immune responses that generate long-
lasting memory. However, without sufficient licensing of DCs upon 
activation, vaccination can have a tolerizing effect (Qiu et al., 2009; Steinman 
et al., 2000). The inclusion of an adjuvant promotes optimal DC activation, to 
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generate effector T cell responses. The glycolipid αGalCer has been shown to 
have potent adjuvant activity, stimulating iNKT cells to license dendritic cells, 
which has been demonstrated to be one of the most effective ways of 
inducing DC maturation (Fujii et al., 2003; Hermans et al., 2003b; Kawano et 
al., 1997; Liu et al., 2005). Initial attempts to use αGalCer in a tumour setting 
involved the infusion of soluble αGalCer. However, this approach was largely 
ineffective due to the induction of iNKT anergy (Parekh et al., 2005). DCs 
loaded with αGalCer have been more successful as a vaccine, inducing potent 
anti-tumour effects in several murine models, including the BRAFWT B16 
melanoma model (Fujii et al., 2002). However, this approach faces technical 
hurdles with difficulty in extracting and expanding DCs from the peripheral 
blood mononuclear cells of patients. These limitations have driven the use of 
γ-irradiated, autologous tumour cells loaded with αGalCer as a preferable 
vaccine approach (Chung et al., 2007; Mattarollo et al., 2012; Shimizu et al., 
2007b).  Irradiation of tumour cells prior to vaccination prevents tumour cell 
growth when delivered intravenously, and increases the immunogenicity of 
tumour cells (Obeid et al., 2007). Further supporting the use of tumour cells 
over DCs as the cellular component of vaccine, αGalCer-loaded tumour cells 
have been shown to induce more effective T cell responses when compared to 
αGalCer-loaded DCs (Shimizu et al., 2007b).  
Delivery of αGalCer-loaded, irradiated tumour cells should allow DCs to 
simultaneously acquire tumour antigens and αGalCer. Therefore, tumour-
derived peptides could be presented on MHC molecules to T cells while 
αGalCer is simultaneously presented on CD1d to iNKT cells. DC and iNKT 
interactions promote CD40-CD40L signalling and lead to DC activation, 
increasing the capacity of DCs to stimulate tumour-specific effector T cell 
responses, as previously introduced (Chapter 1.5.5, Figure 1.3). Importantly, 
vaccines based on the administration of autologous tumour cells and αGalCer 
have been demonstrated to be highly effective in several murine tumour 
models including the B16 model (Gibbins et al., 2014; Hunn et al., 2012; 
Mattarollo et al., 2012; Shimizu et al., 2007b; Weinkove et al., 2013).  
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This approach has translational relevance, with autologous vaccination 
enabling targeting of patient-specific neoantigens. In addition, the use of 
αGalCer as an adjuvant has broad clinical application; as CD1d is not 
polymorphic, iNKT licensing of DCs is not dependent on HLA status. The 
iNKT population required for this approach has been shown to be present in 
late stage melanoma patients.  Circulating iNKT cell populations were 
detected in patients prior to anti-CTLA-4 therapy and shown to be capable of 
eliciting strong anti-tumour immune responses (Ibarrondo et al., 2013).  
5.1.1 Aims 
The research undertaken in this chapter aimed to develop an active 
immunotherapeutic approach with anti-tumour efficacy against BRAFV600E 
melanoma. The following series of experiments were designed to develop and 
characterise an autologous, whole tumour cell vaccine. Specific aims were to: 
• Determine the ability of an irradiated, αGalCer-loaded YUMM1.1 or 
YUMM1.7 tumour cell vaccine to induce an immune response 
• Assess the anti-tumour efficacy of autologous vaccination  
• Characterise the immune cell types involved in vaccine response 
 Results 5.2
5.2.1 Vaccination with irradiated, αGalCer-loaded YUMM1.1 
and YUMM1.7 cells induces T cell-mediated immune 
responses 
Initial experiments were performed to establish whether irradiated, αGalCer-
loaded YUMM1.1 and YUMM1.7 cells could induce an immune response in 
naïve mice. To generate the whole tumour cell vaccine melanoma cells were 
pulsed with αGalCer overnight, washed to remove excess, unbound αGalCer 
and irradiated. Irradiation was performed to prevent tumour outgrowth and 
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to enhance immunogenicity. As iNKT cells are predominantly located in the 
spleen and liver, vaccine was delivered intravenously to provide access to 
these populations. Naïve mice received vaccine intravenously and control 
mice received PBS. Seven days later responses in peripheral lymphoid tissues 
were assessed (Figure 5.1A). Both the spleen and lung-draining mediastinal 
lymph node (mdLN) were collected for analysis as these tissues have 
previously been shown to be sites at which priming occurs with αGalCer-
adjuvanted whole tumour cell vaccines (Gibbins et al., 2014; Hunn et al., 
2012).  
Vaccination with irradiated, αGalCer-loaded YUMM1.1 and YUMM1.7 cells 
resulted in an increase in the overall size of the spleens (Figure 5.1B and C) 
and mdLN. The increased size of these lymphoid tissues was associated with 
significantly increased absolute cell counts and numbers of CD45+ immune 
cells (Figure 5.1D-G). Specific immune cell subsets were assessed by flow 
cytometry, with T cell, NK cell and NKT cell populations defined as shown in 
Figure 5.2A. As changes in lymphocyte numbers following vaccination 
reflected an overall increase in the number of CD45+ immune cells, Data are 
presented as population frequencies. Although vaccination is likely to 
enhance iNKT cell responses, the frequency of general NKT cells within the 
spleen was relatively low and remained unchanged with both YUMM1.1 and 
YUMM1.7 vaccines (Figure 5.2B). Within the mdLN the NKT cell population 
comprised an even smaller proportion of the total CD45+ immune cell 
population, and was decreased following vaccination (Figure 5.3B).  Similarly, 
the NK cell populations within the mdLN and spleen were relatively small 
and remained largely unchanged following vaccination, although YUMM1.7 
vaccine decreased the frequency of splenic NK cells (Figure 5.2C). The T cell 
population represented a large proportion of lymphocytes within the CD45+ 
immune cell population in the mediastinal lymph node, and was unaltered 
with vaccination (Figure 5.3A). Within the spleen the frequency of total T cells 
was slightly decreased with YUMM1.1 vaccine and significantly decreased 
with YUMM1.7 vaccination.   
Despite decreases in the overall T cell population in the spleen, the frequency 
of non-regulatory CD4+ and CD8+ T cells remained unchanged (Figure 5.2D 
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and F). In contrast, while there was no change in the overall T cell population 
within the mdLN both vaccines decreased the frequency of non-regulatory 
CD4+ T cells and increased the frequency of CD8+ T cells (Figure 5.3D and F). 
Interestingly, within both the spleen and mdLN, vaccination significantly 
reduced the proportion of Tregs (Figures 5.2E and 5.3E). The increased 
proportion of CD4+ and CD8+ T cells expressing the activation marker CD44 
and down-regulating the lymph node-homing molecule CD62L were 
indicative of increased effector T cell populations within both tissues (Figures 
5.2G&H, and 5.3G&H). Collectively, these changes in T cell populations 
resulted in significantly increased ratios of non-regulatory CD4+ T cells and 
CD8+ T cells to Tregs, as well as increased ratios of effector T cells to 
regulatory T cells, in both the spleen and mdLN (Figures 5.3 and 5.5).  
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Figure 5.1: Whole tumour cell vaccination induces an immune response. A. 
Naïve C57BL/6 mice were intravenously administered vaccines consisting of 
irradiated, αGalCer-loaded YUMM1.1 or YUMM1.7 cells. Control mice 
received PBS. One week post-vaccination, mice were culled and spleens and 
mdLN were harvested. Cell counts were assessed by trypan blue exclusion 
and CD45 expression was determined by flow cytometric analysis (as shown 
in Figure 5.2A). The number of CD45+ immune cells was calculated by 
multiplying the percentage of CD45+ immune cells by the total number of 
single cells. Single cell numbers were determined by multiplying percentages 
of single cells by total number of live cells as determined by trypan blue 
exclusion. Vaccination resulted in gross splenomegaly (B), increased spleen 
weight (C) and increased spleen and mdLN cellularity (D, F). Numbers of 
CD45+ immune cells were increased both in the spleen and mdlN (E, G). Each 
data point represents an individual mouse, with 4-5 mice used per group. 
Error bars are ± SEM. * p ≤ 0.05, ** p < 0.01, *** p < 0.001, **** p <0.0001, one-
way ANOVA with Bonferroni post-test. Results are representative of two 
independent experiments. 
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Figure 5.2: Vaccination decreases frequencies of Tregs and increases 
frequencies of effector T cells within the spleen. C57BL/6 mice were 
vaccinated as described in Figure 5.1A. One week following vaccination 
spleens were harvested and immune cell frequencies assessed by flow 
cytometry. A. Gating strategy used to define splenic T cell, NK and NKT cell 
populations. Samples were pre-gated on live, single cells. Subsets were 
defined as follows: T cells = CD3+; NKT cells = NK1.1+, CD3+; NK cells = 
NK1.1+, CD3-; Non-regulatory T cells = CD3+, CD4+, FoxP3-; Tregs = CD3+, 
CD4+, FoxP3+; CD8 T cells = CD3+, CD8+; Effector T cells = subset defined as 
previously described then CD44hi, CD62Llo. B-I. Frequencies of T cells, NK 
cells and NKT cells. Values represent individual mice, with 4-5 mice used per 
group. Error bars are ± SEM. * p ≤ 0.05, ** p < 0.01, *** p < 0.001, **** p 
<0.0001, one-way ANOVA with Bonferroni post-test. Results are 
representative of two independent experiments. 
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Figure 5.3: Vaccination decreases frequencies of both non-regulatory CD4+ 
T cells and Tregs and increases frequencies of CD8 T cells and effector T 
cells within the mdLN. C57BL/6 mice were vaccinated as described in Figure 
5.1A. One week following vaccination mdLN were harvested and immune 
cell frequencies assessed by flow cytometry. Samples were pre-gated on live, 
single cells and T cell, NK and NKT cell populations were defined as shown 
in Figure 5.2A. A-H. Frequencies of T cells, NK cells and NKT cells. Values 
represent individual mice, with 4-5 mice used per group. Error bars are ± 
SEM. * p ≤ 0.05, ** p < 0.01, *** p < 0.001, **** p <0.0001, one-way ANOVA 
with Bonferroni post-test. Results are representative of two independent 
experiments. 
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Figure 5.4: Vaccination favourably increases ratios of splenic non-
regulatory and effector T cells to Tregs. C57BL/6 mice were vaccinated as 
described in Figure 5.1A. One week following vaccination spleens were 
harvested and immune cell frequencies assessed by flow cytometry. Samples 
were pre-gated on live, single cells and T cell, NK and NKT cell populations 
were defined as shown in Figure 5.2A. The number of specific T cells was 
calculated by multiplying the population percentage by the total number of 
cells in the preceding gate. Cell numbers within the initial single cell gate 
were determined by multiplying percentages of single cells by total number 
of live cells as determined by trypan blue exclusion. A. Ratio of non-
regulatory CD4+ FoxP3- cells to CD4+ FoxP3+ Tregs. B. Ratio of effector CD4+ 
FoxP3- cells to Tregs. C. Ratio of CD8+ cells to CD4+ FoxP3+ Tregs. D. Ratio of 
effector CD8+ cells to Tregs. Values represent individual mice, with 4-5 mice 
used per group. Error bars are ± SEM. * p ≤ 0.05, ** p < 0.01, *** p < 0.001, one-
way ANOVA with Bonferroni post-test. Results are representative of two 
independent experiments. 
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Figure 5.5: Vaccination favourably increases ratios of mdLN non-regulatory 
and effector T cells to Tregs. C57BL/6 mice were vaccinated as described in 
Figure 5.1A. One week following vaccination spleens were harvested and 
immune cell frequencies assessed by flow cytometry. Samples were pre-gated 
on live, single cells and T cell, NK and NKT cell populations were defined as 
shown in Figure 5.2A. The number of T cells was calculated by multiplying 
the population percentage by the total number of cells in the preceding gate. 
Cell numbers within the initial singlet cell gate were determined by 
multiplying percentages of single cells by total number of live cells as 
determined by trypan blue exclusion. A. Ratio of non-regulatory CD4+ FoxP3- 
cells to CD4+ FoxP3+ Tregs. B. Ratio of effector CD4+ FoxP3- cells to Tregs. C. 
Ratio of CD8+ cells to CD4+ FoxP3+ Tregs. D. Ratio of effector CD8+ cells to 
Tregs. Values represent individual mice, with 4-5 mice used per group. Error 
bars are ± SEM. * p ≤ 0.05, ** p < 0.01, *** p < 0.001, **** p <0.0001, one-way 
ANOVA with Bonferroni post-test. Results are representative of two 
independent experiments. 
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Taken together the data presented in this section show that both irradiated, 
αGalCer-loaded YUMM1.1 and YUMM1.7 cells can induce an immune 
response in naïve mice, which is predominantly T cell-mediated. Vaccination 
enhances effector T cell populations and reduces regulatory T cell frequency.  
5.2.2 Autologous vaccination is partially protective against 
YUMM1.1 tumours but has minimal anti-tumour activity 
in YUMM1.7 tumours  
Having ascertained that irradiated, αGalCer-loaded YUMM1.1 and YUMM1.7 
cells induce an immune response, the anti-tumour efficacy of autologous 
vaccination was assessed in both a prophylactic setting and in mice with 
established tumours. C57BL/6 mice received vaccine either seven days prior 
to tumour challenge, to allow development of an effector T cell response, or 
five days after sub-cutaneous injection of 2 x 105 YUMM1.1 cells or 1 x 105 
YUMM1.7 cells (Figures 5.6A and 5.7A). Tumour growth was monitored and 
size recorded every two to three days. Mice were culled when tumours 
reached 150 mm2 or became severely ulcerated.  
Vaccine provided protection in both prophylactic and therapeutic settings 
against YUMM1.1 tumours, with tumour growth significantly decreased 
(Figure 5.6B) and survival increased (Figure 5.6D). Although vaccination 
significantly delayed tumour growth, no tumour regression was seen 
indicating tumours were able to suppress or escape anti-tumour immune 
responses.  
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Figure 5.6: Prophylactic and therapeutic autologous whole tumour cell 
vaccination slows YUMM1.1 growth and increases survival. A. C57BL/6 
mice were vaccinated intravenously with irradiated, αGalCer-loaded 
YUMM1.1 cells either prophylactically seven days prior to tumour challenge, 
or therapeutically five days post-tumour challenge. Control mice received 
PBS. Mice were challenged sub-cutaneously with 2 x 105 YUMM1.1 cells. 
Tumour growth was monitored and size recorded. Mice were culled when 
tumours reached 150 mm2, or when tumours ulcerated. B. Average tumour 
growth is shown, each symbol represents the mean growth of 4-5 mice, error 
bars are ± SEM. **** P ≤ 0.0001, 2-way ANOVA with Bonferroni post-test, 
statistics shown for Day 27. C. Individual tumour growth, each data point 
represents one mouse. D. Percent survival is shown for 2 combined 
experiments each with 4-5 mice per group. Treatment groups are compared to 
control mice ** P < 0.01, **** P < 0.0001 Mantel-Cox test. Tumour growth is 
representative of two independent experiments (as tumours were measured 
on different days data was unable to be combined). Survival Data are pooled 
from two independent experiments. 
 
 
In a prophylactic setting, vaccination slowed YUMM1.7 tumour growth 
significantly, although no tumour regression was induced (Figure 5.7B). 
Despite the effect of prophylactic vaccination on tumour growth, vaccination 
only conferred a small survival benefit, which was not statistically significant 
over control mice (Figure 5.7D). Vaccine efficacy was also tested in hosts with 
established YUMM1.7 tumours. Although the vaccine provided a small 
benefit in a prophylactic setting, in the therapeutic model no protection was 
evident. Following therapeutic vaccination both tumour growth and mouse 
survival were unchanged (Figures 5.7 B-D).  
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Figure 5.7: Prophylactic but not therapeutic autologous whole tumour cell 
vaccination slows YUMM1.7 growth but does not increase survival. A. 
C57BL/6 mice were vaccinated intravenously with irradiated, αGalCer-
loaded YUMM1.7 cells either prophylactically seven days prior to tumour 
challenge, or therapeutically five days post-tumour challenge. Control mice 
received PBS. Mice were challenged sub-cutaneously with 1 x 105 YUMM1.7 
cells. Tumour growth was monitored and size recorded. Mice were culled 
when tumours reached 150 mm2, or when tumours ulcerated. B. Average 
tumour growth is shown, each symbol represents the mean growth of 4-5 
mice, error bars are ± SEM. *** P < 0.001, 2-way ANOVA with Bonferroni 
post-test, statistics shown for Day 27. C. Individual tumour growth. Each data 
point represents one mouse. D. Percent survival is shown for groups of 4-5 
mice. Treatment groups are compared to control mice. NS= non-significant, 
Mantel-Cox test. Data are representative of two independent experiments. 
 
 
 
 
Figure 5.8: YUMM1.1 and YUMM1.7 cells do not express CD1d. Cells were 
cultured for 48 hours and subsequently harvested. CD1d  expression was 
assessed in triplicate by flow cytometry. Plots are representative of two 
independent experiments. 
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Autologous whole tumour cell vaccination had greater efficacy in the 
YUMM1.1 model, than in the YUMM1.7 model. In both the prophylactic and 
therapeutic setting vaccination significantly decreased YUMM1.1 tumour 
growth and increased survival, while in the YUMM1.7 model only 
prophylactic vaccine showed an anti-tumour effect. CD1d expression was 
analysed to determine if either cell line could directly present αGalCer to 
iNKT cells. Results demonstrated that neither YUMM1.1 nor YUMM1.7 cells 
expressed CD1d (Figure 5.8), indicating that differential responsiveness to 
vaccine is not a result of a different mechanism of αGalCer association with 
tumour cells. Due to the increased efficacy of autologous vaccination against 
YUMM1.1 tumours, this model was used in subsequent experiments to 
investigate combination therapy approaches. While vaccination has 
significant anti-tumour activity in the YUMM1.1 model, the efficacy is only 
moderate as no tumour regression is evident. This “sub-optimal” form of 
immunotherapy is ideal to investigate combination therapy with PLX4720 
because it will allow synergistic effects of targeted chemotherapy and 
immunotherapy to be determined. 
5.2.3 YUMM1.1 vaccination of tumour-bearing mice alters the 
frequencies of T cell sub-populations but does not 
significantly change NK, NKT or myeloid populations 
The preceding experiments established the YUMM1.1 tumour model as the 
preferable model for investigating vaccine and BRAF inhibitor combination 
therapy. In naïve mice YUMM1.1 vaccination induced effector T cell 
responses within the spleen and mdLN. Next, experiments were performed to 
define the immune cell populations within the tumour and peripheral 
lymphoid tissues of tumour bearing mice. The aim of these experiments was 
to identify immune cell subsets mediating anti-tumour effects of the vaccine. 
C57BL/6 mice were vaccinated either prophylactically or therapeutically with 
tumour challenge as previously described. Fourteen days post-tumour 
challenge, mice were culled and tumours, draining inguinal lymph node 
(iLN) and spleens were harvested (Figure 5.8A). Tissues were processed and 
flow cytometric analysis was performed with lymphoid and myeloid cell 
populations defined as shown in Figure 5.8 B and C respectively. As 
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previously described in Section 5.2.1 data are presented as population 
frequencies, because changes in cell number within subsets reflect the overall 
change in cell numbers within the tumours or lymphoid tissues following 
vaccination.  
5.2.3.1 Tumour infiltrating lymphocytes 
Intratumoural lymphocyte populations were assessed and it was found that 
the total frequency of CD3+ T cells, approximately 40% of CD45+ cells, did not 
change following vaccination (Figure 5.9A). There was also no change in the 
NKT population, while the frequency NK cells increased non-significantly 
from around 15% of CD45+ to approximately 20% (Figure 5.9B and C). 
Despite the total T cell population remaining the same, the frequency of sub-
populations changed with vaccine delivery. The proportion of non-regulatory 
CD4+ T cells increased significantly, and correspondingly the frequency of 
Tregs decreased. No change was observed in the frequency of CD8+ T cells 
(Figure 5.9D-F). Furthermore, both effector CD4+ and CD8+ T cells 
populations showed non-significant increases in frequency, while PD-1 
expression decreased (Figure 5.9G-J). These data indicate that following 
vaccination there are decreases in intratumoural Tregs, and increases in CD4+ 
and CD8+ effector populations, along with decreased expression of the 
exhaustion marker PD-1. Changes in the frequency of T cell subpopulations 
were reflected in the significantly increased ratio of non-regulatory CD4+ T 
cells to Tregs and CD8+ T cells to Tregs (Figure 5.10 A and C). However, 
effector T cell to Treg ratios remained unchanged (Figure 5.10 B and D). 
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Figure 5.9: Flow cytometric gating strategy used to define lymphoid and 
myeloid populations within the tumour, spleen and draining iLN. A. 
C57BL/6 mice were vaccinated intravenously with irradiated, αGalCer-
loaded YUMM1.1 cells either seven days prior to tumour challenge, or five 
days post-tumour challenge. Control mice received PBS intravenously. Mice 
were challenged sub-cutaneously with 2 x 105 YUMM1.1 cells. 14 days post-
tumour challenge mice were culled and tumours, draining ilN and spleens 
harvested and processed for flow cytometric analysis. Samples were pre-
gated on single cells. B. Gating strategy used to define T cell, NK and NKT 
cell populations. Subsets were defined as follows: T cells = CD3+; NKT cells = 
NK1.1+, CD3+; NK cells = NK1.1+, CD3-; Non-regulatory T cells = CD3+, CD4+, 
FoxP3-; Tregs = CD3+, CD4+, FoxP3+; CD8 T cells = CD3+, CD8+; Effector T cells 
= subset defined as previously described then CD44hi, CD62Llo. C. Gating 
strategy used to define myeloid (CD11b+), macrophage (CD11b+, F4/80+) and 
MDSC populations (CD11b+, Ly6Chi and Ly6Glo or hi).  
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Figure 5.10: Vaccination increases frequencies of intratumoural non-
regulatory CD4+ T cells and decreases frequencies of Tregs. C57BL/6 mice 
were vaccinated as described in Figure 5.9A. One week following vaccination 
tumours were harvested and immune cell frequencies assessed by flow 
cytometry, lymphocyte populations were defined as shown in Figure 5.9B. A-
F. Frequencies of T cells, NK cells and NKT cells. G-J. Frequencies of effector 
and exhausted CD4+ and CD8+ T cells. Values represent individual mice, with 
5 mice used per group. Error bars are ± SEM. NS= non-significant, * p ≤ 0.05, 
** p < 0.01 one-way ANOVA with Bonferroni post-test. Results are 
representative of two independent experiments. 
 
 
 
Figure 5.11: Vaccination increases intratumoural ratio of non-regulatory 
CD4+ T cells and CD8+ T cells to Tregs. C57BL/6 mice were vaccinated as 
described in Figure 5.9A. One week following vaccination tumours were 
harvested and immune cell frequencies assessed by flow cytometry, 
lymphocyte populations were defined as shown in Figure 5.9B. The number 
of T cells was calculated by multiplying the population percentage by the 
total number of cells in the preceding gate. Cells number within the initial 
singlet cell gate were determined by multiplying percentages of single cells 
by total number of live cells as determined by trypan blue exclusion. A. Ratio 
of non-regulatory CD4+ FoxP3- cells to CD4+ FoxP3+ Tregs. B. Ratio of effector 
CD4+ FoxP3- cells to Tregs. C. Ratio of CD8+ cells to CD4+ FoxP3+ Tregs. D. 
Ratio of effector CD8+ cells to Tregs. Values represent individual mice, with 5 
mice used per group. Error bars are ± SEM. * p ≤ 0.05, ** p < 0.01, one-way 
ANOVA with Bonferroni post-test. Results are representative of two 
independent experiments. 
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5.2.3.2 Tumour infiltrating myeloid cells 
In addition to lymphoid cell populations, the effects of vaccination on 
intratumoural myeloid cell populations were assessed. Initial flow cytometric 
gating was on CD11b, which could include monocytes, moDCs, some 
conventional DCs, neutrophils, eosinophils, macrophages and MDSCs. These 
CD11b+ cells were shown to represent approximately 80% of the CD45+ cells 
within the tumour. However, it is worth noting that the CD45+ cells were pre-
gated on FSC and SSC and these parameters were set at different voltages to 
those used in the lymphocyte panel (based on size and granularity of the 
target population). Thus, when considering frequencies of myeloid cells as a 
proportion of CD45+ it should be considered that this CD45+ gate may not 
include all lymphocytes. Following vaccination no change was seen in the 
total CD11b+ cell population. Furthermore, there were no changes in the 
macrophage population (as defined by CD11b and F4/80 expression), which 
comprised the major subset of CD11b+ cells or in the monocytic MDSC 
(moMDSC) population, which accounted for approximately 15% of CD11b+ 
cells. A small increase in the proportion of granulocytic MDSCs was 
observed, from around 1% of CD11b+ cells to 2% in vaccinated mice, although 
this may not be biologically significant. 
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Figure 5.12: Vaccination does not alter intratumoural frequencies of 
myeloid, macrophage or moMDSCs, but may increase grMDSCs. C57BL/6 
mice were vaccinated as described in Figure 5.9A. One week following 
vaccination tumours were harvested and immune cell frequencies assessed by 
flow cytometry. Myeloid populations were defined as shown in Figure 5.9C. 
A-D. Frequencies of CD11b+, macrophage and MDSC populations. Values 
represent individual mice, with 5 mice used per group. Error bars are ± SEM. 
NS= non-significant, * p ≤ 0.05, ** p < 0.01 one-way ANOVA with Bonferroni 
post-test. Results are representative of two independent experiments. 
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5.2.3.3 Immune cell subsets within the spleen and tumour draining iLN 
The frequency of immune cells within the spleen and tumour draining iLN 
were also analysed. Changes in splenic populations with vaccination reflected 
trends similar to those seen in tumour infiltrating immune cell subsets, while 
the draining iLN populations were largely unaffected by vaccination (Figures 
5.13-5.17). Within the spleen no change was observed in the frequency of total 
T cells, and there were non-significant decreases in the proportion of NKT or 
NK cells. The frequency of non-regulatory CD4+ or CD8+ T cells also remained 
the same following vaccination. However, the proportion of Tregs decreased 
significantly. A small increase in the frequency of effector CD4+ and CD8+ T 
cells was observed, but these changes were largely non-significant. The 
changes in the frequency of Tregs and effector T cells were reflected in the 
ratios of non-regulatory or effector T cells to Tregs, which generally increased 
following vaccination. Similar to the intratumoural populations, the 
frequency of CD4+ T cells expressing the exhaustion marker PD-1 decreased 
significantly with vaccination. In contrast to the tumour and spleen data, no 
significant changes were observed in the frequency of any of the lymphoid 
populations assessed within the tumour draining lymph node (Figure 5.14). 
Similarly, the effector function of populations as determined by CD44/CD62L 
expression and PD-1 expression remained largely unchanged.  
Within the myeloid compartment of the spleen, CD11b+ cells accounted for 
approximately 50% of CD45 + cells, which was unaltered following 
vaccination, as was the frequency of macrophages. Splenic MDSC 
populations appeared to be skewed towards increased proportions of 
granulocytic MDSCs and decreased proportions of moMDSCs during 
vaccination, although as shown in other tissues, moMDSCs were present at 
much higher frequencies than grMDSCs (Figure 5.16). In the draining iLN a 
non-significant reduction in the frequency of total CD11b+ cells was observed. 
However, the proportion of macrophages increased significantly following 
therapeutic vaccination whilst the frequency of MDSCs remained the same 
(Figure 5.17). 
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Figure 5.13: Vaccination decreases frequencies of Tregs and of non-
regulatory cells expressing PD-1 within the spleen. C57BL/6 mice were 
vaccinated as described in Figure 5.9A. One week following vaccination 
spleens were harvested and immune cell frequencies assessed by flow 
cytometry, lymphocyte populations were defined as shown in Figure 5.9B. A-
F. Frequencies of T cells, NK cells and NKT cells. G-J. Frequencies of effector 
and exhausted CD4+ and CD8+ T cells. Values represent individual mice, with 
4-5 mice used per group. Error bars are ± SEM. NS= non-significant, * p ≤ 
0.05, ** p < 0.01, *** p < 0.001 one-way ANOVA with Bonferroni post-test. 
Results are representative of two independent experiments. 
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Figure 5.14: Vaccination does not alter frequencies of lymphocyte 
populations within the draining iLN. C57BL/6 mice were vaccinated as 
described in Figure 5.9A. One week following vaccination mdLN were 
harvested and immune cell frequencies assessed by flow cytometry, 
lymphocyte populations were defined as shown in Figure 5.9B. A-F. 
Frequencies of T cells, NK cells and NKT cells. G-J. Frequencies of effector 
and exhausted CD4+ and CD8+ T cells. Values represent individual mice, with 
4-5 mice used per group. One-way ANOVA with Bonferroni post-test was 
performed, however no differences were significant. Results are 
representative of two independent experiments 
 
 Figure 5.15: Vaccination increases splenic ratio of non-regulatory CD4 T 
cells and effector CD4 and CD8 T cells to Tregs. C57BL/6 mice were 
vaccinated as described in Figure 5.9A. One week following vaccination 
spleens were harvested and immune cell frequencies assessed by flow 
cytometry, lymphocyte populations were defined as shown in Figure 5.9B. 
The number of T cells was calculated by multiplying the population 
percentage by the total number of cells in the preceding gate. Cell numbers 
within the initial singlet cell gate were determined by multiplying 
percentages of single cells by total number of live cells as determined by 
trypan blue exclusion. A. Ratio of non-regulatory CD4+ FoxP3- cells to CD4+ 
FoxP3+ Tregs. B. Ratio of effector CD4+ FoxP3- cells to Tregs. C. Ratio of CD8+ 
cells to CD4+ FoxP3+ Tregs. D. Ratio of effector CD8+ cells to Tregs. Values 
represent individual mice, with 4-5 mice used per group. Error bars are ± 
SEM. * p ≤ 0.05, ** p < 0.01, **** p < 0.0001 one-way ANOVA with Bonferroni 
post-test. Results are representative of two independent experiments.  
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Figure 5.16: Vaccination does not alter splenic frequencies of myeloid cells 
or macrophages but may alter frequencies of MDSCs. C57BL/6 mice were 
vaccinated as described in Figure 5.9A. One week following vaccination 
spleens were harvested and immune cell frequencies assessed by flow 
cytometry, lymphocyte populations were defined as shown in Figure 5.9C. A-
D. Frequencies of myeloid, macrophage and MDSC populations. Values 
represent individual mice, with 5 mice used per group. Error bars are ± SEM. 
** p < 0.01 one-way ANOVA with Bonferroni post-test. Results are 
representative of two independent experiments. 
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Figure 5.17: Vaccination does not alter frequencies of myeloid cells or 
MDSCs but can increases the frequency of macrophages within the 
draining iLN. C57BL/6 mice were vaccinated as described in Figure 5.9. One 
week following vaccination draining iLN were harvested and immune cell 
frequencies assessed by flow cytometry, lymphocyte populations were 
defined as shown in Figure 5.9C. A-D. Frequencies of myeloid, macrophage 
and MDSC populations. Values represent individual mice, with 5 mice used 
per group. Error bars are ± SEM. ** p < 0.01 one-way ANOVA with 
Bonferroni post-test. Results are representative of two independent 
experiments. 
 
5.2.4 Vaccination does not significantly alter lymphocyte 
production of IFNγ and TNFα 
Production of the cytokines IFNγ and TNFα by lymphocyte populations was 
assessed to evaluate the changes in immune cell function following 
vaccination. Both IFNγ and TNFα play significant roles in anti-tumour 
immune responses in many tumour types including melanoma. IFNγ is 
important for the elimination of tumour cells, and is required for the 
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development of Th1 responses and macrophage activation, in addition to 
having numerous other effects in tumour immune responses. The role of 
TNFα in tumours is more contentious. Similar to IFNγ, TNFα can also activate 
macrophages, and additionally acts on endothelial cells to increase migration 
of phagocytes into tissue, as well as being able to directly induce apoptosis of 
target cells such as tumour cells. However, continuous low exposure to TNFα 
has been demonstrated to promote tumour growth, invasion and metastasis 
(Szlosarek et al., 2006). The principal producers of IFNγ are CD4+ and CD8+ T 
cells, NK cells and NKT cells, while TNFα is primarily produced by CD4+ and 
CD8+ T cells, and macrophages. Therefore, effects of therapeutic vaccination 
on the production of IFNγ and TNFα by T cells, NK cells and NKT cells in the 
tumour, tumour draining iLN and spleen were assessed. C57BL/6 mice were 
challenged with 2 x 10% YUMM1.1 cells and vaccinated five days later as 
previously described. Mice were culled nine days after vaccination and 
tissues were harvested and assessed by flow cytometry. Cell populations and 
cytokine production were defined as shown in Figure 5.18.  
5.2.4.1 IFNγ and TNFα production by TILs 
Small proportions of tumour infiltrating lymphocytes (TILs) produced only 
IFNγ, (less than 10% of CD4+ and CD8+ T cells). In comparison, a greater 
frequency of T cells produced only TNFα; approximately 30% of CD4+ and 
40% of CD8+ T cells. There was little change in the frequency of CD4+ and 
CD8+ T cells producing TNFα following vaccination. However, the percentage 
of CD4+ and CD8+ T cells producing both IFNγ and TNFα increased following 
vaccination, with the proportion of CD4+ T cells producing both cytokines 
increasing from around 18% to 30% (Figure 5.19A-F). Intratumoural 
frequency of NK cells producing IFNγ was also low (~3%), while 
approximately 50% of NK cells produced TNFα and a small population (~5%) 
produced both cytokines. NK cell cytokine production was unchanged 
following therapeutic vaccination (Figure 5.19G-I). Only 1-2% of NKT cells 
produced IFNγ but this increased after vaccination, and high proportions (40-
80%) of NKTs produced TNFα, which decreased non-significantly following 
vaccination (Figures 5.19J and K). The proportion of NKT cells producing 
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both cytokines increased from 10% to 20-40% following vaccination (Figure 
5.19L). Together these results indicate that vaccination may alter production 
of cytokines by NKT cells, although the time point used may not be optimal 
for assessing vaccine effect on NKT cell cytokine production.  
 
 
Figure 5.18: Flow cytometric gating strategy used to define IFNγ and TNFα 
producing lymphocytes within the tumour, spleen and draining iLN. Mice 
were tumour challenged and therapeutically vaccinated as described in 
Figure 5.8A. 14 days post-tumour challenge mice were culled and tumours, 
spleens and draining iLN harvested and processed for flow cytometric 
analysis. A. Gating strategy used to define T cell, NK and NKT cell 
production of IFNγ and TNFα. Samples were pre-gated on single, live cells. 
Subsets were defined as follows: T cells = CD3+; NKT cells = NK1.1+, CD3+; 
NK cells = NK1.1+, CD3-; Non-regulatory T cells = CD3+, CD4+, FoxP3-; Tregs 
= CD3+, CD4+, FoxP3+; CD8 T cells = CD3+, CD8+; following which IFNγ and 
TNFα. 
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Figure 5.19: Vaccination does not significantly alter tumour frequencies of 
T cells, NK cells or NKT cells producing IFNγ and/or TNFα. C57BL/6 mice 
were vaccinated as described in Figure 5.9A. One week following vaccination 
tumours were harvested and frequencies of IFNγ and TNFα producing 
lymphocytes were assessed by flow cytometry. Populations were defined as 
shown in Figure 5.12A. A-C. Frequencies of non-regulatory CD4+ T cells 
producing IFNγ and TNFα. D-F. Frequencies of CD8+ T cells producing IFNγ 
and TNFα. G-I. Frequencies of NK cells producing IFNγ and TNFα. J-L. 
Frequencies of NKT cells producing IFNγ and TNFα. Values represent 
individual mice, with 5 mice used per group. Error bars are ± SEM. Unpaired 
t-test was performed. Where no significance is stated differences are non-
significant. For comparisons approaching significance p-values are stated. 
Results are representative of two independent experiments. 
5.2.4.2 IFNγ and TNFα production by immune cells within the spleen and 
tumour draining iLN 
IFNγ and TNFα production by lymphocytes within the spleen and draining 
iLN was also assessed, and showed trends similar to those observed in the 
tumour. Overall there was no major impact of vaccination on the production 
of the cytokines analysed within these lymphoid tissues. Less than 20% of all 
populations, CD4+ and CD8+ T cells, NK and NKT cells, were found to 
produce IFNγ within the spleen and draining iLN (Figures 5.20 and 5.21). 
Generally vaccination did not appear to alter the production of IFNγ by these 
populations, with the exception of splenic NKT cells, which significantly 
increased from approximately 2% to 6% of cells producing IFNγ with 
therapeutic vaccine (Figure 5.20J). As with intratumoural lymphocytes, spleen 
and iLN populations had a greater frequency of cells producing TNFα than 
IFNγ. In both the spleen and iLN 20-50% of CD4+ and CD8+ T cells produced 
TNFα alone, and similarly high proportions of NKT cells produced TNFα (20-
40%), which was unaltered with vaccination except for a reduction in the 
frequency of CD8+ T cell producing TNFα. Again, relatively low proportions 
of T cells and NK cells produced both IFNγ and TNFα in naïve and vaccinated 
mice. Approximately 30% of NKT cells within the draining iLN produced 
both IFNγ and TNFα, which was slightly increased after vaccination, and the 
frequency of splenic NKTs producing both cytokines increased significantly 
from 5 to around 20% with vaccine delivery (Figure 5.20L and 5.21L).  
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Figure 5.20: Vaccination does not significantly alter splenic frequencies of T 
or NK cells producing IFNγ and/or TNFα, but increases the percentage of 
NKT cells producing both IFNγ and TNFα. C57BL/6 mice were vaccinated 
as described in Figure 5.9A. One week following vaccination spleens were 
harvested and frequencies of IFNγ and TNFα producing lymphocytes were 
assessed by flow cytometry. Populations were defined as shown in Figure 
5.12A. A-C. Frequencies of non-regulatory CD4+ T cells producing IFNγ and 
TNFα. D-F. Frequencies of CD8+ T cells producing IFNγ and TNFα. G-I. 
Frequencies of NK cells producing IFNγ and TNFα. J-L. Frequencies of NKT 
cells producing IFNγ and TNFα. Values represent individual mice, with 4-5 
mice used per group. Error bars are ± SEM. ** p < 0.01, unpaired t-test was 
performed. Results are representative of two independent experiments. 
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Figure 5.21: Vaccination does not significantly alter draining iLN 
frequencies of T cells or NK cells producing IFNγ and/or TNFα, but 
increases frequencies of NKT cells producing IFNγ alone or with TNFα. 
C57BL/6 mice were vaccinated as described in Figure 5.9A. One week 
following vaccination draining iLN were harvested and frequencies of IFNγ 
and TNFα producing lymphocytes were assessed by flow cytometry. 
Populations were defined as shown in Figure 5.12A. A-C. Frequencies of non-
regulatory CD4+ T cells producing IFNγ and TNFα. D-F. Frequencies of CD8+ 
T cells producing IFNγ and TNFα. G-I. Frequencies of NK cells producing 
IFNγ and TNFα. J-L. Frequencies of NKT cells producing IFNγ and TNFα. 
Values represent individual mice, with 5 mice used per group. Error bars are 
± SEM. Unpaired t-test was performed. Results are representative of two 
independent experiments.  
5.2.4.3 IFNγ exposure causes YUMM1.1 and YUMM1.7 upregulation of 
PD-L1 expression, but not of MHC Class II expression. 
The effect of IFNγ and TNFα exposure on YUMM1.1 surface marker 
expression was assessed in vitro. Untreated YUMM1.1 cells expressed neither 
PD-L1 nor MHC Class II (Figure 5.22A and B) but expressed high levels of 
MHC Class I, as expected (data not shown). Treatment with IFNγ resulted in 
massive upregulation of PD-L1, but no upregulation of MHC Class II. These 
effects were uniformly evident at all concentrations tested, from 31 U/mL to 
500U/mL (highest concentration shown; Figure 5.22). In contrast, TNFα 
exposure had no effect on YUMM1.1 expression of PD-L1 or MHC Class II at 
with treatment of 6.25 ng/mL to 100 ng/mL (highest concentration shown; 
Figure 5.22). Exposure to IFNγ and TNFα had similar effects on YUMM1.7 
cells; PD-L1 expression was upgregulated following IFNγ treatment, and no 
MHC II expression was detected on untreated, IFNγ or TNFα treated cells 
(Figure 5.22C and D).  
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Figure 5.22: YUMM1.1 and YUMM1.7 cells upregulate expression of PD-L1, 
but not MHC Class II, following IFNγ  exposure. Cells were cultured for 48 
hours in the presence or absence of exogenous IFNγ  at 500U/mL or 
100ng/mL TNFα. MHC Class II and PD-L1 expression was assessed by flow 
cytometry. A. YUMM1.1 expression of MHC II and B. PD-L1. C. YUMM1.7 
expression of MHCII, and D. of PD-L1. Plots are representative of two 
independent experiments, both carried out in triplicate. 
5.2.5 Anti-tumour efficacy of YUMM1.1 vaccination is CD4+ 
but not CD8+ T cell dependent. 
Given the increased frequency of non-regulatory CD4+ and CD8+ T cells 
following vaccination, the requirement of these cell types for vaccine efficacy 
was investigated using gene knockout mice. Experiments were conducted in 
B6AaO hosts deficient in MHC Class II, and thus in CD4+ T cells, and in 
TAP1-/- mice, which lack stable MHC Class I expression and therefore lack 
CD8+ T cells. Knockout mice were vaccinated either prophylactically or 
therapeutically and challenged with 2 x 105 YUMM1.1 cells (Figures 5.23A 
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and 5.24A). Tumour growth was monitored and vaccine protection against 
tumour growth and mouse survival assessed. 
In TAP-/- mice vaccine significantly slowed tumour growth and increased 
survival (Figure 5.23B-D). Similar to the effects observed in wild-type 
C57BL/6 mice (Figure 5.6), vaccination had greater anti-tumour efficacy in a 
prophylactic model than in a therapeutic setting. These data show that 
vaccine protection was retained in the absence of CD8+ T cells, indicating a 
lack of significant involvement of these cells in vaccine protection.  In B6AaO 
mice, neither prophylactic nor therapeutic vaccination had any effect on 
tumour growth, and correspondingly did not improve mouse survival 
(Figure 5.24B and D). This complete loss of vaccine efficacy in the absence of 
CD4+ T cells demonstrates a requirement for these cells in conferring 
protection. Whether CD4+ T cells directly target tumour cells, as has been 
previously demonstrated, or activate a downstream effector cell remains to be 
determined.  
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Figure 5.23: Autologous, whole tumour cell vaccination against YUMM1.1 
tumours is not CD8+ T cell-dependent. A. TAP1-/- mice were vaccinated 
intravenously with irradiated, αGalCer-loaded YUMM1.1 cells either 
prophylactically seven days prior to tumour challenge, or therapeutically five 
days post-tumour challenge. Control mice received PBS. Mice were 
challenged subcutaneously with 2 x 105 YUMM1.1 cells. Tumour growth was 
monitored and size recorded. Mice were culled when tumours reached 150 
mm2, or when tumours ulcerated. B. Average tumour growth is shown, each 
symbol represents the mean growth of 5-6 mice. Error bars are ± SEM. **** P ≤ 
0.0001, 2-way ANOVA with Bonferroni post-test, statistics shown for Day 23. 
C. Individual tumour growth. Each data point represents one mouse. D. 
Percent survival shown for groups of 5-6 mice. Treatment groups are 
compared to the control mice.  NS = non-significant, ** P < 0.01, Mantel-Cox 
test. Data are representative of two concordant, independent experiments. 
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 Figure 5.24: Autologous, whole tumour cell vaccination against YUMM1.1 
tumours is CD4+ T cell-dependent. A. B6AaO mice were prophylactically 
vaccinated intravenously with irradiated, αGalCer-loaded YUMM1.1 cells 
seven days prior to tumour challenge. Control mice received PBS. Mice were 
challenged sub-cutaneously with 2 x 105 YUMM1.1 cells. Tumour growth was 
monitored and size recorded. Mice were culled when tumours ≥ 150 mm2, or 
when tumours ulcerated. B. Average tumour growth is shown. Each symbol 
represents the mean growth of 5 mice. Error bars are ± SEM. C. Individual 
tumour growth, each data point represents one mouse. D. Percent survival 
shown for groups of 5 mice. Treatment groups are compared to the control 
mice.  NS = non-significant Mantel-Cox test. Data are representative of two 
concordant, independent experiments. 
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 Discussion 5.3
The primary objectives of this chapter were to develop and characterize an 
immunotherapeutic approach with anti-tumour activity in a BRAFV600E 
melanoma model. I have generated a novel vaccine comprised of irradiated, 
autologous tumour cells loaded with the iNKT adjuvant αGalCer. This 
vaccine elicits a CD4+ T cell response that has significant anti-tumour efficacy 
in the YUMM1.1 melanoma model.  
The vaccine approach developed in this study utilised administration of 
whole tumour cells loaded with αGalCer, with aim of delivering both antigen 
and adjuvant to the same APC. This would achieve antigen presentation by 
optimally activated DCs, due to efficient iNKT cell licensing of DCs. The 
mechanism by which αGalCer becomes associated with the tumour cells in 
this vaccine is uncertain. As YUMM1.1 and YUMM1.7 cells do not express 
CD1d, the tumour cells do not directly present αGalCer. In the absence of 
CD1d expression it is likely that the lipophilic sphingosine tail of the αGalCer 
molecule becomes embedded in, or adheres to the plasma membrane of the 
tumour cell in an undefined way (Moody et al., 2002). A second possibility is 
that tumour cells sequester αGalCer in intracellular vesicles or phagosomes 
after endocytosis, which is then released upon tumour cell degradation in 
vivo. In both of these scenarioes only modest amounts of αGalCer are 
expected to be associated with tumour cells. It has been previously 
demonstrated that CD1d expression by the cellular component of an αGalCer-
loaded vaccine is not required for vaccine efficacy (Petersen et al., 2011). 
However, CD1d expression may enhance vaccine efficacy. Direct comparison 
of αGalCer-loaded tumour cell vaccines showed increased anti-tumour effects 
when tumour cells were transfected to express CD1d (Shimizu et al., 2007a; 
Shimizu et al., 2007b). This would enable direct presentation of αGalCer by 
tumour cells to iNKT cells and may increase the amount of αGalCer 
incorporated by tumour cell.  
The use of whole tumour cells as the cellular component of the vaccine has 
several advantages over DC or peptide-based vaccines. The delivery of a 
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range of tumour antigens including both known and undefined antigens, and 
MHC class I and II epitopes, will elicit polyclonal responses and reduce the 
risk of tumour immune escape. Additionally, a significant clinical benefit of 
this approach is that it is not HLA-type restricted. There are some safety 
issues surrounding the use of whole tumour cells but irradiation of tumour 
cells prior to their delivery nullifies concerns of tumour cell outgrowth from 
the vaccine. Although acute toxicity is a risk with intravenous infusion of 
irradiated, apoptotic tumour cells this has been well-tolerated in clinical trials 
using several tumour types (de Gruijl et al., 2008). Stimulating immune 
responses to a wide-range of uncharacterized antigens does raise concerns 
about generating autoimmunity. However, no evidence of this was seen in 
mice in this study. Autoimmune responses may represent a greater issue if 
immune regulation is further compromised with additional treatments, such 
as checkpoint blockade. 
The delivery of irradiated, αGalCer-loaded YUMM1.1 and YUMM1.7 cells 
elicited vaccine-induced immune responses in both the spleen and mdLN. 
Splenic priming was anticipated with intravenous delivery of irradiated 
tumour cells, due to the well-known capacity of splenic APCs, in particular 
CD8α+ DCs, to take up antigen from circulating dying cells (Iyoda et al., 2002; 
Shimizu et al., 2007b). Although the mdLN is an unconventional site of 
vaccine priming, its involvement was investigated because it had previously 
been demonstrated as a site of priming with an αGalCer-loaded whole 
tumour cell vaccine in a glioma model (Hunn et al., 2012). It is postulated that 
following intravenous vaccination injected tumour cells may be trapped in 
the lung capillary bed and captured by lung-resident or circulating immune 
cells. Subsequent trafficking of tumour peptides and αGalCer to the lung-
draining mdLN would result in mdLN priming.  
Although both YUMM1.1 and YUMM1.7 cell-based vaccines induced effector 
T cell responses in naïve mice, autologous vaccination only gave significant 
protection against YUMM1.1 tumours. Both in the prophylactic and 
therapeutic setting minimal protection was conferred with autologous 
vaccination against YUMM1.7 tumours. There are several possible 
explanations for this difference. The higher growth rate of YUMM1.7 cells 
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may generate more aggressive tumours, or may facilitate YUMM1.7 escape 
from immune control. Additionally, it is likely the two tumour cell lines 
express different antigenic profiles; YUMM1.1 may express antigens that elicit 
stronger or more durable immune responses. The lack of vaccine efficacy 
against YUMM1.7 tumours does raise some concerns about the broad 
applicability of this vaccine approach. However, efficacy of irradiated 
αGalCer-loaded tumour cell vaccines has been demonstrated in several 
tumour types, in addition to YUMM1.1 tumours (Chung et al., 2007; Gibbins 
et al., 2014; Hunn et al., 2012; Mattarollo et al., 2012; Shimizu et al., 2007b). 
Therefore it is possible that YUMM1.7 represents an unusually 
immunosuppressive model.  
Earlier results demonstrated that neither YUMM1.1 nor YUMM1.7 produced 
soluble T cell-suppressive factors (Chapter 3; Figure 3.13), however there is 
evidence of several other tumour-mediated immunosuppressive mechanisms 
present in these models. Exposure to IFNγ in vitro resulted in both YUMM1.1 
and YUMM1.7 cells significantly upregulating PD-L1 expression. Similar 
tumour cell expression of PD-L1 likely occurs in vivo, as analysis of TILs in 
YUMM1.1 tumours showed subsets of cells producing IFNγ. PD-L1 is one of 
the two ligands for PD-1, which is expressed by activated T cells. PD-1/PD-L1 
interactions negatively regulate T cell effector responses through suppression 
of proliferation, inhibition of cytokine production and even induction of 
apoptosis. In addition to YUMM cells expressing PD-L1, 60-80% of 
intratumoural T cells were shown to highly express PD-1 in the YUMM1.1 
model. Vaccination reduced the frequency of T cells expressing high levels of 
PD-1, indicating that there is some amelioration of T cell exhaustion. 
However the majority of T cells still expressed high PD-1. Co-expression of 
the ligand and receptor, as occurs with YUMM1.1 tumours, has been widely 
implicated as a major mechanism of tumour immune resistance and immune 
evasion (Merelli et al., 2014; Topalian et al., 2012). PD-1/PD-L1 interactions 
can also promote the differentiation of CD4+ FoxP3- T cells into FoxP3+ Tregs 
(Amarnath et al., 2011; Francisco et al., 2009). This may account for the 
relatively large proportion of Tregs present within YUMM1.1 tumours, which 
appeared to increase with tumour progression (data not shown). Again 
vaccination had some impact on this mechanism of suppression, decreasing 
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the frequency of Tregs, but a large population of Tregs remained. 
Collectively, these data demonstrate a highly immunosuppressive 
microenvironment within YUMM1.1 tumours, which was partially reduced 
with vaccination. It is possible that the degree of immunosuppression present 
within the YUMM1.1 and YUMM1.7 tumours could differ. A more 
suppressive microenvironment in YUMM1.7 tumours could be a contributing 
factor towards the differential anti-tumour efficacy of vaccination in the two 
tumour models.  
Interestingly, only CD4+ T cells were required for vaccine efficacy, as 
indicated by the loss of vaccine protection in MHC Class II-deficient mice. 
While the retention of anti-tumour effects following vaccination in TAP-/- 
hosts indicates that CD8+ T cells do not play a critical role in mediating 
vaccine efficacy.  Nonetheless, there are limitations to these experiments that 
must be considered.  MHC II-deficient mice lack cell surface expression of 
class II molecules. Thus CD4+ T cell maturation in the thymus is compromised 
and these mice lack mature CD4+ T cells and CD4+ T cell-mediated responses 
(Grusby et al., 1991). However, a population of peripheral CD4+ T cells have 
been detected. These cells do not express NK1.1 but have unusual reactivity, 
recognizing the CD1 molecule (Cardell et al., 1995). Nonetheless, the complete 
abrogation of vaccine efficacy in the absence of MHC II does demonstrate a 
requirement for CD4+ T cells, which is not satisfied by this residual CD4+ 
population. TAP-1 deficient mice lack peptide transport to MHC Class I 
molecules and therefore are deficient in MHC I-restricted antigen 
presentation. As a result, TAP-/- mice have a very low number of CD8+ T cells 
in the periphery due to impaired positive selection (Van Kaer et al., 1992). 
Additionally there is some evidence that whilst these mice have normal 
numbers of NK cells, NK cell-mediated lysis is impaired (Ljunggren et al., 
1994). Therefore, TAP deficient mice are not only defective in CD8+ T cell 
responses, but also in other factors. However, as the vaccine is still effective in 
this model this does not change the conclusion that CD8+ T cells are not 
required for efficacy.  
Traditionally, CD8+ T cells have been considered the primary effectors of T 
cell mediated tumour elimination, while the contribution of CD4+ T cells has 
 200 
been assumed to be in supporting and enhancing CD8+ responses (Bevan, 
2004). However, there is now substantial evidence that CD4+ T cells exert 
more direct anti-tumour responses independently of CD8+ T cells. In fact, 
CD4+ T cells have been shown to eliminate tumour cells more effectively than 
CD8+ T cells in a side-by-side comparison utilising MHC I or II-restricted TCR 
transgenic mice (Perez-Diez et al., 2007). Building on this, adoptive transfer of 
primed CD4+ T cells has been shown to confer protection against tumour 
challenge, which was not dependent on host CTL responses (Greenberg, 
1986). Several mechanisms have been implicated in direct CD4+ T cell killing 
of tumour cells, including Granzyme B and perforin production and CD4+ T 
cell FasL and tumour cell Fas interactions (Lundin et al., 2004, Quezada, 2010 
#667). However, MHC class II expression by tumour cells has been 
demonstrated to be required for CD4+ T cells to elicit direct cytolytic activity 
in vivo, although not in vitro (Lundin et al., 2004). Many tumour cells are 
induced to express MHC II in response to IFNγ exposure (Haabeth et al., 
2014). However, YUMM cells expressed no detectable MHC II at baseline, and 
did not upregulate expression following 48 hours of exposure to IFNγ or 
TNFα. In the complete absence of MHC II expression CD4+ T cell may 
indirectly induce tumour cell death through IFNγ anti-angiogenic effects or 
activation of tumouricidal macrophages to elicit cytotoxic effects (Corthay et 
al., 2005; Qin and Blankenstein, 2000). 
Several of the effector functions of CD4+ T cells depend on the presence of 
IFNγ including MHC II upregulation on tumours, anti-angiogenic effects and 
activation of macrophages. Analysis of lymphoid subsets producing IFNγ and 
TNFα revealed that the frequency of NKT cells producing IFNγ alone or both 
IFNγ and TNFα was increased in the spleen and tumour following 
vaccination. Additionally, CD4+ T cell production of IFNγ within the tumour 
was augmented with vaccination. This demonstrates that vaccination is 
generating a tumour microenvironment supportive to CD4+ T cell-mediated 
anti-tumour responses. Interestingly, in both untreated and vaccinated mice a 
larger proportion of T, NKT and NK cells produced TNFα than was expected. 
In the inducible BrafV600E Pten-/-CDKN2a tumours, following similar harvest 
and restimulation, 5-30% of CD4+ T cells and less than 5% of CD8+ T cells 
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were shown to produce TNFα (Ho et al., 2014). Comparatively, the frequency 
of cells, and particularly CD8+ T cells, producing TNFα in the YUMM1.1 
model was much higher. This is noteworthy because TNFα has been 
previously implicated in mediating BRAF inhibitor resistance to apoptosis 
(Gray-Schopfer et al., 2007; Menon et al., 2013; Shao et al., 2015). However, the 
frequency of lymphocytes producing TNFα alone was not significantly 
increased following vaccination. Therefore vaccine is not impacting this 
possible mechanism of tumour microenvironment-mediated BRAF inhibitor 
resistance.   
5.3.1 Conclusions 
In this chapter I have generated a simple vaccine, which elicits effector CD4+ 
T cell responses to decrease tumour growth and increase survival in a murine 
model of BRAFV600E melanoma. This vaccine possesses clinical relevance with 
the benefit of generating anti-tumour immunity to undefined neoantigens, 
and provides a strong foundation to investigate BRAF inhibitor combination 
with active immunotherapy in the next chapter. 
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 Introduction 6.1
The rationale for combining BRAF inhibitors with immunotherapy is based 
on the potential for the mechanisms of action of these two approaches to 
work synergistically. In particular, targeted chemotherapy is expected to 
render the tumour microenvironment more favourable to anti-tumour 
immune responses. The induction of tumour cell death, which results in 
increased antigen availability, and reduced tumour mediated immune 
suppression are just some of the justifications that provide a strong basis for 
the combination of BRAF inhibition and immunotherapy. However, the 
results in Chapter 3 of this thesis demonstrate that whilst PLX4720 induces 
apoptosis of BRAFV600E melanoma cells in vitro, no tumour regression is seen 
with PLX4720 in vivo. This observation raises questions about whether 
significant tumour cell death is occurring in vivo. Despite this, non-cytotoxic 
effects of PLX4720 on BRAFV600E tumours in vivo may still be 
immunostimulatory. Previous studies have demonstrated that broad-
spectrum chemotherapies do not necessarily need to induce cell death to 
render tumour cells more immunogenic (Fisk and Ioannides, 1998; Gameiro et 
al., 2011; Kaneno et al., 2011). Targeted BRAF inhibitors are likely to have 
similar effects, with non-cytotoxic concentrations of Vemurafenib and 
PLX4720 shown to enhance MHC expression, tumour antigenicity and 
decrease melanoma-mediated immunosuppression (Donia et al., 2012a; 
Frederick et al., 2013; Sapkota et al., 2013; Sumimoto et al., 2006). 
Although it may not have major bearing on immunogenicity, the mechanism 
by which BRAFV600E melanoma cells are evading PLX4720-induced apoptosis 
in vivo remains of interest. Loss of PTEN, which is a characteristic of the 
YUMM1.1 and YUMM1.7 models, has been previously reported to decrease 
PLX4720 induced apoptosis (Hooijkaas et al., 2012b; Paraiso et al., 2011). 
However, as previously mentioned, this does not account for the 
inconsistency between the ability of BRAF inhibitors to induce apoptosis of 
YUMM1.1 and YUMM1.7 cells in vitro but not in vivo. It is likely that factors 
produced within the tumour microenvironment in vivo are playing a 
protective role. Interestingly, in Chapter 5 a high frequency of NK, NKT and 
T cells were shown to produce TNFα, which has previously been 
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demonstrated to confer resistance to apoptosis induced by BRAF inhibition 
(Gray-Schopfer et al., 2007; Menon et al., 2013; Shao et al., 2015). Exposure of 
BRAFV600E melanoma cell lines to TNFα reduced apoptosis induced by 
PLX4720, Vemurafenib and siRNA inhibition of mutant BRAF. In the studies 
by Gray-Schopfer and collegues, and Shao and colleagues the protective effect 
of TNFα was shown to be specific to mutant BRAF inhibition, and was 
associated with activation of NFκB, which is involved in a number of essential 
cellular functions, including cell survival.  Similarly, Menon et al. attributed 
the protective effect of TNFα to increased levels of the anti-apoptotic protein 
Twist1. These findings are complementary as Twist1 is a downstream target 
of NFκB.  Furthermore, the protective effect of TNFα is not dependent on 
PTEN mutation status. The models used in these studies were all BRAFV600E 
melanoma cell lines with varied PTEN mutation status (wild-type, 
heterozygous and homozygous loss of function), indicating TNFα mediated 
resistance can have diverse implications. Therefore, TNFα represents an 
interesting therapeutic target to consider in combination with BRAF 
inhibition.  
Preclinical and clinical studies have revealed the importance of timing on the 
efficacy of combination therapy (Ascierto et al., 2012; Zitvogel et al., 2008). It 
is generally accepted that immunotherapy is more successful in a setting of 
minimal tumour burden, perhaps due to tumour-associated 
immunosuppression (Bilusic and Gulley, 2012). Therefore, a role for 
chemotherapy in combination therapy can be to reduce surgically 
inaccessible, or metastatic, tumour burden prior to immunotherapy. This 
induction of tumour cell death will also serve to augment anti-tumour 
immunity through previously described mechanisms including the release of 
tumour antigen. However, even in the absence of induced tumour cell death, 
chemotherapy prior to immunotherapy can increase the immunogenicity and 
decrease tumour-mediated immunosuppression. In addition to the direct 
tumour effects, pre-treatment with chemotherapy allows potentiation of the 
immune system to occur through immunomodulatory effects. Consistent with 
this, in most instances immunotherapy administered post-chemotherapy has 
been shown to be the most effective combination therapy strategy (Lake and 
Robinson, 2005). Despite this, there is evidence for the potentiation of 
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chemotherapy by prior immunotherapy. Retrospective analysis of the 
sequential use of Vemurafenib and Ipilimumab revealed that BRAF-mutant 
melanoma patients appeared to benefit from the administration of 
Ipilimumab prior to BRAF inhibitors rather than the delivery of therapies in 
the reverse order (Ascierto et al., 2012). Furthermore, delivery of vaccine-
based immunotherapy followed by chemotherapy with cyclophosphamide 
has been shown to be more effective than either single agent in a B16 model of 
melanoma (Hermans et al., 2003a). Whilst algorithms have been devised to 
guide the sequencing of BRAF inhibitor and immunotherapy administration, 
the optimal timing of delivery requires further pre-clinical and clinical studies 
(Ascierto et al., 2012; Srivastava and McDermott, 2014).  
6.1.1 Aims 
There is a strong theoretical framework supporting the combination of 
immunotherapy and BRAF inhibitors. To date the majority of research into 
combination therapy has been pre-clinical, and the immunotherapeutic 
approaches utilised have focussed on checkpoint blockade or adoptive cell 
transfer. The experiments described in this chapter explore the combination of 
BRAF inhibition with active immunotherapy, using the whole tumour cell 
vaccine developed in Chapter 5.   
In particular these experiments aimed to: 
• Assess whether there is basal immune cell involvement in the anti-
tumour effects of PLX4720 in a BRAFV600E tumour model 
• Characterise the intratumoural, tumour draining lymph node and 
splenic immune milieu before and after PLX4720 treatment, to identify 
changes in immune cell populations associated with PLX4720 
treatment 
• Determine if TNFα inhibition improves PLX4720 induction of 
BRAFV600E melanoma cell death 
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• Investigate PLX4720 and vaccine combination therapy strategies, and 
the impact of Treg depletion on vaccine and combination therapy 
efficacy.  
 Results 6.2
6.2.1 The anti-tumour effects of PLX4720 in a BRAFV600E 
tumour model are partially dependent on host-mediated 
immunity 
Prior to undertaking combination therapy experiments, the involvement of 
the immune system in PLX4720 anti-tumour efficacy was investigated with 
the aim of better informing combination strategies. To determine the 
involvement of the adaptive immune system in PLX4720 treatment, anti-
tumour efficacy was compared between immunocompetent C57BL/6 and 
immunocompromised NOD/Scid mice. NOD/Scid mice are highly 
immunodeficient with impaired B and T lymphocyte development, and 
additional immunological dysfunction including reduced macrophage and 
NK cell function (Ito et al., 2002; Schultz et al., 1995). Mice were tumour 
challenged with 2 x 105 YUMM1.1 cells, and daily treatment with 20 or 50 
mg/kg PLX4720 or vehicle control was initiated one week later (Figure 6.1A). 
Tumour growth was monitored, with size recorded every two to three days, 
and when tumours reached 150 mm2 or ulcerated mice were culled and 
survival was recorded. 
As seen previously, both 20 and 50 mg/kg PLX4720 treatment slowed 
YUMM1.1 tumour growth in C57BL/6 mice and increased survival 
significantly (Figure 6.1B-D). Strikingly, in NOD/Scid mice the anti-tumour 
efficacy of PLX4720 was reduced. Although PLX4720 still decreased tumour 
growth and increased survival significantly, PLX4720 treatment provided less 
protection against tumour growth and less of a survival advantage in 
immunocompromised hosts (Figure 6.1B-D). However, tumours of vehicle-
treated control mice grew at different rates in the two hosts, with control 
tumour growth slower in NOD/Scid mice than in C57BL/6 mice (Figure 
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6.1B). In fact, when directly compared, the growth of control tumours in each 
strain differed significantly (P >0.0001), as did survival (P=0.015). As a result, 
direct comparisons of the effect of PLX4720 on growth and survival in the two 
different hosts were unable to be made. To allow comparison of the survival 
benefit whilst accounting for the difference in controls, the survival of treated 
mice relative to the vehicle control mice was determined. This data 
demonstrated that both 20 and 50 mg/kg PLX4720 were significantly more 
effective at prolonging survival in immunocompetent hosts than in 
immunocompromised hosts (Figure 6.1E). These results indicate that 
PLX4720, in the absence of any immunotherapy, involves host immune 
responses. PLX4720 anti-tumour effects may be T cell, B cell, NK cell or 
macrophage mediated, as functions of these cell populations are absent or 
compromised in NOD/Scid mice. 
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Figure 6.1: PLX4720 treatment of YUMM1.1 tumours is partially dependent 
on host-mediated immunity. A. C57BL/6 or NOD/SCID mice were injected 
subcutaneously in the left flank with 2 x 105 YUMM1.1 cells. Daily drug 
treatment was begun 7 days post-tumour challenge with 20 or 50 mg/kg 
PLX4720 given by oral gavage, with control mice receiving a vehicle solution. 
Tumour growth was monitored and size recorded. Mice were culled when 
tumours reached 150 mm2, or when tumours ulcerated. B. Average tumour 
growth is shown, each symbol represents the mean growth of 13-14 mice. 
Error bars are ± SEM. C. Individual tumour growth for each treatment group 
is shown, each data point represents an individual mouse. D. Kaplan-Meier 
plot showing survival. E. Effect of PLX4720 on survival relative to the 
particular mouse strain is shown. Relative survival was calculated by 
averaging the survival of control mice and subtracting this from the number 
of days survived following PLX4720 treatment. Data shown is combined from 
3 independent experiments with concordant results. Each experiment had 4-5 
mice per treatment group.   
 
6.2.2 PLX4720 does not alter the frequency of immune cell 
subsets present within the tumour milieu 
After establishing the dependence of PLX4720 on host-mediated immunity 
further experiments were designed to identify the immune cell subsets 
involved.  C57BL/6 mice were tumour challenged and treatment with 20 
mg/kg, 50 mg/kg PLX4720 or vehicle began one week later. After treating 
with drug or control for one week by daily oral gavage mice were culled and 
tumours, tumour draining iLN and spleens were harvested, processed and 
analysed by flow cytometry. Cell populations were defined as previously 
described in Chapter 5 (Figures 5.8 and 5.12). The frequency of several 
immune cell subsets, and functional properties of T cells, NK cells and NKT 
cells were investigated.  
Within the tumour, no change was seen in the frequency of total T cells or any 
subsets examined including CD4+FoxP3-, CD4+FoxP3+ and CD8+ T cells 
(Figure 6.2A, and D-F). Of note, within the tumour, CD4+FoxP3+ Tregs 
comprised a large proportion of the T cell population accounting for 40-50% 
of CD4+ T cells. The proportions of T cells expressing the effector phenotype 
of CD44hi and CD62Llo, and expressing the exhaustion marker PD-1 were also 
unchanged following therapy (Figure 6.2G-J). These results were reflected in 
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the ratio of non-regulatory CD4+ and CD8+ T cells to Tregs, and effector cells 
to Tregs, which also remained the same with PLX4720 treatment (Figure 6.3).  
Intratumoural frequencies of NK and NKT cells, total CD11b+ cells, 
macrophages and both grMDSCs and moMDSC were also assessed, and no 
changes were observed in the proportions of any of these populations (Figure 
6.2B and C, Figure 6.4). Furthermore, the production of IFNγ and TNFα by T 
cells, NK cells and NKT cells was found to be unaltered with PLX4720 
treatment of tumours. Interestingly, as was observed previously (Figure 5.13), 
a large proportion of all cell types produced TNFα, while the frequency of 
cells producing IFNγ was much lower. Approximately 60% of CD4+ T cells, 
10% of CD8+ T cells and NK cells, and 20-40% of NKT cells produced TNFα, 
while less than 10% of all cell subsets produced IFNγ alone.  
Similar to the results obtained with analysis of intratumoural immune cell 
subsets no differences were detected in the frequency of T, NK, or NKT cell, 
macrophage or MDSC populations within the tumour draining iLN or spleen 
(Appendices C1, C2, C5, C6). The expression of effector and exhaustion 
markers on T cells remained the same in vehicle treated or PLX4720-treated 
mice, as did the ratio of non-regulatory or effector T cells to Tregs 
(Appendices C1-C4). The production of IFNγ and TNFα by T cells, NK cells 
and NKT cells also did not change with PLX4720 treatment. Thus, the 
suggested role for host immune responses in the efficacy of PLX4720 could 
not be explained by differences in the frequency of immune cell subsets in the 
tissues examined. As no changes were detected in population frequency or 
effector function, the requirement for specific immune cell populations for 
PLX4720 efficacy was not further investigated. 
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Figure 6.2: PLX4720 treatment does not alter intratumoural frequencies of 
lymphocytes. C57BL/6 mice were treated with PLX4720 as described in 
Figure 6.1A. One week following initiation of PLX4720 treatment tumours 
were harvested and immune cell frequencies assessed by flow cytometry. 
Lymphocyte populations were defined as shown in Figure 5.8B. A-F. 
Frequencies of T cells, NK cells and NKT cells. G-J. Frequencies of effector 
and PD-1-high CD4+ and CD8+ T cells. Values represent individual mice, with 
5 mice used per group. Error bars are ± SEM. Statistical analysis was 
performed using one-way ANOVA with Bonferroni post-test. No significant 
differences were identified. Results are representative of two independent 
experiments. 
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Figure 6.3: PLX4720 treatment does not alter the intratumoural ratio of 
Tregs to non-regulatory CD4 T cells or CD8 T cells, or effector T cells. 
C57BL/6 mice were treated with PLX4720 as described in Figure 6.1A. One 
week following initiation of PLX4720 treatment tumours were harvested and 
immune cell frequencies assessed by flow cytometry. Lymphocyte 
populations were defined as shown in Figure 5.8B. The number of T cells was 
calculated by multiplying the population percentage by the total number of 
cells in the preceding gate. Cell numbers within the initial singlet cell gate 
were determined by multiplying percentages of single cells by total number 
of live cells as determined by trypan blue exclusion. A. Ratio of non-
regulatory CD4+ FoxP3- cells to CD4+ FoxP3+ Tregs. B. Ratio of effector CD4+ 
FoxP3- cells to Tregs. C. Ratio of CD8+ cells to CD4+ FoxP3+ Tregs. D. Ratio of 
effector CD8+ cells to Tregs. Values represent individual mice, with 5 mice 
used per group.  Error bars are ± SEM. Statistical analysis was performed 
using one-way ANOVA with Bonferronis post-test. No significant differences 
were identified.  Results are representative of two independent experiments. 
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Figure 6.4: PLX4720 treatment does not significantly alter intratumoural 
frequencies of myeloid, macrophage or MDSCs. C57BL/6 mice were 
treated with PLX4720 as described in Figure 6.1A. One week following 
initiation of PLX4720 treatment tumours were harvested and immune cell 
frequencies assessed by flow cytometry. Myeloid populations were defined 
as shown in Figure 5.8C. A-D. Frequencies of CD11b+, macrophage and 
MDSC populations. Values represent individual mice, with 5 mice used per 
group. Statistical analysis was performed using one-way ANOVA with 
Bonferroni post-test. No significant differences were identified.  Error bars 
are ± SEM. Results are representative of two independent experiments. 
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Figure 6.5: PLX4720 treatment does not significantly alter intra-tumoural 
frequencies of lymphocytes producing IFNγ and/or TNFα. C57BL/6 mice 
were treated with PLX4720 as described in Figure 6.1A. One week following 
initiation of PLX4720 treatment tumours were harvested and frequencies of 
IFNγ- and TNFα-producing lymphocytes were assessed by flow cytometry. 
Populations were defined as shown in Figure 5.12A. A-C. Frequencies of non-
regulatory CD4+ T cells producing IFNγ and TNFα. D-F. Frequencies of CD8+ 
T cells producing IFNγ and TNFα. G-I. Frequencies of NK cells producing 
IFNγ and TNFα. J-L. Frequencies of NKT cells producing IFNγ and TNFα. 
Values represent individual mice with 5 mice used per group. Error bars are ± 
SEM. Statistical analysis was performed using one-way ANOVA with 
Bonferroni post-test. No significant differences were identified. Results are 
representative of two independent experiments. 
 
6.2.3 TNFα inhibition does not augment the anti-tumour 
effects of PLX4720 treatment  
Etanercept is an antagonistic inhibitor of human TNFα, originally developed 
for use in rheumatoid arthritis. It is now used in the treatment of several 
autoimmune and inflammatory diseases (Willrich et al., 2015). Etanercept is a 
recombinant fusion protein, which consists of human TNFα receptor proteins 
bound to human IgG1. In addition to inhibiting human TNFα, Etanercept has 
also been shown to effectively block murine TNFα and significantly reduce 
serum levels of TNFα in different strains of mice (Fries et al., 2008; Genovese 
et al., 2006; Liu et al., 2006; Popivanova et al., 2008). 
C57BL/6 mice were tumour challenged, and six days later 100 µg of 
Etanercept or PBS was injected intraperitoneally and these injections were 
repeated every 3 days for the length of the experiment. As with previous 
experiments, daily gavage of PLX4720 at 50 mg/kg or vehicle control was 
initiated seven days after tumour challenge, and mice were monitored for 
tumour growth (Figure 6.11A). Inhibition of TNFα slightly decreased tumour 
growth and increased survival, however this effect was not significant. 
Consistent with previous experiments single agent PLX4720 significantly 
reduced tumour growth and increased survival, which did not result in 
tumour regression. When mice were treated with 50 mg/kg PLX4720 
alongside TNFα inhibition, a non-significant reduction in tumour growth was 
observed in comparison to PLX4720 monotherapy. However, inhibition of 
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tumour growth did not translate to increased survival and no tumour 
regression was seen (Figure 6.11B-D).  
A similar experiment was also performed once with just two doses of 
Etanercept; the first dose delivered six days after tumour challenge, and the 
second 18 hours later. PLX4720 treatment commenced six hours after the 
second dose of Etanercept. In this setting TNFα inhibition did not improve 
PLX4720 anti-tumour efficacy (data not shown). 
These results clearly show that TNFα inhibition does not improve the anti-
tumour effects of PLX4720. The absence of tumour regression (and thus 
significant tumour cell death) with TNFα inhibition and PLX4720 treatment 
suggests it is unlikely that TNFα is preventing PLX4720 from inducing 
apoptosis.  
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Figure 6.6: TNFα inhibition does not augment anti-tumour effects of 
PLX4720 treatment of YUMM1.1 tumours. A. C57BL/6 mice were injected 
subcutaneously in the left flank with 2 x 105 YUMM1.1 cells and given PC61 
or PBS intraperitoneally. From six days post-tumour challenge mice received 
100 µg Etanercept or PBS control injected intraperitoneally, every three days. 
Daily drug treatment with PLX4720 was initiated seven days post-tumour 
challenge. Mice received 50 mg/kg PLX4720 given by oral gavage, or a 
vehicle solution. Tumour growth was monitored and size recorded. Mice 
were culled when tumours reached 150 mm2, or when tumours ulcerated. B. 
Average tumour growth is shown. Each symbol represents the mean growth 
of 5 mice, error bars are ± SEM. NS = non-significant, ** P < 0.01,  **** P < 
0.0001, 2-way ANOVA with Bonferroni post-test, statistics shown for Day 23. 
C. Individual tumour growth for each treatment group; each data point 
represents an individual mouse D. Kaplan-Meier plot showing survival for 
groups of 5 mice. NS = non-significant, ** P < 0.01, Mantel-Cox test. Data are 
representative of two independent experiments. 
 
6.2.4 PLX4720 and autologous vaccination can be combined 
to achieve an additive, but not synergistic, anti-tumour 
effect 
The final set of experiments for this thesis aimed to develop a strategy for 
combination of autologous vaccine and PLX4720 that improved the anti-
tumour efficacy of either single-agent treatment.  
The first combination therapy experiment involved initiation of PLX4720 
treatment followed by therapeutic vaccination. The rationale for this 
approach was that PLX4720-induced tumour cell death would increase the 
release of tumour antigen to stimulate vaccine mediated anti-tumour 
responses. PLX4720 treatment was delivered at 20 mg/kg, as this dose has 
been previously identified to directly stimulate sub-optimal T cell 
proliferation in vivo (Chapter 4). Mice were tumour challenged, followed five 
days later by daily administration of 20 mg/kg PLX4720, and two days later 
mice were vaccinated (Figure 6.6A). Tumour growth was monitored and 
recorded, and mice were culled when tumours reached 150 mm2 or ulcerated.  
The efficacy of vaccine monotherapy, when delivered seven days after 
tumour challenge, was minimal. Tumour growth was not significantly 
reduced, while survival did not improve with therapeutic vaccination in this 
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setting (Figure 6.7B-D). In contrast, the single agent 20 mg/kg PLX4720 
significantly slowed tumour growth and increased survival. Combination of 
PLX4720 and vaccine did not decrease tumour growth when compared to the 
protection afforded by PLX4720 alone (Figure 6.7B). However, when tumour 
growth of individual mice was assessed several mice had periods of tumour 
regression followed by aggressive tumour growth. This may indicate the 
development of an anti-tumour response, which was unable to overcome 
tumour-mediated immune suppression. Combination therapy did not 
improve the survival of mice significantly, although one mouse had 
significantly increased survival within the combination therapy treated group 
(Figure 6.7D). Overall, the sequential combination of PLX4720 followed by 
vaccine did not significantly improve anti-tumour efficacy of these 
monotherapies. This may be a result of the vaccine failing to induce sufficient 
anti-tumour responses when delivered seven days post-tumour challenge.   
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Figure 6.7: Combination therapy with 20 mg/kg PLX4720 followed by 
vaccination does not significantly improve anti-tumour efficacy. A. 
C57BL/6 mice were injected subcutaneously in the left flank with 2 x 105 
YUMM1.1 cells. Daily drug treatment was begun five days post-tumour 
challenge with 20 mg/kg PLX4720 given by oral gavage, and control mice 
receiving a vehicle solution. Seven days post-tumour challenge mice were 
vaccinated intravenously with irradiated, αGalCer-loaded YUMM1.1 cells. 
Control mice received PBS. Tumour growth was monitored and size 
recorded. Mice were culled when tumours reached 150 mm2, or when 
tumours ulcerated. B. Average tumour growth is shown. Each symbol 
represents the mean growth of 4 - 5 mice. Error bars are ± SEM. NS = non-
significant, *** P < 0.001  **** P < 0.0001, 2-way ANOVA with Bonferroni post-
test, statistics shown for Day 23. Tumour growth is representative of three 
independent experiments (as tumours were measured on different days data 
was unable to be combined). C. Individual tumour growth for each treatment 
group is shown. Each data point represents an individual mouse D. Kaplan-
Meier plot showing survival for 2 combined experiments each with 4-5 mice 
per group. NS = non-significant, *** P < 0.001  **** P < 0.0001, Mantel-Cox test. 
 
 
Based on the previous findings (Figure 6.7), the optimal timing for 
therapeutic vaccine in this model was considered to be no later than five days 
post-tumour challenge. The next strategic approach delivered therapeutic 
vaccine five days post-tumour challenge, and PLX4720 treatment was 
initiated two days later  (Figure 6.8A). Both therapeutic vaccine and PLX4720 
as single-agent therapies significantly slowed tumour growth and increased 
survival (Figure 6.8B-D). However, the combination of these two treatments 
in this sequence also did not improve the anti-tumour efficacy over 
monotherapies (Figure 6.8B-D). 
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Figure 6.8: Combination therapy with vaccination followed by 20 mg/kg 
PLX4720 does not significantly improve anti-tumour efficacy. A. C57BL/6 
mice were injected subcutaneously in the left flank with 2 x 105 YUMM1.1 
cells. Five days post-tumour challenge mice were vaccinated intravenously 
with irradiated, αGalCer-loaded YUMM1.1 cells or PBS. Two days later, daily 
treatment was initiated with 20 mg/kg PLX4720 given by oral gavage, and 
control mice receiving a vehicle solution. Tumour growth was monitored and 
size recorded. Mice were culled when tumours reached 150 mm2, or 
ulcerated. B. Average tumour growth is shown. Each symbol represents the 
mean growth of 4 - 5 mice. Error bars are ± SEM. NS = non-significant, *** P < 
0.001  **** P < 0.0001, 2-way ANOVA with Bonferroni post-test, statistics 
shown for Day 24. Tumour growth is representative of three independent 
experiments (as tumours were measured on different days data was unable to 
be combined). C. Individual tumour growth for each treatment group is 
shown. Each data point represents an individual mouse D. Kaplan-Meier plot 
showing survival for 2 combined experiments each with 4-5 mice per group. 
NS = non-significant, * P ≤ 0.05, ** P < 0.01, **** P < 0.0001, Mantel-Cox test. 
 
The third and final strategy assessed the effect of higher dose PLX4720 in 
combination therapy. Therapeutic vaccination was delivered five days after 
tumour challenge and two days later 50 mg/kg PLX4720 treatment 
commenced (Figure 6.9A). Again, vaccine or 50 mg/kg PLX4720 
monotherapy slowed tumour growth and improved survival significantly 
(Figure 6.9B-D). Combination therapy significantly reduced tumour growth 
and improved survival significantly when compared with single agent 
treatments (Figure 6.9B-D). The increased benefit observed with the 
sequential combination of vaccine and 50 mg/kg PLX4720 appeared to be 
additive rather than synergistic. Additionally, tumour regression remained 
elusive and long-term survival was only achieved in 10% of mice, with all 
hosts eventually culled due to tumour size or ulceration. 
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Figure 6.9: Combination therapy with vaccination followed by 50 mg/kg 
PLX4720 significantly improves anti-tumour efficacy. A. C57BL/6 mice 
were injected subcutaneously in the left flank with 2 x 105 YUMM1.1 cells. 
Five days post-tumour challenge mice were vaccinated intravenously with 
irradiated, αGalCer-loaded YUMM1.1 cells. Control mice received PBS. Daily 
drug treatment was begun seven days post-tumour challenge with 50 mg/kg 
PLX4720 given by oral gavage, and control mice receiving a vehicle solution. 
Tumour growth was monitored and size recorded. Mice were culled when 
tumours reached 150 mm2, or when tumours ulcerated. B. Average tumour 
growth is shown. Each symbol represents the mean growth of 4 - 5 mice. 
Error bars are ± SEM. * P ≤ 0.05, *** P < 0.001  **** P < 0.0001, 2-way ANOVA 
with Bonferroni post-test, statistics shown for Day 23. Tumour growth is 
representative of two independent experiments (as tumours were measured 
on different days data was unable to be combined). C. Individual tumour 
growth for each treatment group is shown. Each data point represents an 
individual mouse D. Kaplan-Meier plot showing survival  for 2 combined 
experiments each with 4-5 mice per group. * P ≤ 0.05, *** P < 0.001  **** P < 
0.0001, Mantel-Cox test. 
 
Collectively these data demonstrate that it is possible to achieve increased 
anti-tumour efficacy by combining therapeutic vaccination and PLX4720. 
However, both drug dose and the sequence of therapy must be optimized. 
The benefit achieved with the combination therapy strategy developed still 
leaves room for improvement. 
6.2.5 Treg depletion does not improve vaccine, PLX4720 or 
combination therapy efficacy 
The suppressive capacity of Tregs presents a major hurdle to effective 
immunotherapy. Due to the high frequency of Tregs present in YUMM1.1 
tumours it is possible that these cells are limiting both vaccine, and 
combination therapy efficacy. Experiments were undertaken to establish 
whether depletion of Tregs could improve the benefit achieved with these 
therapies. 
PC61 (anti-CD25 depleting antibody) depletion of Tregs within peripheral 
blood was assessed with each batch of antibody used. Naïve FoxP3 GFP mice 
were injected with 250 µg of PC61 intraperitoneally and peripheral blood was 
collected and analysed by flow cytometry (Appendix B2). PC61 significantly 
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reduced the proportion of Tregs present within the peripheral blood CD4+ T 
cell population, with depletion maintained for at least seven days after 
antibody delivery (Appendix B2).  
The effect of Treg depletion on vaccine monotherapy or vaccine and PLX4720 
combination therapy was assessed. Mice were tumour challenged, and on the 
day of tumour implantation received either 250 µg of PC61 or PBS delivered 
intraperitoneally. Tumour challenge and Treg depletion were performed on 
the same day to maximise the effect of depletion on the suppressive tumour 
microenvironment, and to maximum ensure Treg depletion at the time of 
vaccination. Five days later mice were vaccinated intravenously, and two 
days after vaccination daily treatment with PLX4720 or vehicle control was 
commenced (Figures 6.10A and 6.11A). Depletion of Tregs by PC61 did not 
improve vaccine or combination therapy efficacy, with the effect of therapy 
on tumour growth and survival remaining unchanged (Figures 6.10B-D and 
6.11B-D). As a control, the effect of Treg depletion on PLX4720 monotherapy 
was also assessed and found to have no impact on treatment efficacy 
(Appendix B3).  
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Figure 6.10: Depletion of Tregs does not augment anti-tumour effects of 
therapeutic vaccination against YUMM1.1 tumours. A. C57BL/6 mice were 
challenged sub-cutaneously with 2 x 105 YUMM1.1 cells, and given PC61 or 
PBS intraperitoneally. Mice were vaccinated intravenously with irradiated, 
αGalCer-loaded YUMM1.1 cells therapeutically five days post-tumour 
challenge. Control mice received PBS. Tumour growth was monitored and 
size recorded. Mice were culled when tumours reached 150 mm2, or when 
tumours ulcerated. B. Average tumour growth is shown, each symbol 
represents the mean growth of 4-5 mice. Error bars are ± SEM. 2-way ANOVA 
with Bonferroni post-test was performed with no significant differences 
between groups. C. Individual tumour growth is shown. Each data point 
represents one mouse. D. Kaplan-Meier plot showing survival with 4-5 mice 
per group. Treatment groups are compared to control mice. Statistical 
analysis with the Mantel-Cox test revealed no significant differences between 
groups. Data are representative of two concordant, independent experiments. 
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Figure 6.11: Depletion of Tregs does not augment anti-tumour effects of 
combination PLX4720 and vaccine therapy. A. C57BL/6 mice were injected 
subcutaneously in the left flank with 2 x 105 YUMM1.1 cells, and given PC61 
or PBS intraperitoneally. Five days post-tumour challenge mice were 
vaccinated intravenously with irradiated, αGalCer-loaded YUMM1.1 cells. 
Control mice received PBS. Daily drug treatment was begun seven days post-
tumour challenge with 50 mg/kg PLX4720 given by oral gavage, with control 
mice receiving a vehicle solution. Tumour growth was monitored and size 
recorded. Mice were culled when tumours reached 150 mm2, or when 
tumours ulcerated. B. Average tumour growth is shown. Each symbol 
represents the mean growth of 4 - 5 mice. Error bars are ± SEM. NS= non-
significant, **** P < 0.0001, 2-way ANOVA with Bonferroni post-test, statistics 
shown for Day 23. C. Individual tumour growth for each treatment group is 
shown. Each data point represents an individual mouse D. Kaplan-Meier plot 
showing survival for groups of 4-5 mice. NS = non-significant, ** P < 0.01, 
Mantel-Cox test. This experiment was performed only once as neither single 
agent treatment demonstrated benefit of Treg depletion. 
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 Discussion 6.3
The primary aims of the work described in this chapter were to determine if 
host-mediated immune responses contributed to PLX4720 anti-tumour 
efficacy, and to devise an effective strategy to combine PLX4720 and vaccine 
to improve therapy outcomes. Additionally, targeting of potential mediators 
of therapy resistance was explored, with the aim of increasing tumour 
sensitivity to PLX4720 and vaccine.  
Comparison of PLX4720 anti-tumour efficacy in the immunocompetent 
C57BL/6 mice and immunocompromised NOD/Scid mice revealed a clear 
role for host immune responses in anti-tumour effects of BRAF inhibitors. The 
use of NOD/Scid mice is a potential limitation of this study, as these mice 
have a different genetic background to the C57BL/6 mice for which 
YUMM1.1 tumours are syngeneic. In this context syngeneic Rag-1 deficient 
mice may have been a better choice. However, NOD/Scid mice were used as 
they exhibit not only defective T and B lymphoyctes (a commonality shared 
with Rag-1-deficient mice), but also have defective NK and macrophage 
responses (Shultz et al., 1995). Diminished NK cell and macrophage responses 
were desirable as these cells can be important mediators of anti-tumour 
immunity, and NK cells have been previously implicated in BRAF inhibitor-
mediated anti-tumour efficacy (Ferrari de Andrade et al., 2014). Additionally, 
NOD/Scid mice have been shown to be the preferable model for 
xenotransplantation, with a 100% engraftment rate for many human tumours 
(Hudson et al., 1998), indicating that the difference in genetic background of 
the tumours should not be a major issue. Whilst delayed YUMM1.1 growth 
was observed in NOD/Scid mice compared to C57BL/6 mice this was 
attributed to a technical problem. The skin of NOD/Scid mice was “leakier” 
than that of C57BL/6 mice. Consequently, following subcutaneous injection 
of tumour cells a greater volume of cell suspension seeped from the tumour 
injection site. Slow, careful injection minimized this but did not completely 
stop seepage. 
The finding that BRAF inhibitors require host immunity to be fully effective 
supports a growing body of literature demonstrating that these inhibitors 
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enhance anti-tumour immune responses. In melanoma patients, Vemurafenib 
treatment has been shown to increase CD4+ and CD8+ T cell infiltration of 
tumours, which has been associated with increased expression of melanoma 
antigens and upregulation of MHC Class I expression (Frederick et al., 2013; 
Sapkota et al., 2013; Wilmott et al., 2012). Similarly, in the inducible model of 
BrafV600E Pten-/- Cdkn2a-/- tumours PLX4720 treatment increased CD4+ FoxP3- 
and CD8+ T cell infiltration of tumours, and reduced the frequency of FoxP3+ 
Tregs (Ho et al., 2014). The associated increased IFNγ production and CD40L 
expression by non-regulatory CD4+ T cells, was shown by specific blockade to 
be required for optimal PLX4720 anti-tumour efficacy. However, the 
immunological effects or requirements of BRAF inhibitor treatment do vary 
between patients and between models. In the SM1 model of BRAFV600E 
melanoma PLX4720 and Vemurafenib treatment increased ratios of CD8+ T 
cells to Tregs, but also significantly increased NK cell infiltration of tumours 
(Knight et al., 2013). Furthermore, in this model PLX4720 augmented NK cell 
function, and NK cells were required for PLX4720 anti-tumour efficacy in a 
perforin-dependent manner (Ferrari de Andrade et al., 2014).  
Despite the requirement for host-mediated immune responses for PLX4720 
efficacy, further characterisation of the tumour milieu following PLX4720 
treatment did not reveal any of the previously reported augmented 
antitumour responses. T, NK and NKT cell, macrophage and MDSC 
frequencies, ratios, and numbers (data not shown) were unaffected by 
PLX4720 treatment. Evidently, the PLX4720 induced tumour infiltration 
demonstrated in other models does not occur in YUMM1.1 tumours. Effector 
T cells, T cell expression of PD-1, and IFNγ and TNFα production by T, NK 
and NKT cells were also unchanged with BRAF inhibition. Therefore, 
although PLX4720 efficacy requires host-immunity, in the YUMM1.1 model it 
does not appear to specifically enhance tumour infiltration or effector 
function of any of the immune cell populations previously shown to be 
important in other models. The immune mediated component of PLX4720 
efficacy may be a consequence of PLX4720 treatment changing the 
equilibrium within the YUMM1.1 tumour microenvironment, allowing 
existing host immune responses to achieve greater efficacy. One such 
mechanism may be through BRAF inhibitor-mediated attenuation of 
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melanoma-mediated immunosuppression, or reduction of stromal cell 
production of suppressive factors. Diminished immunosuppression would 
allow cell populations already infiltrating the tumour to mediate greater anti-
tumour effects. Although a specific effector population was unable to be 
identified, these data demonstrate that anti-tumour immune responses 
develop against YUMM1.1 tumours, which are associated or possibly 
augmented with PLX4720 treatment. 
The role for host-immunity in PLX4720 anti-tumour efficacy and PLX4720 
augmentation of T cell responses (Chapter 4) provided strong support for the 
combination of PLX4720 and vaccine. Three combination strategies were 
investigated, with permutations in PLX4720 dose and timing of delivery of 
the two therapies. Surprisingly, of these three strategies only one yielded 
improved anti-tumour efficacy. No advantage was achieved when vaccine 
was combined with PLX4720 at a dose of 20 mg/kg. The 20 mg/kg dose of 
PLX4720 was initially favoured for combination therapy T cell stimulatory 
effects were achieved at this dose in vivo (Figure 4.9) and this dose offered a 
greater survival advantage when responses in C57BL/6 and NOD/Scid mice 
were compared (Figure 6.1). Despite this, combination of 20 mg/kg PLX4720 
and vaccine did not improve efficacy over 20 mg/kg PLX4720 monotherapy 
regardless of which treatment was given first. However, when vaccine was 
followed by 50 mg/kg PLX4720 treatment, increased anti-tumour efficacy 
was achieved, with a benefit that appears to be additive.  
Initially, PLX4720 followed by vaccination was anticipated to be the 
preferable combination strategy, as it would allow PLX4720-induced cell 
death to potentiate anti-tumour vaccine immune responses. However, the 
greatest benefit was achieved when vaccine was followed by PLX4720. 
Theoretically, this setting would still allow for PLX4720 potentiation of 
vaccine immune responses, when the effects are considered temporally. The 
tumour specific CD4+ T cell response elicited with vaccination would be 
expected to peak approximately seven days after vaccine delivery. PLX4720 
would be expected to reach peak, stable plasma concentration after 48 hours 
and begin to have either cytostatic or cytotoxic effects on melanoma cells 
within 36-48 hours of initiating drug treatment. Therefore, if PLX4720 
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treatment is commenced shortly after vaccine delivery, PLX4720 is likely to 
begin to have anti-tumour effects, which are expected to potentiate immune 
responses, prior to the peak of the vaccine effector response. However, the 
benefit achieved in this model with vaccine and 50 mg/kg PLX4720 was an 
additive effect, indicating that synergy of the two mechanisms of action did 
not occur.  
Interestingly, PLX4720 as a monotherapy or in combination with 
immunotherapy did not induce regression of YUMM1.1 tumours in vivo, even 
at the maximum recommended dose of 100 mg/kg daily (Dr Gideon Bollag, 
personal communication). Despite this, YUMM1.1 cells were relatively 
sensitive to PLX4720 induced apoptosis in vitro, indicating that factors within 
the tumour microenvironment are conferring some in vivo resistance. The 
relatively high frequency of lymphocytes producing TNFα alongside previous 
reports of TNFα-mediated resistance to BRAF inhibition prompted 
investigation of the role of TNFα in YUMM1.1 . However, in the YUMM1.1 
model TNFα inhibition did not improve the anti-tumour efficacy. Etanercept 
was delivered at a dose of 100 µg, which is well established to reduce serum 
TNFα levels, but the efficacy of this dose at inhibiting intratumoural TNFα is 
unknown. Therefore, it is possible that either TNFα is not a key mediator of 
resistance to BRAF inhibition in the YUMM1.1 model, or alternatively that the 
dose of Etanercept used was insufficient to inhibit intratumoural TNFα. 
Nonetheless, the dose of Etanercept commonly used for inflammatory 
diseases did not improve PLX4720 anti-tumour effects in vivo.  
Next, depletion of Tregs was investigated with the aim of augmenting vaccine 
efficacy. Tregs are widely acknowledged to present a significant hurdle to 
immunotherapy, suppressing the development of effective anti-tumour 
immune responses through immunoregulatory functions. Additionally, Tregs 
can promote tumour progression through the production of factors such as 
VEGF. In the inducible model of BrafV600E Pten-/- Cdkn2a-/- melanoma 
accumulation of intratumoural Tregs, as well as MDSCs, was shown to drive 
tumour growth and suppress T cell-mediated anti-tumour effector responses 
(Ho et al., 2014). Within YUMM1.1 tumours, Tregs represent a significant 
population, accounting for approximately 30-40% of the total CD4+ T cell 
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population at Day 14 post-tumour challenge. Depletion of Tregs improved 
endogenous tumour responses in a number of murine tumour models, and 
has been shown to improve efficacy of a range of vaccine strategies in mouse 
models of melanoma (Klages et al., 2010; Shimizu et al., 1999; Steitz et al., 
2001; Tan et al., 2013). Furthermore, Treg depletion significantly enhanced 
efficacy of an autologous irradiated, αGalCer-loaded vaccine in a mouse 
model of glioma (Hunn et al., 2012). Surprisingly, depletion of Tregs with the 
anti-CD25 depleting antibody PC61 did not improve the efficacy of 
vaccination in the YUMM1.1 tumour model. There was no benefit in 
combining Treg depletion with vaccine monotherapy, or with vaccine and 
PLX4720 combination therapy. Despite this, PC61 significantly reduced the 
peripheral Treg populations for at least seven days after delivery, indicating 
efficacy of antibody depletion. However, this peripheral depletion does not 
demonstrate that effective depletion was achieved intratumourally. Thus, it is 
possible that factors produced by melanoma cells caused persistent 
differentiation of inducible Tregs, which were not sufficiently depleted by 
PC61. To more definitively deplete Tregs the DEREG mice could be used, 
these mice have DTR-eGFP under control of the FoxP3 gene locus allowing 
diphtheria toxin depletion of FoxP3+ Tregs (Lahl, 2007 #1005).  Alternatively, 
given the plethora of immunosuppressive mechanisms present within 
established tumours, such as MDSCs, tumour-associated macrophages and 
direct melanoma-mediated immunosuppression, it is possible that depletion 
of only one suppressive subset did not adequately reduce the overall 
immunosuppression by the tumour microenvironment.  
6.3.1 Conclusions 
The anti-tumour effects of PLX4720 incorporate endogenous host immune 
responses. However, there was no evidence of potentiation of a specific 
effector response following treatment, indicating that drug therapy may be 
unleashing pre-existing anti-tumour immunity. Investigation of three 
different strategies of vaccine and PLX4720 combination revealed an 
approach that achieved increased anti-tumour efficacy over single agent 
therapies. The success of this combination therapy was shown to be 
dependent on drug dose and timing of therapy delivery, emphasizing the 
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need for robust investigation of combination strategies. Despite achieving 
increased anti-tumour efficacy with PLX4720 and vaccine combination, lack 
of tumour regression leaves room for improvement of this therapeutic 
strategy. Inhibiting potential mediators of therapy resistance, TNFα and 
Tregs, was unsuccessful at improving PLX4720 or vaccine efficacy, 
respectively.  
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CHAPTER 7:  
General Discussion  
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Metastatic melanoma is an aggressive form of skin cancer that presents a 
serious clinical issue, and has increased significantly in incidence over the 
past few decades (Giblin and Thomas, 2007; Siegel et al., 2014). Recent 
breakthroughs in treatment with the approval of targeted BRAF inhibition 
and checkpoint blockade immunotherapy have improved the prognosis of 
patients with advanced disease. Despite these advances, treatment resistance 
and non-responsiveness remains an issue in a large proportion of patients. 
Combination therapy is widely expected to be the way forward. The research 
undertaken in this thesis was motivated by the need for greater 
understanding of the immunological effects of BRAF inhibition and pre-
clinical investigation of combination therapy strategies.  
7.1.1 Modelling BRAFV600E melanoma and BRAF inhibitor 
responses in mice 
The investigation of targeted BRAF inhibitors and immunotherapy, either as 
single agents or in combination, required a murine melanoma model that 
recapitulates genetic mutations common to human melanomas in an 
immunocompetent system. Two novel BRafV600E, Pten-/-; CDKN2a-/- murine 
melanoma cell lines were generously provided by Prof. Marcus Bosenberg of 
Yale University. These cell lines were derived from inducible tumours of 
Tyr::CreER; BRafCA; Ptenlox5/lox5 mice. The genetic profile of these cells represents 
mutations common to human melanomas. The BRAFV600E mutation is found in 
40 to 70% of human melanomas (Davies et al., 2002; Lee et al., 2011; Long et 
al., 2011), while loss of PTEN is observed in 38% of primary melanomas and 
58% of metastases (Birck et al., 2000). Finally, loss of CDKN2a has been 
demonstrated to occur in 56% of primary melanomas (Young et al., 2014). The 
C57BL/6 background of these cell lines allowed transplantation to 
immunocompetent, syngeneic mice. However, it must be acknowledged that 
within this thesis tumour implantation was performed subcutaneously to 
allow ongoing measurement of tumour size. Therefore, tumours are growing 
at an ectopic site, not within the tissue of origin, the epidermis. Although not 
without their limitations, these cell lines meet the key requirements of a 
suitable model for preclinical assessment of targeted therapy and 
immunotherapy.  
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Initial experiments revealed that YUMM cell lines were not highly sensitive to 
BRAF inhibition in comparison with the highly sensitive human BRAFV600E 
melanoma cell line A375. PTEN status is an important difference between 
these two models as it has been associated with BRAF inhibitor resistance 
(Deng et al., 2012; Paraiso et al., 2011; Xing et al., 2012; Ye et al., 2013). A375 
express functional PTEN, whereas the YUMM cells have homozygous Pten 
inactivation. This likely contributes to the inherent insensitivity of YUMM 
cells to BRAF inhibitor targeting. Additionally, tumour heterogeneity and 
acquired resistance may contribute to the outgrowth of YUMM1.1 and 
YUMM1.7 tumours in vivo during PLX4720 treatment.  
The development of BRAF inhibitor resistance was investigated in a recent 
study, with proteomic and genetic analysis performed on tumour samples at 
baseline, during BRAF inhibitor responsiveness and after the development of 
drug resistance (Kwong et al., 2015). Known resistance-conferring mutations, 
such as loss of PTEN, were identified in 50% of patients. Protein expression 
allowed categorization of patient resistance into three subsets, two of which 
were defined by reactivation of the MAPK pathway and a third was MAPK-
independent. Interestingly, in this study, a mouse model that recapitulates the 
resistance phenotype seen in patients was generated. This mouse model has 
inducible BrafV600E, conditional loss of Pten and constitutive knockout of 
Cdkn2a. This mouse model shared not only mutations similar to those in 
resistant patients but also a similar protein expression pattern to that 
identified in patients tumour samples. When treated with PLX4720, tumour 
growth was effectively inhibited for a median of 32 days, after which tumour 
growth increased. At this point the tumours were considered to have 
developed a fully resistant phenotype. The model developed in that study has 
the same mutational profile as that of the BRAFV600E models utilised in this 
thesis, and also shares similarities in drug responsiveness. In the YUMM1.1 
and YUMM1.7 models, PLX4720 treatment appears to control tumour 
outgrowth efficiently until 20 to 30 days post-tumour challenge, dependent 
on drug dose, at which point tumour growth rapidly increases. Taken 
together this supports the conclusion that YUMM tumours are also 
representative of BRAF inhibitor resistant patients. Given that virtually all 
patients treated with targeted BRAF inhibitors develop resistance, with an 
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average onset of only eight months after commencement of treatment, this 
model is highly clinically relevant. 
Combination of PLX4720 and vaccine could only be investigated in one of the 
two BRafV600E, Pten-/-; CDKN2a-/- models, due to time and resource limitations. 
Although the YUMM1.1 and YUMM1.7 cell lines exhibited similar sensitivity 
to PLX4720 treatment in vitro and in vivo, the efficacy of autologous 
vaccination differed between the models. Vaccines comprised of both 
YUMM1.1 and YUMM1.7 cells, irradiated and αGalCer loaded, induced 
immune responses in naïve mice demonstrating that both cell lines were, to 
some extent, immunogenic. Despite this, autologous vaccination only 
demonstrated protection in the YUMM1.1 model. On the basis of vaccine 
efficacy, the YUMM1.1 model was used for further investigation of 
combination therapy approaches, and exploration of the immune interactions 
of PLX4720.  
7.1.2 Immune interactions of targeted BRAF inhibitors 
Elucidating immunological interactions of BRAF inhibitors is of utmost 
importance to fully understand the effects of this treatment, and is critical in 
informing uptake of combination therapy. The research carried out in this 
thesis supports the prediction that BRAF inhibitor therapy will generate a 
tumour microenvironment favourable to effective anti-tumour immune 
responses. Indirectly, BRAF inhibitors can modulate immune responses by 
reducing immunosuppression mediated by melanoma-produced soluble 
factors. This was demonstrated in both BRAF inhibitor-sensitive and de novo 
resistant human BRAFV600E cell lines, but YUMM cells were not shown to be 
immunosuppressive in this manner. Previous studies have reported similar 
effects of BRAF inhibition, indicating reduction of melanoma-mediated 
immunosuppression, through soluble factors or other mechanisms, is a 
widespread phenomenon (Frederick et al., 2013; Ho et al., 2014; Schilling et 
al., 2013; Steinberg et al., 2014; Sumimoto et al., 2006). 
BRAF inhibitors have paradoxical effects on T cell responses and viability, 
inhibiting or enhancing T cell proliferation and activation in a concentration 
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and stimulus dependent manner. The protective effect of high serum 
environments indicates that inhibitory effects will be limited in vivo, although 
decreased peripheral lymphocyte numbers in Vemurafenib-treated patients 
cautions against ignoring the potential detrimental effects of BRAF inhibition 
(Schilling et al., 2014). The stimulatory effects of BRAF inhibition on 
lymphocyte proliferation were demonstrated to occur in an in vivo antigen-
specific setting, supporting the concept that in a similar manner, BRAF 
inhibition could strengthen anti-tumour T cell responses. However, the effects 
of BRAF inhibitors on tumour-directed T cell responses were difficult to 
assess. Investigation of this required a BRAF wild-type melanoma model, 
however in this setting BRAF inhibitor treatment significantly increased the 
rate of tumour growth. This strengthens the evidence for BRAF inhibitor 
stimulation of BRAF wild-type cell proliferation but confounded assessment 
of efficacy of vaccine-induced anti-tumour T cell responses.  
The finding that BRAF inhibitor efficacy is reliant on host anti-tumour 
immunity complements clinical reports that immune activation correlates 
with improved BRAF inhibitor responses. A gene expression profile marking 
tumour infiltration by activated T cells has been shown to positively correlate 
with Vemurafenib-induced tumour regression (Kwong et al., 2015). Similarly, 
immune serum markers, including decreased IL-8 and increased IFNγ, TNFα 
and macrophage inflammatory protein-1β, were associated with BRAF 
inhibitor responses (Wilmott et al., 2014). Collectively, these data demonstrate 
a strong role for host immunity in BRAF inhibitor efficacy and suggest that 
pre-existing anti-tumour immune responses are predictive of patient 
responses to BRAF inhibition. This may be very important clinically for 
patient stratification for therapy. Interestingly, the association of anti-tumour 
immune responses with outcome of metastatic melanoma patients is not 
limited to those undergoing BRAF inhibitor treatment. Generally, micro-
array-based signatures of tumour immune infiltration positively correlate 
with metastatic melanoma patient survival (Bogunovic et al., 2009; 
Mandruzzato et al., 2006; Mann et al., 2013).  
 
 243 
7.1.3 Active immunotherapy for BRAFV600E melanoma 
Immunotherapeutic treatment, and to some extent research on metastatic 
melanoma, is currently focussed on blockade of immune checkpoints, fuelled 
by recent approval of Ipilimumab, Pembrolizumab and Nivolumab. 
Following many years of relatively discouraging clinical results with 
immunotherapies, checkpoint blockade antibodies have reinvigorated 
enthusiasm for immunotherapy as a viable treatment for cancer. There are 
many benefits of checkpoint blockade, most notably the durable response 
rates, which can achieve progression-free survival of up to ten years in some 
patients. However, these treatments are not without limitations, the most 
significant of which are low response rates and side effects. Ipilimumab has a 
response rate of only 20%, while Nivolumab and Pembrolizumab response 
rates range from 20-40% (Hamid et al., 2013; Robert et al., 2015a; Robert et al., 
2014; Schadendorf et al., 2015a; Topalian et al., 2015; Topalian et al., 2014). As 
has been previously discussed, checkpoint blockade allows pre-existing 
immune responses to be released from suppression by regulatory molecules. 
Thus, it is probable that in some non-responsive patients there is minimal pre-
existing anti-tumour immunity. Active immunotherapy with cancer vaccines 
has the potential to address this by generating anti-tumour responses. 
Historically, vaccines have achieved disappointing outcomes, however, 
increased understanding of the immune system will facilitate design of more 
effective vaccines.  
Recent studies have revealed that neoantigens can drive potent T cell anti-
tumour immunity, with neoantigen-specific CD8+ T cells highly effective at 
targeting tumours (Rizvi et al., 2015; Rooney et al., 2015; Schumacher and 
Schreiber, 2015; Snyder et al., 2014). Information supporting a critical role of 
neoantigens in immune control of tumours is continuing to build. This 
knowledge when applied to cancer vaccine design could significantly 
improve the efficacy of vaccines. Supporting this concept, a Phase I clinical 
trial by Carreno et al demonstrated DC-based vaccines loaded with 
neoantigen-derived peptides generated a highly diverse melanoma-specific T 
cell repertoire (Carreno et al., 2015). Assessment of T cell responses was the 
primary readout of the trial, and results indicated vaccination increased the 
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breadth of anti-tumour T cell responses, as well as increasing T cell cytotoxic 
activity and type 1 cytokine production. Because patients underwent surgical 
resection prior to vaccination, tumour regression was unable to be monitored. 
However vaccination against neoantigens appears to be safe with patients 
experiencing no autoimmune adverse events and patient survival is ongoing 
(Carreno et al., 2015).  The key limitation of the approach undertaken in this 
study is the technical difficulty associated with defining patient-specific, 
immunogenic neoantigens. For each patient several hundred mutant peptides 
were identified and screened based on MHC I affinity and mRNA expression 
level. One-third of peptides were found to be non-immunogenic, and of the 
remaining candidates seven were selected for each patient based on MHC I 
binding. This approach involves an extremely complex manufacturing 
process, which is time-consuming and requires high throughput sequencing 
and data analysis that would make it difficult to carry out for a large patient 
cohort. Ongoing technological development will markedly reduce costs and 
time associated with these approaches making patient-specific vaccines 
increasingly feasible, as will progress towards defining optimal target 
antigens (Boisguerin et al., 2014). As an alternative, autologous tumour cell 
vaccines can circumvent these difficulties whilst providing a broad range of 
patient-specific neoantigens. 
The vaccine design used in this thesis has several advantages, in addition to 
including neoantigens it provides both CD4+ and CD8+ T cell epitopes, and 
has the practical benefits of avoiding the need to identify and select 
neoantigens, or generate autologous DCs ex vivo. As many patients will 
undergo surgical resection of primary tumours prior to immunotherapy the 
acquisition of patient tumour material would not be difficult. Furthermore, 
the incorporation of cell-associated αGalCer enables strong adjuvant activity 
whilst limiting the potential for induction of iNKT cell anergy, which occurs 
when soluble αGalCer is delivered (Parekh et al., 2005). Infusion of αGalCer-
loaded DCs retains iNKT responsiveness to a subsequent delivery of vaccine 
30 days later (Fujii et al., 2002). Therefore, by using cell-associated αGalCer it 
may be feasible to deliver multiple doses of vaccine in a prime-boost regime 
without developing iNKT anergy. However, further research into the efficacy 
of such a regime is required.   
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The anti-tumour responses induced by vaccination slowed tumour growth, 
but did not control tumour outgrowth in the long term or induce regression, 
indicating tumour escape from immune responses occurred. Despite this, 
YUMM1.1 cells appear to be immunogenic, based on the contribution of 
endogenous anti-tumour immune responses to PLX4720 efficacy and the 
induction of immune responses following intravenous injection of irradiated, 
αGalCer-loaded cells into naïve mice. Therefore, it is likely that vaccine 
efficacy was limited by the establishment of a highly immunosuppressive 
tumour microenvironment, which is characteristic of melanoma. Although 
YUMM cells did not directly produce immunosuppressive soluble factors in 
vitro, there was evidence of several other suppressive mechanisms including 
tumour cell expression of PD-L1, TIL expression of PD-1, accumulation of 
Tregs and a sizable population of MDSCs within the CD11b+ compartment. 
Vaccination decreased the frequency of PD-1 high CD4+ T cells, and increased 
ratios of non-regulatory T cells to Tregs. However, this was only a partial 
effect. The presence of multiple suppressive mechanisms within the YUMM 
tumour model may have contributed to the lack of therapeutic benefit 
achieved with Treg depletion. Despite this highly suppressive environment, 
vaccination did drive the development of effector T cell responses with 
significant anti-tumour activity, which appeared to be augmented in a 
combination therapy regime. 
Interestingly, the anti-tumour efficacy of vaccination was determined to be 
CD4+ T cell mediated, with no requirement for CD8+ T cells observed. CD4+ T 
cells can exert anti-tumour effects in a number of CTL-independent ways, 
including direct cytotoxic targeting of tumour cells, recruitment and 
promotion of cytotoxic functions of innate immune cells and anti-angiogenic 
effects of IFNγ and TNFα (Corthay et al., 2005; Haabeth et al., 2014; Lundin et 
al., 2004; Qin and Blankenstein, 2000). In this model tumour cells did not 
upregulate MHC Class II expression following IFNγ exposure. Thus CD4+ T 
cells are unlikely to be killing tumour cells through granzyme- and perforin-
mediated mechanisms, which are MHC II dependent (Quezada et al., 2010). It 
is possible that CD4+ T cells are indirectly eliciting tumour cell cytotoxicity, 
through activation of tumouricidal macrophages. Although, direct CD4+ T cell 
killing in this model cannot be completely excluded as CD4+ T cells may be 
 246 
able to induce cytotoxicity of MHC II-negative tumour cells through Fas-FasL 
interactions (Lundin et al., 2004). The broader implications of a CD4+ T cell-
mediated vaccine are positive. One of the major benefits of an autologous, 
whole tumour cell vaccine is the stimulation of immune responses against a 
complement of neoantigens. Recently, CD4= T cells have been demonstrated 
to recognise neoantigens and elicit neoantigen-targeted anti-tumour 
responses (Linnemann et al., 2015; Tran et al., 2014). Vaccination of a patient 
with advanced epithelial cancer with neoantigen-reactive CD4+ T cells led to 
long-term tumour regression, which appeared to be mediated by direct 
cytolytic activity of effector memory CD4+ T cells (Tran et al., 2014). This 
highlights the potential clinical efficacy of immunotherapeutic strategies, such 
as the one devised in this thesis, which boost CD4+ T cell responses against 
neoantigens. 
7.1.4 Combining targeted BRAF inhibition with 
immunotherapy 
The combination of BRAF inhibitors with immunotherapy is widely touted as 
being the way forward for treatment of metastatic melanoma. The 
combination of these therapies is expected to increase response rates and 
circumvent the development of BRAF inhibitor resistance. Moreover, a key 
requirement of combination therapies is to improve efficacy whilst keeping 
toxicity at a clinically manageable level. As has been previously discussed, the 
only clinical trial to date that has investigated combination of immunotherapy 
with BRAF inhibition combined Ipilmumab with Vemurafenib and resulted 
in significant toxicities (Ribas et al., 2013). Despite attempts to limit the 
serious adverse events with decreased drug doses, patient enrolment was 
halted early. There is a precedent for chemotherapy and immunotherapy 
combination resulting in increased toxicity but failing to achieve increased 
benefit. A Phase III clinical trial for metastatic melanoma investigated 
chemotherapy, comprised of Tamoxifen, Cisplatin, and Dacarbazine, in 
combination with subsequent IL-2 and IFNα2b therapy (Rosenberg et al., 
1999). The outcome for patients randomized to combination therapy was 
significantly increased toxicities, and no improvement in overall survival. 
These results led the trial investigators to recommend combination of chemo- 
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and immunotherapy should be undertaken with caution, and on the basis of 
well-designed pre-clinical studies demonstrating clear benefit. Despite this, 
there have been some encouraging trial results of combination chemo- and 
immunotherapy. A phase III clinical trial combining Ipilimumab and 
Dacarbazine achieved significantly improved overall survival and higher one-
year survival rates with combination therapy, although toxicity issues were 
still present (Robert et al., 2011). Grade 3-4 adverse events were reported in 
56.3% of combination therapy patients compared with only 27.5% of patients 
receiving dacarbazine alone. Interestingly, the most commonly increased 
adverse event in patients receiving combination therapy was immune-related 
compromised liver-function, which the trial authors deemed unexpected 
based on previous studies. This is analogous to the adverse events observed 
with Vemurafenib and Ipilimumab combination (Ribas et al., 2013), and the 
reason for these events warrants further investigation.  
When considering concerns surrounding toxicity of combined chemo- and 
immunotherapy, the combination strategy devised in this thesis holds 
considerable promise. The primary safety concern with vaccination 
comprised of autologous tumour cells is the induction of autoimmunity 
arising from stimulation of immune responses against normal self-peptides. 
No evidence of autoimmune events was observed in mice following the 
delivery of autologous vaccine against either YUMM1.1 or YUMM1.7 
tumours. Furthermore, neither vaccination alone or in combination with 
BRAF inhibition was associated with obvious toxicity. This is supported by 
clinical trials of similar vaccine strategies incorporating αGalCer or using 
autologous melanoma cells, which reported minimal toxicities of low grade, 
with no reports of autoimmunity (Baars et al., 2000; Berd et al., 2004; Chang et 
al., 2005). 
In addition to minimal toxicities, the combination of vaccination with BRAF 
inhibition has much to recommend it. Vaccine induction of CD4+ T cell 
responses is advantageous for combination with BRAF inhibitor therapy. 
Previous reports of increased tumour infiltrating lymphocytes following 
BRAF inhibitor treatment have primarily demonstrated increased CD8+ T cell 
infiltration (Frederick et al., 2013; Liu et al., 2013), with only one report of 
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increased CD4+ T cell infiltration (Wilmott et al., 2012). Therefore, if 
vaccination is eliciting CD4+ T cell anti-tumour responses, and BRAF 
inhibition drives CD8+ T cell anti-tumour immunity, combining these 
therapies may induce a range of T cell effector responses against multiple 
independent epitopes, ensuring broad immune targeting of the tumour. This 
would be particularly beneficial when considering the propensity melanoma 
has for escaping anti-tumour immune responses, and for developing 
resistance to targeted therapies. Furthermore, the combination therapy 
approach devised in this thesis had the ability to achieve significant anti-
tumour efficacy in a model that is resistant to BRAF inhibitor-induced cell 
death in vivo. This is an encouraging result, which demonstrates the potential 
of combination targeted BRAF inhibition with immunotherapy in overcoming 
therapy resistance.  
 Conclusions 7.2
In conclusion, the results presented in this thesis demonstrate that targeted 
BRAF inhibition, in the right conditions, can enhance T cell proliferation and 
activation, which translate into augmented antigen-specific T cell responses in 
vivo. In a tumour setting, BRAF inhibitor responses were shown to involve 
host immunity, demonstrating beneficial immunological effects of targeted 
BRAF inhibitors. Furthermore, BRAF inhibition reduced melanoma-mediated 
immune suppression implicating a role for BRAF inhibitors in creating a 
microenvironment more favourable to anti-tumour immunity. The 
development of a novel CD4+ T cell-mediated, autologous tumour cell vaccine 
lead to a successful combination of active immunotherapy and targeted BRAF 
inhibition. The combination therapy approach devised in this study achieved 
significant anti-tumour efficacy in a model of BRAF inhibitor-resistant 
melanoma, an exciting finding that highlights the potential of combination 
BRAF inhibitor and immunotherapy to achieve improved outcomes for 
therapy-resistant patients. 
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 Future Directions 7.3
The research in this thesis assessed immunological interactions of BRAF 
inhibitors and generated an autologous tumour cell vaccine and BRAF 
inhibitor combination therapy with significant anti-tumour efficacy in a 
therapy-resistant melanoma model. Below I outline experiments and 
strategies that may improve the specific approaches used in this study, and 
may benefit combination therapy approaches more broadly to achieve 
increased treatment efficacy in metastatic melanoma. 
A key finding of this thesis was the requirement for host-mediated immunity 
in PLX4720 efficacy. Although it was demonstrated that PLX4720 does not 
enhance tumour infiltration by T cells, NK cells or cells of CD11b+ lineage, 
further characterisation of the requirement for these cell subsets could be a 
productive question to address. This could be achieved by assessing anti-
tumour efficacy of PLX4720 in mice deficient in the aforementioned cell 
subsets, either through antibody depletion or the use of knockout mice. 
Further understanding of the cell types involved in BRAF inhibitor 
responsiveness may facilitate development of improved combination therapy 
approaches.  
In addition to further characterizing the cell types involved in the anti-tumour 
efficacy of BRAF inhibitors, the effects of BRAF inhibition on T cells could be 
explored in more detail. The effects of BRAF inhibitors on T cell proliferation 
and viability were assessed in Chapter 4, and these experiments revealed 
paradoxical effects of BRAF inhibition. T cell proliferation could be inhibited 
or augmented depending on the stimulus and drug concentration. To further 
understand the effects of BRAF inhibitors on T cells it would be of interest to 
perform experiments assessing effects on more functional parameters, such as 
specific killing and cytokine production.  
The vaccine developed in this thesis elicited anti-tumour immune responses 
in vivo. However, these responses were only partially protective against 
established tumours, even when combined with targeted BRAF inhibition. 
There are several additional strategies that could be explored to enhance both 
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vaccine and combination therapy efficacy. Autologous tumour cells 
incorporated in the vaccine could be transduced to stably express CD1d. This 
would be expected to increase the amount of αGalCer associated with tumour 
cells, and would allow iNKT cells to directly recognize αGalCer presented by 
the tumour cells. Secondly, a prime-boost approach could be investigated. As 
αGalCer is cell-associated upon intravenous injection iNKT cells would be 
expected to remain responsive to a second vaccination. However, this would 
require testing and the optimal timing of a second vaccination would need to 
be assessed, especially in combination with BRAF inhibitors.  
The impact of checkpoint blockade on the combination therapy regime 
devised in this thesis would also be of interest. There is significant risk of 
toxicity associated with α-CTLA-4 when combined with BRAF inhibitors. One 
potential approach to reduce toxicities would be to deliver minimal doses of 
checkpoint blockade antibody. In support of this, colleagues at the Malaghan 
Institute have recently demonstrated that delivery of a single dose of α-CTLA-
4 in combination with an αGalCer-loaded tumour cell vaccine achieves long-
term protection in a murine model of glioma (Cameron Field, personal 
communication). Additionally, other forms of checkpoint blockade therapy 
may result in less toxicity when combined with BRAF inhibition. As both PD-
1 and PD-L1 are expressed in the tumour microenvironment in YUMM1.1 
tumours, inhibitors of these checkpoints may prove most effective in this 
model. Additionally, investigation of newer checkpoint blockade therapies, 
such as α-LAG-3 or α-TIM-3, would be worthwhile as the differential 
expression of these targets will likely confer different efficacy and toxicity 
profiles that may make them more complementary for combination therapy.   
Combining vaccination with chemotherapies other than 
PLX4720/Vemurafenib may also be worthwhile exploring. One alternative 
that would be interesting to investigate is second-generation BRAF inhibitors, 
such as PLX PB-3, which are currently in development. Early reports suggest 
these inhibitors do not induce paradoxical activation of the MAPK pathway, 
have higher specificity for mutant-BRAF and may overcome some 
mechanisms of acquired BRAF-inhibitor resistance (Dr Gideon Bollag, 
personal communication). Combining second-generation BRAF inhibitors 
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with immunotherapy may have important implications for both efficacy and 
toxicities. As well as considering next generation targeted chemotherapies for 
combination with vaccine, low-dose delivery of traditional cytotoxics, such as 
Cisplatin or Dacarbazine, could also be considered.   
For future pre-clinical investigation of combination therapy approaches 
appropriate models must be used. Mouse models that recapitulate both the 
genetic mutations and therapy responsiveness of patients should be selected. 
On this basis, the YUMM1.1 and YUMM1.7 models are a good choice. 
Although it is difficult to achieve therapeutic benefit in such models, they 
more accurately represent clinical challenges. However, the use of an 
inducible, transgenic system with tumours growing in the tissue of origin 
would be ideal. This would require imaging technology to accurately monitor 
tumour responses to therapy. In such models it would also be pertinent to 
investigate tumour resection followed by therapy, to reflect clinical scenarios. 
Ultimately, there is unlikely to be a single therapy or combination therapy 
regime that is effective for all patients. As the number of available therapeutic 
options increases the identification of molecular or genetic signatures to 
predict therapy responsiveness is going to be critical to improving patient 
outcomes. Stratification of patients with pre-existing anti-tumour immune 
responses may predict outcomes with BRAF inhibitor treatment and 
checkpoint blockade therapy. In patients with an absence of existing anti-
tumour immunity an αGalCer-loaded, whole tumour cell vaccine in 
combination with either BRAF inhibition, checkpoint blockade therapy or 
both could conceivably be a highly effective therapeutic regime. Nevertheless, 
it should be emphasized that complex combination therapy regimes must be 
well grounded in pre-clinical evidence.   
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Appendix A: Representative flow cytometry plots 
 
Figure A1: Flow cytometric data showing A375 apoptosis. A375 cells were 
treated with 1 µM-100 µM PLX4720 (A) or Vemurafenib (B) for 18-36 hours. 
Cell viability and phosphatidylserine expression was then analysed by flow 
cytometry. Representative flow cytometry plots are shown for each treatment 
condition. DAPI-, AV- are live cells, DAPI-, AV+ are early apoptotic cells, and 
late apoptotic/necrotic cells are DAPI+, AV+.  
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Figure A2: Flow cytometric data showing YUMM1.1 apoptosis. YUMM1.1 
cells were treated with 1 µM-100 µM PLX4720 (A) or Vemurafenib (B) for 18-
36 hours. Cell viability and phosphatidylserine expression was then analysed 
by flow cytometry. Representative flow cytometry plots are shown for each 
treatment condition. DAPI-, AV- are live cells, DAPI-, AV+ are early apoptotic 
cells, and late apoptotic/necrotic cells are DAPI+, AV+. 
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Figure A3: Flow cytometric data showing YUMM1.7 apoptosis. YUMM1.7 
cells were treated with 1 µM-100 µM PLX4720 (A) or Vemurafenib (B) for 18-
36 hours. Cell viability and phosphatidylserine expression was then analysed 
by flow cytometry. Representative flow cytometry plots are shown for each 
treatment condition. DAPI-, AV- are live cells, DAPI-, AV+ are early apoptotic 
cells, and late apoptotic/necrotic cells are DAPI+, AV+. 
 297 
 
Figure A4: Flow cytometric control data for human MLRs evaluated in 
Figure 3.11. T cell proliferation was evaluated in a one-way mixed 
lymphocyte reaction and measured by flow cytometry. Example plots of the 
unstained and CFSE single stained controls are shown above, as are biological 
controls in triplicate (responder only to show baseline proliferation and the 
no supernatant, or untreated, control).  
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Figure A5: Flow cytometric control data for human anti-CD3/28 
stimulation performed in Figure 3.12. T cell proliferation was evaluated 
following anti-CD3/28 stimulation and measured by flow cytometry. 
Example plots of the unstained and CFSE single stained controls are 
shown above, as are biological controls in triplicate (unstimulated to 
show baseline proliferation and the no supernatant, or untreated, 
control). 
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 Figure A6: Flow cytometric control data of CFSE staining for murine anti-
CD3/28 stimulation performed in Figure 3.13. T cell proliferation was 
evaluated following anti-CD3/28 stimulation and measured by flow 
cytometry. Example plots of the CFSE single stained control are shown above, 
as are biological controls in triplicate (unstimulated to show baseline 
proliferation and the no supernatant, or untreated, control). 
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 Figure A7: Flow cytometric control data of CD69 staining for murine anti-
CD3/28 stimulation performed in Figure 3.13. T cell activation was evaluated 
following anti-CD3/28 stimulation and measured by flow cytometry. 
Example plots of the CD69 single stained control are shown above, as are 
biological controls in triplicate (unstimulated to show baseline proliferation 
and the no supernatant, or untreated, control). 
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Figure A8: Flow cytometric control data for human MLRs performed 
in Figure 4.1. T cell proliferation was evaluated following a one-way 
MLR and measured by flow cytometry. Example plots of the unstained 
and CFSE single stained controls are shown above, as are biological 
controls in triplicate (unstimulated to show baseline proliferation and 
the vehicle control). 
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Figure A9: Flow cytometric control data for human anti-CD3/28 stimulation 
performed in Figure 4.2. Total T cell (CD3+) proliferation was evaluated 
following anti-CD3/28 stimulation and measured by flow cytometry. 
Example plots of the unstained and CFSE single stained controls are shown 
above, as are biological controls in triplicate (unstimulated to show baseline 
proliferation and the vehicle control). 
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 Figure A10: Flow cytometric control data for T cell subsets following 
human anti-CD3/28 stimulation performed in Figure 4.2. Proliferation of 
specific T cell subsets (CD4+ or CD8+) was evaluated following anti-CD3/28 
stimulation and measured by flow cytometry. Example plots of the biological 
controls in triplicate are shown above; unstimulated to show baseline 
proliferation and the vehicle control. 
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 Figure A11; Flow cytometric control data of CFSE staining for murine anti-
CD3/28 stimulation performed in Figures 4.4. T cell proliferation was 
evaluated following anti-CD3/28 stimulation and measured by flow 
cytometry. Example plots of the unstained and CFSE single stained controls 
are shown above, as are biological controls in triplicate (unstimulated to show 
baseline proliferation and the vehicle treated control). 
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Figure A12: Flow cytometric control data of CFSE staining for human anti-
CD3/28 stimulation performed in Figures 4.5 or 4.6. T cell proliferation was 
evaluated following anti-CD3/28 stimulation and measured by flow 
cytometry. Example plots of the unstained and CFSE single stained controls 
are shown above, as are biological controls in triplicate (unstimulated to show 
baseline proliferation and the vehicle treated control). 
  
 306 
 
Appendix B: Experimental validation 
 
 
 
  
Figure B1: Titration of YUMM1.1 and YUMM1.7 growth in vivo. A. C57BL/6 
mice were injected subcutaneously in the left flank with 1-4 x 105 YUMM1.1 or 
YUMM1.7 cells, tumour growth was monitored and size recorded. Mice were 
culled when tumours reached 150 mm2, or when tumours ulcerated. B. 
Average YUMM1.1 tumour growth is shown. Each symbol represents the 
mean growth of three mice. Error bars are ± SEM. C. Average YUMM1.7 
tumour growth is shown. Each symbol represents the mean growth of three 
mice. Error bars are ± SEM. D. Individual YUMM1.1 tumour growth is shown, 
each symbol represents one mouse.  E. Individual YUMM1.7 tumour growth 
is shown, each symbol represents one mouse. This was a preliminary 
experiment and was only performed once. 
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Figure B2: PC61 successfully depletes Tregs within the blood. Naïve FoxP3 
GFP mice were injected with 250 µg PC61 or PBS intraperitoneally. Two, four 
and seven days following PC61 delivery mice were lateral tail vein bleed and 
peripheral blood was analysed for Treg frequencies by flow cytometry. A. 
Gating strategy used to identify CD3+, CD4+, FoxP3+ Tregs. Samples were pre-
gated on single, live cells. B. Frequency of Tregs within the CD4+ T cell 
compartment in peripheral blood with or without PC61 treatment. C. 
Representative flow plots of Treg frequency. Experiment was performed in 
duplicate, and was repeated twice. 
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 Figure B3: Depletion of Tregs does not affect PLX4720 treatment of 
YUMM1.1 tumours. A. C57BL/6 mice were injected SC in the left flank with 2 
x 105 YUMM1.1 cells and given PC61 or PBS IP. Daily drug treatment began 7 
days post-tumour challenge with 50 mg/kg PLX4720 given by oral gavage. 
Control mice received a vehicle solution. Tumour growth was monitored and 
size recorded. Mice were culled when tumours reached 150 mm2 or ulcerated. 
B. Average tumour growth is shown, each symbol represents the mean 
growth of 5 mice. Error bars are ± SEM. NS = non-significant, *** P < 0.001,  
**** P < 0.0001, 2-way ANOVA with Bonferroni post-test, statistics shown for 
Day 23. C. Individual tumour growth for each treatment group is shown, each 
data point represents an individual mouse D. Kaplan-Meier plot showing 
survival for groups of 5 mice. NS = non-significant, ** P < 0.01, Mantel-Cox 
test. Graphs are representative of two independent experiments. 
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Appendix C: Immunophenotyping of spleens and 
mdLN following PLX4720 treatment 
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Figure C1: PLX4720 treatment does not alter splenic frequencies of 
lymphocytes. C57BL/6 mice were treated with PLX4720 as described in 
Figure 6.1A. One week following initiation of PLX4720 treatment spleens 
were harvested and immune cell frequencies assessed by flow cytometry. 
Lymphocyte populations were defined as shown in Figure 5.8B. A-F. 
Frequencies of T cells, NK cells and NKT cells. G-J. Frequencies of effector 
and exhausted CD4+ and CD8+ T cells. Values represent individual mice, with 
5 mice used per group. Error bars are ± SEM. Statistical analysis was 
performed using one-way ANOVA with Bonferroni post-test, no significant 
differences were identified. Results are representative of two independent 
experiments. 
  
 311 
 
  
 312 
Figure C2: PLX4720 treatment does not alter draining iLN frequencies of 
lymphocytes. C57BL/6 mice were treated with PLX4720 as described in 
Figure 6.1A. One week following initiation of PLX4720 treatment draining 
iLN were harvested and immune cell frequencies assessed by flow cytometry. 
Lymphocyte populations were defined as shown in Figure 5.8B. A-F. 
Frequencies of T cells, NK cells and NKT cells. G-J. Frequencies of effector 
and exhausted CD4+ and CD8+ T cells. Values represent individual mice, with 
5 mice used per group. Error bars are ± SEM. Statistical analysis was 
performed using one-way ANOVA with Bonferroni post-test, no significant 
differences were identified. Results are representative of two independent 
experiments. 
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Figure C3: PLX4720 treatment does not alter the splenic ratio of Tregs to 
non-regulatory CD4 T cells or CD8 T cells, or effector T cells. C57BL/6 mice 
were treated with PLX4720 as described in Figure 6.1A. One week following 
initiation of PLX4720 treatment spleens were harvested and immune cell 
frequencies assessed by flow cytometry, lymphocyte populations were 
defined as shown in Figure 5.8B. The number of T cells was calculated by 
multiplying the population percentage by the total number of cells in the 
preceding gate. Cell numbers within the initial singlet cell gate were 
determined by multiplying percentages of single cells by total number of live 
cells as determined by trypan blue exclusion. A. Ratio of non-regulatory CD4+ 
FoxP3- cells to CD4+ FoxP3+ Tregs. B. Ratio of effector CD4+ FoxP3- cells to 
Tregs. C. Ratio of CD8+ cells to CD4+ FoxP3+ Tregs. D. Ratio of effector CD8+ 
cells to Tregs. Values represent individual mice, with 5 mice used per group. 
Error bars are ± SEM. Statistical analysis was performed using one-way 
ANOVA with Bonferroni post-test, no significant differences were identified. 
Results are representative of two independent experiments. 
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Figure C4: PLX4720 treatment does not alter the ratio of Tregs to non-
regulatory CD4 T cells or CD8 T cells, or effector T cells within the 
draining iLN. C57BL/6 mice were treated with PLX4720 as described in 
Figure 6.1A. One week following initiation of PLX4720 treatment draining 
iLN were harvested and immune cell frequencies assessed by flow cytometry, 
lymphocyte populations were defined as shown in Figure 5.8B. The number 
of T cells was calculated by multiplying the population percentage by the 
total number of cells in the preceding gate. Cell numbers within the initial 
singlet cell gate were determined by multiplying percentages of single cells 
by total number of live cells as determined by trypan blue exclusion. A. Ratio 
of non-regulatory CD4+ FoxP3- cells to CD4+ FoxP3+ Tregs. B. Ratio of effector 
CD4+ FoxP3- cells to Tregs. C. Ratio of CD8+ cells to CD4+ FoxP3+ Tregs. D. 
Ratio of effector CD8+ cells to Tregs. Values represent individual mice, with 5 
mice used per group. Error bars are ± SEM. Statistical analysis was performed 
using one-way ANOVA with Bonferroni post-test, no significant differences 
were identified. Results are representative of two independent experiments. 
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Figure C5: PLX4720 treatment does not significantly alter splenic 
frequencies of myeloid cells or macrophage, but increases the frequency of 
MDSCs. C57BL/6 mice were treated with PLX4720 as described in Figure 
6.1A. One week following initiation of PLX4720 treatment spleens were 
harvested and immune cell frequencies assessed by flow cytometry, myeloid 
populations were defined as shown in Figure 5.8C. A-D. Frequencies of 
CD11b+, macrophage and MDSC populations. Values represent individual 
mice, with 5 mice used per group. Statistical analysis was performed using 
one-way ANOVA with Bonferroni post-test, no significant differences were 
identified.  Error bars are ± SEM. Results are representative of two 
independent experiments. 
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Figure C6: PLX4720 treatment does not significantly alter draining iLN 
frequencies of myeloid, macrophage or MDSCs. C57BL/6 mice were treated 
with PLX4720 as described in Figure 6.1A. One week following initiation of 
PLX4720 treatment draining iLN were harvested and immune cell frequencies 
assessed by flow cytometry. Myeloid populations were defined as shown in 
Figure 5.8C. A-D. Frequencies of CD11b+, macrophage and MDSC 
populations. Values represent individual mice, with 5 mice used per group. 
Statistical analysis was performed using one-way ANOVA with Bonferroni 
post-test, no significant differences were identified.  Error bars are ± SEM. 
Results are representative of two independent experiments. 
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Figure C7: PLX4720 treatment does not significantly alter splenic 
frequencies of lymphocytes producing IFNγ and/or TNFα. C57BL/6 mice 
were treated with PLX4720 as described in Figure 6.1A. One week following 
initiation of PLX4720 treatment spleens were harvested and frequencies of 
IFNγ and TNFα producing lymphocytes were assessed by flow cytometry. 
Populations were defined as shown in Figure 5.12A. A-C. Frequencies of non-
regulatory CD4+ T cells producing IFNγ and TNFα. D-F. Frequencies of CD8+ 
T cells producing IFNγ and TNFα. G-I. Frequencies of NK cells producing 
IFNγ and TNFα. J-L. Frequencies of NKT cells producing IFNγ and TNFα. 
Values represent individual mice, with 5 mice used per group. Error bars are 
± SEM. Statistical analysis was performed using one-way ANOVA with 
Bonferroni post-test, no significant differences were identified. Results are 
representative of two independent experiments. 
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Figure C8: PLX4720 treatment does not significantly alter draining iLN 
frequencies of lymphocytes producing IFNγ and/or TNFα. C57BL/6 mice 
were treated with PLX4720 as described in Figure 6.1A. One week following 
initiation of PLX4720 treatment draining iLN were harvested and frequencies 
of IFNγ and TNFα producing lymphocytes were assessed by flow cytometry. 
Populations were defined as shown in Figure 5.12A. A-C. Frequencies of non-
regulatory CD4+ T cells producing IFNγ and TNFα. D-F. Frequencies of CD8+ 
T cells producing IFNγ and TNFα. G-I. Frequencies of NK cells producing 
IFNγ and TNFα. J-L. Frequencies of NKT cells producing IFNγ and TNFα. 
Values represent individual mice, with 5 mice used per group. Error bars are 
± SEM. Statistical analysis was performed using one-way ANOVA with 
Bonferroni post-test, no significant differences were identified. Results are 
representative of two independent experiments. 
 
 
 
